[
  {
    "Column": "record",
    "Description": "record: Record number",
    "Answer_Options": "NA"
  },
  {
    "Column": "uuid",
    "Description": "uuid: Participant identifier",
    "Answer_Options": "NA"
  },
  {
    "Column": "date",
    "Description": "date: Completion time and date",
    "Answer_Options": "NA"
  },
  {
    "Column": "status",
    "Description": "status: Participant status",
    "Answer_Options": "1=Terminated,2=Overquota,3=Qualified,4=Partial"
  },
  {
    "Column": "Screening_Criteriar1",
    "Description": "Screening_Criteriar1: I do not consent - Thank you for your interest in our survey. We know that this is a difficult time, especially for health care professionals. As such, we want you to know that we greatly appreciate you taking a break from all of the",
    "Answer_Options": "1=",
    "ParentQuestion": "Screening_Criteria"
  },
  {
    "Column": "S0",
    "Description": "S0: Are you or anyone in your immediate family affiliated in any way with any of the following on a full time or part time basis: the FDA, a pharmaceutical or biotech manufacturing company (other than for clinical trials), a market research, public relati",
    "Answer_Options": "1=Yes,2=No"
  },
  {
    "Column": "S1",
    "Description": "S1: In what state is your primary practice setting/organization located?",
    "Answer_Options": "1=Alabama,2=Alaska,3=Arizona,4=Arkansas,5=California,6=Colorado,7=Connecticut,8=Delaware,9=Florida,10=Georgia,11=Hawaii,12=Idaho,13=Illinois,14=Indiana,15=Iowa,16=Kansas,17=Kentucky,18=Louisiana,19=Maine,20=Maryland,21=Massachusetts,22=Michigan,23=Minnesota,24=Mississippi,25=Missouri,26=Montana,27=Nebraska,28=Nevada,29=New Hampshire,30=New Jersey,31=New Mexico,32=New York,33=North Carolina,34=North Dakota,35=Ohio,36=Oklahoma,37=Oregon,38=Pennsylvania,39=Rhode Island,40=South Carolina,41=South Dakota,42=Tennessee,43=Texas,44=Utah,45=Vermont,46=Virginia,47=Washington,48=Washington DC,49=West Virgina,50=Wisconsin,51=Wyoming"
  },
  {
    "Column": "Hid_Division",
    "Description": "Hid_Division: Hidden question: to punch region",
    "Answer_Options": "1=New England,2=Mid Atlantic,3=E North Central,4=W North Central,5=South Atlantic,6=E South Central,7=W South Central,8=Mountain,9=Pacific"
  },
  {
    "Column": "Hid_Region",
    "Description": "Hid_Region: Hidden question: to punch region",
    "Answer_Options": "1=North East,2=South,3=Midwest,4=West"
  },
  {
    "Column": "S1a",
    "Description": "S1a: Which of the following best describes your primary practice setting/organization? Please check the description that best applies to the practice location at which you spend the greatest amount of time.",
    "Answer_Options": "1=Major academic medical center,2=Affiliated teaching hospital,3=Community hospital (not affiliated with an academic medical center),4=Community hospital (affiliated with an academic medical center),5=Multi-specialty private practice (group),6=Single-specialty private practice (group),7=Private practice (solo),8=VA / Military hospital / DoD,9=Nursing homes,10=Other (please specify:)"
  },
  {
    "Column": "S1ar10oe",
    "Description": "S1ar10oe: Which of the following best describes your primary practice setting/organization? Please check the description that best applies to the practice location at which you spend the greatest amount of time. - Other (please specify:)",
    "Answer_Options": "NA",
    "ParentQuestion": "S1a",
    "Context": "S1a: S1a: Which of the following best describes your primary practice setting/organization? Please check the description that best applies to the practice location at which you spend the greatest amount of time."
  },
  {
    "Column": "hS1b",
    "Description": "hS1b: Hidden question to punch Academic/Community",
    "Answer_Options": "1=Academic,2=Community"
  },
  {
    "Column": "S2",
    "Description": "S2: Please select the title/role that best describes your current position within your practice/organization.",
    "Answer_Options": "1=Physician,2=Nurse,3=Nurse practitioner,4=Physician assistant,5=Medical assistant,6=Pharmacist,7=Practice administrator,8=Practice manager,9=Financial counselor or social worker,10=Reimbursement support role,11=Receptionist, administrative assistant or other administrative role,12=Other (please specify:)"
  },
  {
    "Column": "S2r12oe",
    "Description": "S2r12oe: Please select the title/role that best describes your current position within your practice/organization. - Other (please specify:)",
    "Answer_Options": "NA",
    "ParentQuestion": "S2",
    "Context": "S2: S2: Please select the title/role that best describes your current position within your practice/organization."
  },
  {
    "Column": "Hid_Position",
    "Description": "Hid_Position: Hidden question to punch Position",
    "Answer_Options": "1=MD,2=PM (PRACTICE MANAGER)"
  },
  {
    "Column": "S3",
    "Description": "S3: Which of the following best describes your primary medical specialty?",
    "Answer_Options": "1=Hematology,2=Hematology and Oncology, or Hematologic Oncology,3=Radiation Oncology,4=Urology,5=Urological Oncologist,6=Cardiology,7=Medical Oncology,8=Primary Care, Internal Medicine, General Practice or Family Practice,9=Other (please specify:)"
  },
  {
    "Column": "S3r9oe",
    "Description": "S3r9oe: Which of the following best describes your primary medical specialty? - Other (please specify:)",
    "Answer_Options": "NA",
    "ParentQuestion": "S3",
    "Context": "S3: S3: Which of the following best describes your primary medical specialty?"
  },
  {
    "Column": "S3a",
    "Description": "S3a: Which specialty do you most closely identify yourself with?",
    "Answer_Options": "1=Oncologist,2=Urologist"
  },
  {
    "Column": "Hid_S3a",
    "Description": "Hid_S3a: Hidden for S3a",
    "Answer_Options": "1=HEM ONC,2=URO,3=MED ONC"
  },
  {
    "Column": "S4",
    "Description": "S4: Are you currently board-certified or board-eligible in your area of specialty?",
    "Answer_Options": "1=Board-certified,2=Board-eligible,3=Neither"
  },
  {
    "Column": "S5r1",
    "Description": "S5r1: For how many years have you practiced in this primary specialty, post-residency?",
    "Answer_Options": "NA",
    "ParentQuestion": "S5"
  },
  {
    "Column": "S6r1",
    "Description": "S6r1: What percentage of your professional time is devoted to direct patient care / clinical practice as opposed to teaching, research or administration?",
    "Answer_Options": "NA",
    "ParentQuestion": "S6"
  },
  {
    "Column": "S7_Hr1c1",
    "Description": "S7_Hr1c1: Acute myeloid leukemia (AML) - In the past 12 months, how many patients were presented with the following hematologic oncology conditions in your practice? Please consider all patients who came to your practice including those who were: diagnose",
    "Answer_Options": "NA",
    "ParentQuestion": "S7_H"
  },
  {
    "Column": "S7_Hr2c1",
    "Description": "S7_Hr2c1: Acute lymphoblastic leukemia (ALL) - In the past 12 months, how many patients were presented with the following hematologic oncology conditions in your practice? Please consider all patients who came to your practice including those who were: di",
    "Answer_Options": "NA",
    "ParentQuestion": "S7_H"
  },
  {
    "Column": "S7_Hr3c1",
    "Description": "S7_Hr3c1: Prostate cancer - In the past 12 months, how many patients were presented with the following hematologic oncology conditions in your practice? Please consider all patients who came to your practice including those who were: diagnosed in your pra",
    "Answer_Options": "NA",
    "ParentQuestion": "S7_H"
  },
  {
    "Column": "S7_Hr4c1",
    "Description": "S7_Hr4c1: Multiple myeloma - In the past 12 months, how many patients were presented with the following hematologic oncology conditions in your practice? Please consider all patients who came to your practice including those who were: diagnosed in your pr",
    "Answer_Options": "NA",
    "ParentQuestion": "S7_H"
  },
  {
    "Column": "S7_Hr5c1",
    "Description": "S7_Hr5c1: Chronic lymphocytic leukemia (CLL) - In the past 12 months, how many patients were presented with the following hematologic oncology conditions in your practice? Please consider all patients who came to your practice including those who were: di",
    "Answer_Options": "NA",
    "ParentQuestion": "S7_H"
  },
  {
    "Column": "S7_Hr6c1",
    "Description": "S7_Hr6c1: Bladder cancer - In the past 12 months, how many patients were presented with the following hematologic oncology conditions in your practice? Please consider all patients who came to your practice including those who were: diagnosed in your prac",
    "Answer_Options": "NA",
    "ParentQuestion": "S7_H"
  },
  {
    "Column": "Hid_S7_H",
    "Description": "Hid_S7_H: Hidden for S7_H",
    "Answer_Options": "1=LOW VOLUME,2=HIGH VOLUME"
  },
  {
    "Column": "S7a_Hr1c1",
    "Description": "S7a_Hr1c1: Acute myeloid leukemia (AML) - Of all those patients, in the past 12 months, how many unique patients have you personally actively managed with the following hematologic oncology conditions? For “actively managed” please refer to patients y",
    "Answer_Options": "NA",
    "ParentQuestion": "S7a_H"
  },
  {
    "Column": "S7a_Hr2c1",
    "Description": "S7a_Hr2c1: Acute lymphoblastic leukemia (ALL) - Of all those patients, in the past 12 months, how many unique patients have you personally actively managed with the following hematologic oncology conditions? For “actively managed” please refer to pati",
    "Answer_Options": "NA",
    "ParentQuestion": "S7a_H"
  },
  {
    "Column": "S7a_Hr3c1",
    "Description": "S7a_Hr3c1: Prostate cancer - Of all those patients, in the past 12 months, how many unique patients have you personally actively managed with the following hematologic oncology conditions? For “actively managed” please refer to patients you have seen",
    "Answer_Options": "NA",
    "ParentQuestion": "S7a_H"
  },
  {
    "Column": "S7a_Hr4c1",
    "Description": "S7a_Hr4c1: Multiple myeloma - Of all those patients, in the past 12 months, how many unique patients have you personally actively managed with the following hematologic oncology conditions? For “actively managed” please refer to patients you have seen",
    "Answer_Options": "NA",
    "ParentQuestion": "S7a_H"
  },
  {
    "Column": "S7a_Hr5c1",
    "Description": "S7a_Hr5c1: Chronic lymphocytic leukemia (CLL) - Of all those patients, in the past 12 months, how many unique patients have you personally actively managed with the following hematologic oncology conditions? For “actively managed” please refer to pati",
    "Answer_Options": "NA",
    "ParentQuestion": "S7a_H"
  },
  {
    "Column": "S7a_Hr6c1",
    "Description": "S7a_Hr6c1: Bladder cancer - Of all those patients, in the past 12 months, how many unique patients have you personally actively managed with the following hematologic oncology conditions? For “actively managed” please refer to patients you have seen a",
    "Answer_Options": "NA",
    "ParentQuestion": "S7a_H"
  },
  {
    "Column": "S7_Or1c1",
    "Description": "S7_Or1c1: Prostate cancer - In the past 12 months, how many patients were presented with the following oncology conditions in your practice? Please consider all patients who came to your practice including those who were: diagnosed in your practice and no",
    "Answer_Options": "NA",
    "ParentQuestion": "S7_O"
  },
  {
    "Column": "S7_Or2c1",
    "Description": "S7_Or2c1: Acute myeloid leukemia (AML) - In the past 12 months, how many patients were presented with the following oncology conditions in your practice? Please consider all patients who came to your practice including those who were: diagnosed in your pr",
    "Answer_Options": "NA",
    "ParentQuestion": "S7_O"
  },
  {
    "Column": "S7_Or3c1",
    "Description": "S7_Or3c1: Acute lymphoblastic leukemia (ALL) - In the past 12 months, how many patients were presented with the following oncology conditions in your practice? Please consider all patients who came to your practice including those who were: diagnosed in y",
    "Answer_Options": "NA",
    "ParentQuestion": "S7_O"
  },
  {
    "Column": "S7_Or4c1",
    "Description": "S7_Or4c1: Breast cancer - In the past 12 months, how many patients were presented with the following oncology conditions in your practice? Please consider all patients who came to your practice including those who were: diagnosed in your practice and not",
    "Answer_Options": "NA",
    "ParentQuestion": "S7_O"
  },
  {
    "Column": "S7_Or5c1",
    "Description": "S7_Or5c1: Colorectal cancer - In the past 12 months, how many patients were presented with the following oncology conditions in your practice? Please consider all patients who came to your practice including those who were: diagnosed in your practice and",
    "Answer_Options": "NA",
    "ParentQuestion": "S7_O"
  },
  {
    "Column": "S7_Or6c1",
    "Description": "S7_Or6c1: Bladder cancer - In the past 12 months, how many patients were presented with the following oncology conditions in your practice? Please consider all patients who came to your practice including those who were: diagnosed in your practice and not",
    "Answer_Options": "NA",
    "ParentQuestion": "S7_O"
  },
  {
    "Column": "Hid_S7_O",
    "Description": "Hid_S7_O: Hidden for S7_O",
    "Answer_Options": "1=LOW VOLUME,2=HIGH VOLUME"
  },
  {
    "Column": "S7a_Or1c1",
    "Description": "S7a_Or1c1: Prostate cancer - Of all those patients, in the past 12 months, how many unique patients have you personally actively managed with the following oncology conditions? For “actively managed” please refer to patients you have seen at least onc",
    "Answer_Options": "NA",
    "ParentQuestion": "S7a_O"
  },
  {
    "Column": "S7a_Or2c1",
    "Description": "S7a_Or2c1: Acute myeloid leukemia (AML) - Of all those patients, in the past 12 months, how many unique patients have you personally actively managed with the following oncology conditions? For “actively managed” please refer to patients you have seen",
    "Answer_Options": "NA",
    "ParentQuestion": "S7a_O"
  },
  {
    "Column": "S7a_Or3c1",
    "Description": "S7a_Or3c1: Acute lymphoblastic leukemia (ALL) - Of all those patients, in the past 12 months, how many unique patients have you personally actively managed with the following oncology conditions? For “actively managed” please refer to patients you hav",
    "Answer_Options": "NA",
    "ParentQuestion": "S7a_O"
  },
  {
    "Column": "S7a_Or4c1",
    "Description": "S7a_Or4c1: Breast cancer - Of all those patients, in the past 12 months, how many unique patients have you personally actively managed with the following oncology conditions? For “actively managed” please refer to patients you have seen at least once",
    "Answer_Options": "NA",
    "ParentQuestion": "S7a_O"
  },
  {
    "Column": "S7a_Or5c1",
    "Description": "S7a_Or5c1: Colorectal cancer - Of all those patients, in the past 12 months, how many unique patients have you personally actively managed with the following oncology conditions? For “actively managed” please refer to patients you have seen at least o",
    "Answer_Options": "NA",
    "ParentQuestion": "S7a_O"
  },
  {
    "Column": "S7a_Or6c1",
    "Description": "S7a_Or6c1: Bladder cancer - Of all those patients, in the past 12 months, how many unique patients have you personally actively managed with the following oncology conditions? For “actively managed” please refer to patients you have seen at least once",
    "Answer_Options": "NA",
    "ParentQuestion": "S7a_O"
  },
  {
    "Column": "S7_Ur1c1",
    "Description": "S7_Ur1c1: Prostate cancer - In the past 12 months, how many patients were presented with the following urology conditions in your practice? Please consider all patients who came to your practice including those who were: diagnosed in your practice and not",
    "Answer_Options": "NA",
    "ParentQuestion": "S7_U"
  },
  {
    "Column": "S7_Ur2c1",
    "Description": "S7_Ur2c1: Bladder cancer - In the past 12 months, how many patients were presented with the following urology conditions in your practice? Please consider all patients who came to your practice including those who were: diagnosed in your practice and not",
    "Answer_Options": "NA",
    "ParentQuestion": "S7_U"
  },
  {
    "Column": "S7_Ur3c1",
    "Description": "S7_Ur3c1: Testicular cancer - In the past 12 months, how many patients were presented with the following urology conditions in your practice? Please consider all patients who came to your practice including those who were: diagnosed in your practice and n",
    "Answer_Options": "NA",
    "ParentQuestion": "S7_U"
  },
  {
    "Column": "S7_Ur4c1",
    "Description": "S7_Ur4c1: Kidney cancer - In the past 12 months, how many patients were presented with the following urology conditions in your practice? Please consider all patients who came to your practice including those who were: diagnosed in your practice and not t",
    "Answer_Options": "NA",
    "ParentQuestion": "S7_U"
  },
  {
    "Column": "Hid_S7_U",
    "Description": "Hid_S7_U: Hidden for S7_U",
    "Answer_Options": "1=LOW VOLUME,2=HIGH VOLUME"
  },
  {
    "Column": "S7a_Ur1c1",
    "Description": "S7a_Ur1c1: Prostate cancer - Of all those patients, in the past 12 months, how many unique patients have you personally actively managed with the following urology conditions? For “actively managed” please refer to patients you have seen at least once",
    "Answer_Options": "NA",
    "ParentQuestion": "S7a_U"
  },
  {
    "Column": "S7a_Ur2c1",
    "Description": "S7a_Ur2c1: Bladder cancer - Of all those patients, in the past 12 months, how many unique patients have you personally actively managed with the following urology conditions? For “actively managed” please refer to patients you have seen at least once",
    "Answer_Options": "NA",
    "ParentQuestion": "S7a_U"
  },
  {
    "Column": "S7a_Ur3c1",
    "Description": "S7a_Ur3c1: Testicular cancer - Of all those patients, in the past 12 months, how many unique patients have you personally actively managed with the following urology conditions? For “actively managed” please refer to patients you have seen at least on",
    "Answer_Options": "NA",
    "ParentQuestion": "S7a_U"
  },
  {
    "Column": "S7a_Ur4c1",
    "Description": "S7a_Ur4c1: Kidney cancer - Of all those patients, in the past 12 months, how many unique patients have you personally actively managed with the following urology conditions? For “actively managed” please refer to patients you have seen at least once i",
    "Answer_Options": "NA",
    "ParentQuestion": "S7a_U"
  },
  {
    "Column": "S7_Br1",
    "Description": "S7_Br1: Of your [pipe: S7_B_Pipe] prostate cancer patients, how many were actively managed for non-curative prostate cancer in the past 12 months? Non-curative prostate cancer patients are those that have progressed after receiving definitive therapy (e.g",
    "Answer_Options": "NA",
    "ParentQuestion": "S7_B"
  },
  {
    "Column": "S7_Cr1",
    "Description": "S7_Cr1: Of your [pipe: S7_C_Pipe] bladder cancer patients actively managed in the past 12 months, how many were locally advanced or metastatic? Include patients you treat currently AND patients you referred to clinical trial in the last 12 months AND your",
    "Answer_Options": "NA",
    "ParentQuestion": "S7_C"
  },
  {
    "Column": "S8r1",
    "Description": "S8r1: General Practice - [pipe: S8_QText] If your practice has multiple locations, please consider your primary location.",
    "Answer_Options": "0=NO TO: General Practice,1=General Practice",
    "ParentQuestion": "S8"
  },
  {
    "Column": "S8r2",
    "Description": "S8r2: Hematology - [pipe: S8_QText] If your practice has multiple locations, please consider your primary location.",
    "Answer_Options": "0=NO TO: Hematology,1=Hematology",
    "ParentQuestion": "S8"
  },
  {
    "Column": "S8r3",
    "Description": "S8r3: Hematology-Oncology - [pipe: S8_QText] If your practice has multiple locations, please consider your primary location.",
    "Answer_Options": "0=NO TO: Hematology-Oncology,1=Hematology-Oncology",
    "ParentQuestion": "S8"
  },
  {
    "Column": "S8r4",
    "Description": "S8r4: Medical Oncology - [pipe: S8_QText] If your practice has multiple locations, please consider your primary location.",
    "Answer_Options": "0=NO TO: Medical Oncology,1=Medical Oncology",
    "ParentQuestion": "S8"
  },
  {
    "Column": "S8r5",
    "Description": "S8r5: Gastroenterology - [pipe: S8_QText] If your practice has multiple locations, please consider your primary location.",
    "Answer_Options": "0=NO TO: Gastroenterology,1=Gastroenterology",
    "ParentQuestion": "S8"
  },
  {
    "Column": "S8r6",
    "Description": "S8r6: Urology - [pipe: S8_QText] If your practice has multiple locations, please consider your primary location.",
    "Answer_Options": "0=NO TO: Urology,1=Urology",
    "ParentQuestion": "S8"
  },
  {
    "Column": "S8r7",
    "Description": "S8r7: Cardiology - [pipe: S8_QText] If your practice has multiple locations, please consider your primary location.",
    "Answer_Options": "0=NO TO: Cardiology,1=Cardiology",
    "ParentQuestion": "S8"
  },
  {
    "Column": "S8r8",
    "Description": "S8r8: Other (please specify:) - [pipe: S8_QText] If your practice has multiple locations, please consider your primary location.",
    "Answer_Options": "0=NO TO: Other (please specify:),1=Other (please specify:)",
    "ParentQuestion": "S8"
  },
  {
    "Column": "S8r8oe",
    "Description": "S8r8oe: [pipe: S8_QText] If your practice has multiple locations, please consider your primary location. - Other (please specify:)",
    "Answer_Options": "NA",
    "ParentQuestion": "S8"
  },
  {
    "Column": "S9r1c1",
    "Description": "S9r1c1: General Practice - [pipe: S9_QText] If your practice has multiple locations, please consider your primary location.",
    "Answer_Options": "NA",
    "ParentQuestion": "S9"
  },
  {
    "Column": "S9r2c1",
    "Description": "S9r2c1: Hematologist - [pipe: S9_QText] If your practice has multiple locations, please consider your primary location.",
    "Answer_Options": "NA",
    "ParentQuestion": "S9"
  },
  {
    "Column": "S9r3c1",
    "Description": "S9r3c1: Hematologist-Oncologist - [pipe: S9_QText] If your practice has multiple locations, please consider your primary location.",
    "Answer_Options": "NA",
    "ParentQuestion": "S9"
  },
  {
    "Column": "S9r4c1",
    "Description": "S9r4c1: Medical Oncologist - [pipe: S9_QText] If your practice has multiple locations, please consider your primary location.",
    "Answer_Options": "NA",
    "ParentQuestion": "S9"
  },
  {
    "Column": "S9r5c1",
    "Description": "S9r5c1: Gastroenterologist - [pipe: S9_QText] If your practice has multiple locations, please consider your primary location.",
    "Answer_Options": "NA",
    "ParentQuestion": "S9"
  },
  {
    "Column": "S9r6c1",
    "Description": "S9r6c1: Urologist - [pipe: S9_QText] If your practice has multiple locations, please consider your primary location.",
    "Answer_Options": "NA",
    "ParentQuestion": "S9"
  },
  {
    "Column": "S9r7c1",
    "Description": "S9r7c1: Cardiologist - [pipe: S9_QText] If your practice has multiple locations, please consider your primary location.",
    "Answer_Options": "NA",
    "ParentQuestion": "S9"
  },
  {
    "Column": "S9r8c1",
    "Description": "S9r8c1: $ {S8.r8.open} - [pipe: S9_QText] If your practice has multiple locations, please consider your primary location.",
    "Answer_Options": "NA",
    "ParentQuestion": "S9"
  },
  {
    "Column": "S9ar1",
    "Description": "S9ar1: General Practice - What is the primary medical specialty of the physicians with whom you yourself work directly?",
    "Answer_Options": "0=NO TO: General Practice,1=General Practice",
    "ParentQuestion": "S9a"
  },
  {
    "Column": "S9ar2",
    "Description": "S9ar2: Hematology - What is the primary medical specialty of the physicians with whom you yourself work directly?",
    "Answer_Options": "0=NO TO: Hematology,1=Hematology",
    "ParentQuestion": "S9a"
  },
  {
    "Column": "S9ar3",
    "Description": "S9ar3: Hematology-Oncology - What is the primary medical specialty of the physicians with whom you yourself work directly?",
    "Answer_Options": "0=NO TO: Hematology-Oncology,1=Hematology-Oncology",
    "ParentQuestion": "S9a"
  },
  {
    "Column": "S9ar4",
    "Description": "S9ar4: Medical Oncology - What is the primary medical specialty of the physicians with whom you yourself work directly?",
    "Answer_Options": "0=NO TO: Medical Oncology,1=Medical Oncology",
    "ParentQuestion": "S9a"
  },
  {
    "Column": "S9ar5",
    "Description": "S9ar5: Gastroenterology - What is the primary medical specialty of the physicians with whom you yourself work directly?",
    "Answer_Options": "0=NO TO: Gastroenterology,1=Gastroenterology",
    "ParentQuestion": "S9a"
  },
  {
    "Column": "S9ar6",
    "Description": "S9ar6: Urology - What is the primary medical specialty of the physicians with whom you yourself work directly?",
    "Answer_Options": "0=NO TO: Urology,1=Urology",
    "ParentQuestion": "S9a"
  },
  {
    "Column": "S9ar7",
    "Description": "S9ar7: Cardiology - What is the primary medical specialty of the physicians with whom you yourself work directly?",
    "Answer_Options": "0=NO TO: Cardiology,1=Cardiology",
    "ParentQuestion": "S9a"
  },
  {
    "Column": "S9ar8",
    "Description": "S9ar8: $ {S8.r8.open} - What is the primary medical specialty of the physicians with whom you yourself work directly?",
    "Answer_Options": "0=NO TO: $ {S8.r8.open},1=$ {S8.r8.open}",
    "ParentQuestion": "S9a"
  },
  {
    "Column": "S10r1",
    "Description": "S10r1: Acute myeloid leukemia (AML) - Which types of cancer are commonly treated by physicians with whom you yourself work directly?",
    "Answer_Options": "0=NO TO: Acute myeloid leukemia (AML),1=Acute myeloid leukemia (AML)",
    "ParentQuestion": "S10"
  },
  {
    "Column": "S10r2",
    "Description": "S10r2: Prostate cancer - Which types of cancer are commonly treated by physicians with whom you yourself work directly?",
    "Answer_Options": "0=NO TO: Prostate cancer,1=Prostate cancer",
    "ParentQuestion": "S10"
  },
  {
    "Column": "S10r3",
    "Description": "S10r3: Acute lymphoblastic leukemia (ALL) - Which types of cancer are commonly treated by physicians with whom you yourself work directly?",
    "Answer_Options": "0=NO TO: Acute lymphoblastic leukemia (ALL),1=Acute lymphoblastic leukemia (ALL)",
    "ParentQuestion": "S10"
  },
  {
    "Column": "S10r4",
    "Description": "S10r4: Breast cancer - Which types of cancer are commonly treated by physicians with whom you yourself work directly?",
    "Answer_Options": "0=NO TO: Breast cancer,1=Breast cancer",
    "ParentQuestion": "S10"
  },
  {
    "Column": "S10r5",
    "Description": "S10r5: Colorectal cancer - Which types of cancer are commonly treated by physicians with whom you yourself work directly?",
    "Answer_Options": "0=NO TO: Colorectal cancer,1=Colorectal cancer",
    "ParentQuestion": "S10"
  },
  {
    "Column": "S10r6",
    "Description": "S10r6: Multiple myeloma - Which types of cancer are commonly treated by physicians with whom you yourself work directly?",
    "Answer_Options": "0=NO TO: Multiple myeloma,1=Multiple myeloma",
    "ParentQuestion": "S10"
  },
  {
    "Column": "S10r7",
    "Description": "S10r7: Chronic lymphocytic leukemia (CLL) - Which types of cancer are commonly treated by physicians with whom you yourself work directly?",
    "Answer_Options": "0=NO TO: Chronic lymphocytic leukemia (CLL),1=Chronic lymphocytic leukemia (CLL)",
    "ParentQuestion": "S10"
  },
  {
    "Column": "S10r8",
    "Description": "S10r8: Bladder cancer - Which types of cancer are commonly treated by physicians with whom you yourself work directly?",
    "Answer_Options": "0=NO TO: Bladder cancer,1=Bladder cancer",
    "ParentQuestion": "S10"
  },
  {
    "Column": "S10r9",
    "Description": "S10r9: Testicular cancer - Which types of cancer are commonly treated by physicians with whom you yourself work directly?",
    "Answer_Options": "0=NO TO: Testicular cancer,1=Testicular cancer",
    "ParentQuestion": "S10"
  },
  {
    "Column": "S10r10",
    "Description": "S10r10: Kidney cancer - Which types of cancer are commonly treated by physicians with whom you yourself work directly?",
    "Answer_Options": "0=NO TO: Kidney cancer,1=Kidney cancer",
    "ParentQuestion": "S10"
  },
  {
    "Column": "S10r11",
    "Description": "S10r11: Other (please specify:) - Which types of cancer are commonly treated by physicians with whom you yourself work directly?",
    "Answer_Options": "0=NO TO: Other (please specify:),1=Other (please specify:)",
    "ParentQuestion": "S10"
  },
  {
    "Column": "S10r12",
    "Description": "S10r12: None, physicians I work with directly do not commonly treat cancer - Which types of cancer are commonly treated by physicians with whom you yourself work directly?",
    "Answer_Options": "0=NO TO: None, physicians I work with directly do not commonly treat cancer,1=None, physicians I work with directly do not commonly treat cancer",
    "ParentQuestion": "S10"
  },
  {
    "Column": "S10r11oe",
    "Description": "S10r11oe: Which types of cancer are commonly treated by physicians with whom you yourself work directly? - Other (please specify:)",
    "Answer_Options": "NA",
    "ParentQuestion": "S10"
  },
  {
    "Column": "S11r1",
    "Description": "S11r1: Manage initiation kits/bridge programs (free drug for new starts while benefits are being verified or getting approval for coverage) - In which of the following ways do you, yourself, interface with pharmaceutical manufacturers regarding cancer dru",
    "Answer_Options": "0=NO TO: Manage initiation kits/bridge programs (free drug for new starts while benefits are being verified or getting app,1=Manage initiation kits/bridge programs (free drug for new starts while benefits are being verified or getting approval f",
    "ParentQuestion": "S11"
  },
  {
    "Column": "S11r2",
    "Description": "S11r2: Enroll patients in patient assistance/free drug programs - In which of the following ways do you, yourself, interface with pharmaceutical manufacturers regarding cancer drugs?",
    "Answer_Options": "0=NO TO: Enroll patients in patient assistance/free drug programs,1=Enroll patients in patient assistance/free drug programs",
    "ParentQuestion": "S11"
  },
  {
    "Column": "S11r3",
    "Description": "S11r3: Coordinate with specialty pharmacies to get patients access to medications - In which of the following ways do you, yourself, interface with pharmaceutical manufacturers regarding cancer drugs?",
    "Answer_Options": "0=NO TO: Coordinate with specialty pharmacies to get patients access to medications,1=Coordinate with specialty pharmacies to get patients access to medications",
    "ParentQuestion": "S11"
  },
  {
    "Column": "S11r4",
    "Description": "S11r4: Call manufacturer-sponsored reimbursement assistance hotlines - In which of the following ways do you, yourself, interface with pharmaceutical manufacturers regarding cancer drugs?",
    "Answer_Options": "0=NO TO: Call manufacturer-sponsored reimbursement assistance hotlines,1=Call manufacturer-sponsored reimbursement assistance hotlines",
    "ParentQuestion": "S11"
  },
  {
    "Column": "S11r5",
    "Description": "S11r5: Analyze and work with patients on coverage verification and patient out-of-pocket responsibility amounts - In which of the following ways do you, yourself, interface with pharmaceutical manufacturers regarding cancer drugs?",
    "Answer_Options": "0=NO TO: Analyze and work with patients on coverage verification and patient out-of-pocket responsibility amounts,1=Analyze and work with patients on coverage verification and patient out-of-pocket responsibility amounts",
    "ParentQuestion": "S11"
  },
  {
    "Column": "S11r6",
    "Description": "S11r6: Work with drug companies to negotiate contracts and/or billing terms - In which of the following ways do you, yourself, interface with pharmaceutical manufacturers regarding cancer drugs?",
    "Answer_Options": "0=NO TO: Work with drug companies to negotiate contracts and/or billing terms,1=Work with drug companies to negotiate contracts and/or billing terms",
    "ParentQuestion": "S11"
  },
  {
    "Column": "S11r7",
    "Description": "S11r7: Coordinate with drug companies to ensure supplies of samples, address issues with expired drugs, etc. - In which of the following ways do you, yourself, interface with pharmaceutical manufacturers regarding cancer drugs?",
    "Answer_Options": "0=NO TO: Coordinate with drug companies to ensure supplies of samples, address issues with expired drugs, etc.,1=Coordinate with drug companies to ensure supplies of samples, address issues with expired drugs, etc.",
    "ParentQuestion": "S11"
  },
  {
    "Column": "S11r8",
    "Description": "S11r8: Work with physicians and insurance companies to obtain prior authorizations - In which of the following ways do you, yourself, interface with pharmaceutical manufacturers regarding cancer drugs?",
    "Answer_Options": "0=NO TO: Work with physicians and insurance companies to obtain prior authorizations,1=Work with physicians and insurance companies to obtain prior authorizations",
    "ParentQuestion": "S11"
  },
  {
    "Column": "S11r9",
    "Description": "S11r9: I do not routinely perform any of the tasks above - In which of the following ways do you, yourself, interface with pharmaceutical manufacturers regarding cancer drugs?",
    "Answer_Options": "0=NO TO: I do not routinely perform any of the tasks above,1=I do not routinely perform any of the tasks above",
    "ParentQuestion": "S11"
  },
  {
    "Column": "S12r1",
    "Description": "S12r1: Astellas - In the past 6 months, please indicate whether you have interacted with each of the following companies related to their oncology drugs. This could include any type of interaction such as an in-person discussion, virtual detail, conversat",
    "Answer_Options": "1=Yes, have interacted in past 6 months,2=No, have not interacted in past 6 months",
    "ParentQuestion": "S12"
  },
  {
    "Column": "S12r2",
    "Description": "S12r2: Merck - In the past 6 months, please indicate whether you have interacted with each of the following companies related to their oncology drugs. This could include any type of interaction such as an in-person discussion, virtual detail, conversation",
    "Answer_Options": "1=Yes, have interacted in past 6 months,2=No, have not interacted in past 6 months",
    "ParentQuestion": "S12"
  },
  {
    "Column": "S12r3",
    "Description": "S12r3: Bristol-Myers Squibb (BMS) - In the past 6 months, please indicate whether you have interacted with each of the following companies related to their oncology drugs. This could include any type of interaction such as an in-person discussion, virtual",
    "Answer_Options": "1=Yes, have interacted in past 6 months,2=No, have not interacted in past 6 months",
    "ParentQuestion": "S12"
  },
  {
    "Column": "S12r4",
    "Description": "S12r4: Genentech / Roche - In the past 6 months, please indicate whether you have interacted with each of the following companies related to their oncology drugs. This could include any type of interaction such as an in-person discussion, virtual detail,",
    "Answer_Options": "1=Yes, have interacted in past 6 months,2=No, have not interacted in past 6 months",
    "ParentQuestion": "S12"
  },
  {
    "Column": "S12r5",
    "Description": "S12r5: Pfizer - In the past 6 months, please indicate whether you have interacted with each of the following companies related to their oncology drugs. This could include any type of interaction such as an in-person discussion, virtual detail, conversatio",
    "Answer_Options": "1=Yes, have interacted in past 6 months,2=No, have not interacted in past 6 months",
    "ParentQuestion": "S12"
  },
  {
    "Column": "S12r6",
    "Description": "S12r6: Janssen / Johnson & Johnson - In the past 6 months, please indicate whether you have interacted with each of the following companies related to their oncology drugs. This could include any type of interaction such as an in-person discussion, virtua",
    "Answer_Options": "1=Yes, have interacted in past 6 months,2=No, have not interacted in past 6 months",
    "ParentQuestion": "S12"
  },
  {
    "Column": "S12r7",
    "Description": "S12r7: Bayer - In the past 6 months, please indicate whether you have interacted with each of the following companies related to their oncology drugs. This could include any type of interaction such as an in-person discussion, virtual detail, conversation",
    "Answer_Options": "1=Yes, have interacted in past 6 months,2=No, have not interacted in past 6 months",
    "ParentQuestion": "S12"
  },
  {
    "Column": "S12r8",
    "Description": "S12r8: Abbvie - In the past 6 months, please indicate whether you have interacted with each of the following companies related to their oncology drugs. This could include any type of interaction such as an in-person discussion, virtual detail, conversatio",
    "Answer_Options": "1=Yes, have interacted in past 6 months,2=No, have not interacted in past 6 months",
    "ParentQuestion": "S12"
  },
  {
    "Column": "S12r9",
    "Description": "S12r9: Sanofi - In the past 6 months, please indicate whether you have interacted with each of the following companies related to their oncology drugs. This could include any type of interaction such as an in-person discussion, virtual detail, conversatio",
    "Answer_Options": "1=Yes, have interacted in past 6 months,2=No, have not interacted in past 6 months",
    "ParentQuestion": "S12"
  },
  {
    "Column": "S12r10",
    "Description": "S12r10: Lilly - In the past 6 months, please indicate whether you have interacted with each of the following companies related to their oncology drugs. This could include any type of interaction such as an in-person discussion, virtual detail, conversatio",
    "Answer_Options": "1=Yes, have interacted in past 6 months,2=No, have not interacted in past 6 months",
    "ParentQuestion": "S12"
  },
  {
    "Column": "S12r11",
    "Description": "S12r11: Novartis - In the past 6 months, please indicate whether you have interacted with each of the following companies related to their oncology drugs. This could include any type of interaction such as an in-person discussion, virtual detail, conversa",
    "Answer_Options": "1=Yes, have interacted in past 6 months,2=No, have not interacted in past 6 months",
    "ParentQuestion": "S12"
  },
  {
    "Column": "S12r12",
    "Description": "S12r12: Daiichi-Sankyo - In the past 6 months, please indicate whether you have interacted with each of the following companies related to their oncology drugs. This could include any type of interaction such as an in-person discussion, virtual detail, co",
    "Answer_Options": "1=Yes, have interacted in past 6 months,2=No, have not interacted in past 6 months",
    "ParentQuestion": "S12"
  },
  {
    "Column": "S12r13",
    "Description": "S12r13: Amgen - In the past 6 months, please indicate whether you have interacted with each of the following companies related to their oncology drugs. This could include any type of interaction such as an in-person discussion, virtual detail, conversatio",
    "Answer_Options": "1=Yes, have interacted in past 6 months,2=No, have not interacted in past 6 months",
    "ParentQuestion": "S12"
  },
  {
    "Column": "S12r14",
    "Description": "S12r14: Seattle Genetics - In the past 6 months, please indicate whether you have interacted with each of the following companies related to their oncology drugs. This could include any type of interaction such as an in-person discussion, virtual detail,",
    "Answer_Options": "1=Yes, have interacted in past 6 months,2=No, have not interacted in past 6 months",
    "ParentQuestion": "S12"
  },
  {
    "Column": "S12r15",
    "Description": "S12r15: GSK - In the past 6 months, please indicate whether you have interacted with each of the following companies related to their oncology drugs. This could include any type of interaction such as an in-person discussion, virtual detail, conversation",
    "Answer_Options": "1=Yes, have interacted in past 6 months,2=No, have not interacted in past 6 months",
    "ParentQuestion": "S12"
  },
  {
    "Column": "S12r16",
    "Description": "S12r16: AstraZeneca - In the past 6 months, please indicate whether you have interacted with each of the following companies related to their oncology drugs. This could include any type of interaction such as an in-person discussion, virtual detail, conve",
    "Answer_Options": "1=Yes, have interacted in past 6 months,2=No, have not interacted in past 6 months",
    "ParentQuestion": "S12"
  },
  {
    "Column": "S12r17",
    "Description": "S12r17: Immunomedics - In the past 6 months, please indicate whether you have interacted with each of the following companies related to their oncology drugs. This could include any type of interaction such as an in-person discussion, virtual detail, conv",
    "Answer_Options": "1=Yes, have interacted in past 6 months,2=No, have not interacted in past 6 months",
    "ParentQuestion": "S12"
  },
  {
    "Column": "Fin_Treater",
    "Description": "Fin_Treater: Listfill for Final Treater",
    "Answer_Options": "1=PC TREATER,2=AML TREATER,3=BLADDER CANCER TREATER"
  },
  {
    "Column": "Final_PM",
    "Description": "Final_PM: Listfill for Final PM Category.",
    "Answer_Options": "1=PC TREATER PM,2=AML TREATER PM,3=BLADDER CANCER TREATER PM"
  },
  {
    "Column": "Q1r1c1",
    "Description": "Q1r1c1: Astellas - You indicated that you have interacted with the following companies in the past 6 months: . For each of these companies, approximately how many times have you interacted with the company related to oncology drugs in the past 6 months?Pl",
    "Answer_Options": "NA",
    "ParentQuestion": "Q1"
  },
  {
    "Column": "Q1r1c2",
    "Description": "Q1r1c2: Merck - You indicated that you have interacted with the following companies in the past 6 months: . For each of these companies, approximately how many times have you interacted with the company related to oncology drugs in the past 6 months?Pleas",
    "Answer_Options": "NA",
    "ParentQuestion": "Q1"
  },
  {
    "Column": "Q1r1c3",
    "Description": "Q1r1c3: Bristol-Myers Squibb (BMS) - You indicated that you have interacted with the following companies in the past 6 months: . For each of these companies, approximately how many times have you interacted with the company related to oncology drugs in th",
    "Answer_Options": "NA",
    "ParentQuestion": "Q1"
  },
  {
    "Column": "Q1r1c4",
    "Description": "Q1r1c4: Genentech / Roche - You indicated that you have interacted with the following companies in the past 6 months: . For each of these companies, approximately how many times have you interacted with the company related to oncology drugs in the past 6",
    "Answer_Options": "NA",
    "ParentQuestion": "Q1"
  },
  {
    "Column": "Q1r1c5",
    "Description": "Q1r1c5: Pfizer - You indicated that you have interacted with the following companies in the past 6 months: . For each of these companies, approximately how many times have you interacted with the company related to oncology drugs in the past 6 months?Plea",
    "Answer_Options": "NA",
    "ParentQuestion": "Q1"
  },
  {
    "Column": "Q1r1c6",
    "Description": "Q1r1c6: Janssen / Johnson & Johnson - You indicated that you have interacted with the following companies in the past 6 months: . For each of these companies, approximately how many times have you interacted with the company related to oncology drugs in t",
    "Answer_Options": "NA",
    "ParentQuestion": "Q1"
  },
  {
    "Column": "Q1r1c7",
    "Description": "Q1r1c7: Bayer - You indicated that you have interacted with the following companies in the past 6 months: . For each of these companies, approximately how many times have you interacted with the company related to oncology drugs in the past 6 months?Pleas",
    "Answer_Options": "NA",
    "ParentQuestion": "Q1"
  },
  {
    "Column": "Q1r1c8",
    "Description": "Q1r1c8: Abbvie - You indicated that you have interacted with the following companies in the past 6 months: . For each of these companies, approximately how many times have you interacted with the company related to oncology drugs in the past 6 months?Plea",
    "Answer_Options": "NA",
    "ParentQuestion": "Q1"
  },
  {
    "Column": "Q1r1c9",
    "Description": "Q1r1c9: Sanofi - You indicated that you have interacted with the following companies in the past 6 months: . For each of these companies, approximately how many times have you interacted with the company related to oncology drugs in the past 6 months?Plea",
    "Answer_Options": "NA",
    "ParentQuestion": "Q1"
  },
  {
    "Column": "Q1r1c10",
    "Description": "Q1r1c10: Lilly - You indicated that you have interacted with the following companies in the past 6 months: . For each of these companies, approximately how many times have you interacted with the company related to oncology drugs in the past 6 months?Plea",
    "Answer_Options": "NA",
    "ParentQuestion": "Q1"
  },
  {
    "Column": "Q1r1c11",
    "Description": "Q1r1c11: Novartis - You indicated that you have interacted with the following companies in the past 6 months: . For each of these companies, approximately how many times have you interacted with the company related to oncology drugs in the past 6 months?P",
    "Answer_Options": "NA",
    "ParentQuestion": "Q1"
  },
  {
    "Column": "Q1r1c12",
    "Description": "Q1r1c12: Daiichi-Sankyo - You indicated that you have interacted with the following companies in the past 6 months: . For each of these companies, approximately how many times have you interacted with the company related to oncology drugs in the past 6 mo",
    "Answer_Options": "NA",
    "ParentQuestion": "Q1"
  },
  {
    "Column": "Q1r1c13",
    "Description": "Q1r1c13: Amgen - You indicated that you have interacted with the following companies in the past 6 months: . For each of these companies, approximately how many times have you interacted with the company related to oncology drugs in the past 6 months?Plea",
    "Answer_Options": "NA",
    "ParentQuestion": "Q1"
  },
  {
    "Column": "Q1r1c14",
    "Description": "Q1r1c14: Seattle Genetics - You indicated that you have interacted with the following companies in the past 6 months: . For each of these companies, approximately how many times have you interacted with the company related to oncology drugs in the past 6",
    "Answer_Options": "NA",
    "ParentQuestion": "Q1"
  },
  {
    "Column": "Q1r1c15",
    "Description": "Q1r1c15: GSK - You indicated that you have interacted with the following companies in the past 6 months: . For each of these companies, approximately how many times have you interacted with the company related to oncology drugs in the past 6 months?Please",
    "Answer_Options": "NA",
    "ParentQuestion": "Q1"
  },
  {
    "Column": "Q1r1c16",
    "Description": "Q1r1c16: AstraZeneca - You indicated that you have interacted with the following companies in the past 6 months: . For each of these companies, approximately how many times have you interacted with the company related to oncology drugs in the past 6 month",
    "Answer_Options": "NA",
    "ParentQuestion": "Q1"
  },
  {
    "Column": "Q1r1c17",
    "Description": "Q1r1c17: Immunomedics - You indicated that you have interacted with the following companies in the past 6 months: . For each of these companies, approximately how many times have you interacted with the company related to oncology drugs in the past 6 mont",
    "Answer_Options": "NA",
    "ParentQuestion": "Q1"
  },
  {
    "Column": "Q2c1",
    "Description": "Q2c1: Astellas - For each company, please indicate when, to the best of your recollection, you had your MOST RECENT interaction:",
    "Answer_Options": "1=Within the past week,2=2-3 weeks ago,3=1-3 months ago,4=Between 3 and 6 months ago",
    "ParentQuestion": "Q2"
  },
  {
    "Column": "Q2c2",
    "Description": "Q2c2: Merck - For each company, please indicate when, to the best of your recollection, you had your MOST RECENT interaction:",
    "Answer_Options": "1=Within the past week,2=2-3 weeks ago,3=1-3 months ago,4=Between 3 and 6 months ago",
    "ParentQuestion": "Q2"
  },
  {
    "Column": "Q2c3",
    "Description": "Q2c3: Bristol-Myers Squibb (BMS) - For each company, please indicate when, to the best of your recollection, you had your MOST RECENT interaction:",
    "Answer_Options": "1=Within the past week,2=2-3 weeks ago,3=1-3 months ago,4=Between 3 and 6 months ago",
    "ParentQuestion": "Q2"
  },
  {
    "Column": "Q2c4",
    "Description": "Q2c4: Genentech / Roche - For each company, please indicate when, to the best of your recollection, you had your MOST RECENT interaction:",
    "Answer_Options": "1=Within the past week,2=2-3 weeks ago,3=1-3 months ago,4=Between 3 and 6 months ago",
    "ParentQuestion": "Q2"
  },
  {
    "Column": "Q2c5",
    "Description": "Q2c5: Pfizer - For each company, please indicate when, to the best of your recollection, you had your MOST RECENT interaction:",
    "Answer_Options": "1=Within the past week,2=2-3 weeks ago,3=1-3 months ago,4=Between 3 and 6 months ago",
    "ParentQuestion": "Q2"
  },
  {
    "Column": "Q2c6",
    "Description": "Q2c6: Janssen / Johnson & Johnson - For each company, please indicate when, to the best of your recollection, you had your MOST RECENT interaction:",
    "Answer_Options": "1=Within the past week,2=2-3 weeks ago,3=1-3 months ago,4=Between 3 and 6 months ago",
    "ParentQuestion": "Q2"
  },
  {
    "Column": "Q2c7",
    "Description": "Q2c7: Bayer - For each company, please indicate when, to the best of your recollection, you had your MOST RECENT interaction:",
    "Answer_Options": "1=Within the past week,2=2-3 weeks ago,3=1-3 months ago,4=Between 3 and 6 months ago",
    "ParentQuestion": "Q2"
  },
  {
    "Column": "Q2c8",
    "Description": "Q2c8: Abbvie - For each company, please indicate when, to the best of your recollection, you had your MOST RECENT interaction:",
    "Answer_Options": "1=Within the past week,2=2-3 weeks ago,3=1-3 months ago,4=Between 3 and 6 months ago",
    "ParentQuestion": "Q2"
  },
  {
    "Column": "Q2c9",
    "Description": "Q2c9: Sanofi - For each company, please indicate when, to the best of your recollection, you had your MOST RECENT interaction:",
    "Answer_Options": "1=Within the past week,2=2-3 weeks ago,3=1-3 months ago,4=Between 3 and 6 months ago",
    "ParentQuestion": "Q2"
  },
  {
    "Column": "Q2c10",
    "Description": "Q2c10: Lilly - For each company, please indicate when, to the best of your recollection, you had your MOST RECENT interaction:",
    "Answer_Options": "1=Within the past week,2=2-3 weeks ago,3=1-3 months ago,4=Between 3 and 6 months ago",
    "ParentQuestion": "Q2"
  },
  {
    "Column": "Q2c11",
    "Description": "Q2c11: Novartis - For each company, please indicate when, to the best of your recollection, you had your MOST RECENT interaction:",
    "Answer_Options": "1=Within the past week,2=2-3 weeks ago,3=1-3 months ago,4=Between 3 and 6 months ago",
    "ParentQuestion": "Q2"
  },
  {
    "Column": "Q2c12",
    "Description": "Q2c12: Daiichi-Sankyo - For each company, please indicate when, to the best of your recollection, you had your MOST RECENT interaction:",
    "Answer_Options": "1=Within the past week,2=2-3 weeks ago,3=1-3 months ago,4=Between 3 and 6 months ago",
    "ParentQuestion": "Q2"
  },
  {
    "Column": "Q2c13",
    "Description": "Q2c13: Amgen - For each company, please indicate when, to the best of your recollection, you had your MOST RECENT interaction:",
    "Answer_Options": "1=Within the past week,2=2-3 weeks ago,3=1-3 months ago,4=Between 3 and 6 months ago",
    "ParentQuestion": "Q2"
  },
  {
    "Column": "Q2c14",
    "Description": "Q2c14: Seattle Genetics - For each company, please indicate when, to the best of your recollection, you had your MOST RECENT interaction:",
    "Answer_Options": "1=Within the past week,2=2-3 weeks ago,3=1-3 months ago,4=Between 3 and 6 months ago",
    "ParentQuestion": "Q2"
  },
  {
    "Column": "Q2c15",
    "Description": "Q2c15: GSK - For each company, please indicate when, to the best of your recollection, you had your MOST RECENT interaction:",
    "Answer_Options": "1=Within the past week,2=2-3 weeks ago,3=1-3 months ago,4=Between 3 and 6 months ago",
    "ParentQuestion": "Q2"
  },
  {
    "Column": "Q2c16",
    "Description": "Q2c16: AstraZeneca - For each company, please indicate when, to the best of your recollection, you had your MOST RECENT interaction:",
    "Answer_Options": "1=Within the past week,2=2-3 weeks ago,3=1-3 months ago,4=Between 3 and 6 months ago",
    "ParentQuestion": "Q2"
  },
  {
    "Column": "Q2c17",
    "Description": "Q2c17: Immunomedics - For each company, please indicate when, to the best of your recollection, you had your MOST RECENT interaction:",
    "Answer_Options": "1=Within the past week,2=2-3 weeks ago,3=1-3 months ago,4=Between 3 and 6 months ago",
    "ParentQuestion": "Q2"
  },
  {
    "Column": "Q3r1c1",
    "Description": "Q3r1c1: In person discussion (i.e. at practice setting) - Astellas - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions yo",
    "Answer_Options": "0=NO TO: In person discussion (i.e. at practice setting),1=In person discussion (i.e. at practice setting)",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r8c1",
    "Description": "Q3r8c1: Virtual detail / discussion - Astellas - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had since Oct",
    "Answer_Options": "0=NO TO: Virtual detail / discussion,1=Virtual detail / discussion",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r2c1",
    "Description": "Q3r2c1: Telephone call - Astellas - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had since October 2019.",
    "Answer_Options": "0=NO TO: Telephone call,1=Telephone call",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r3c1",
    "Description": "Q3r3c1: Email communication - Astellas - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had since October 201",
    "Answer_Options": "0=NO TO: Email communication,1=Email communication",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r4c1",
    "Description": "Q3r4c1: Conference discussion (e.g. booth visit, meeting) - Astellas - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions",
    "Answer_Options": "0=NO TO: Conference discussion (e.g. booth visit, meeting),1=Conference discussion (e.g. booth visit, meeting)",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r5c1",
    "Description": "Q3r5c1: Website / Online portal - Astellas - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had since October",
    "Answer_Options": "0=NO TO: Website / Online portal,1=Website / Online portal",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r6c1",
    "Description": "Q3r6c1: Other type of interaction, Specify: - Astellas - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had s",
    "Answer_Options": "0=NO TO: Other type of interaction, Specify:,1=Other type of interaction, Specify:",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r7c1",
    "Description": "Q3r7c1: Other type of interaction, Specify: - Astellas - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had s",
    "Answer_Options": "0=NO TO: Other type of interaction, Specify:,1=Other type of interaction, Specify:",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r1c2",
    "Description": "Q3r1c2: In person discussion (i.e. at practice setting) - Merck - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you",
    "Answer_Options": "0=NO TO: In person discussion (i.e. at practice setting),1=In person discussion (i.e. at practice setting)",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r8c2",
    "Description": "Q3r8c2: Virtual detail / discussion - Merck - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had since Octobe",
    "Answer_Options": "0=NO TO: Virtual detail / discussion,1=Virtual detail / discussion",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r2c2",
    "Description": "Q3r2c2: Telephone call - Merck - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had since October 2019.",
    "Answer_Options": "0=NO TO: Telephone call,1=Telephone call",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r3c2",
    "Description": "Q3r3c2: Email communication - Merck - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had since October 2019.",
    "Answer_Options": "0=NO TO: Email communication,1=Email communication",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r4c2",
    "Description": "Q3r4c2: Conference discussion (e.g. booth visit, meeting) - Merck - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you",
    "Answer_Options": "0=NO TO: Conference discussion (e.g. booth visit, meeting),1=Conference discussion (e.g. booth visit, meeting)",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r5c2",
    "Description": "Q3r5c2: Website / Online portal - Merck - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had since October 20",
    "Answer_Options": "0=NO TO: Website / Online portal,1=Website / Online portal",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r6c2",
    "Description": "Q3r6c2: Other type of interaction, Specify: - Merck - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had sinc",
    "Answer_Options": "0=NO TO: Other type of interaction, Specify:,1=Other type of interaction, Specify:",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r7c2",
    "Description": "Q3r7c2: Other type of interaction, Specify: - Merck - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had sinc",
    "Answer_Options": "0=NO TO: Other type of interaction, Specify:,1=Other type of interaction, Specify:",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r1c3",
    "Description": "Q3r1c3: In person discussion (i.e. at practice setting) - Bristol-Myers Squibb (BMS) - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider A",
    "Answer_Options": "0=NO TO: In person discussion (i.e. at practice setting),1=In person discussion (i.e. at practice setting)",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r8c3",
    "Description": "Q3r8c3: Virtual detail / discussion - Bristol-Myers Squibb (BMS) - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you",
    "Answer_Options": "0=NO TO: Virtual detail / discussion,1=Virtual detail / discussion",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r2c3",
    "Description": "Q3r2c3: Telephone call - Bristol-Myers Squibb (BMS) - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had sinc",
    "Answer_Options": "0=NO TO: Telephone call,1=Telephone call",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r3c3",
    "Description": "Q3r3c3: Email communication - Bristol-Myers Squibb (BMS) - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had",
    "Answer_Options": "0=NO TO: Email communication,1=Email communication",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r4c3",
    "Description": "Q3r4c3: Conference discussion (e.g. booth visit, meeting) - Bristol-Myers Squibb (BMS) - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider",
    "Answer_Options": "0=NO TO: Conference discussion (e.g. booth visit, meeting),1=Conference discussion (e.g. booth visit, meeting)",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r5c3",
    "Description": "Q3r5c3: Website / Online portal - Bristol-Myers Squibb (BMS) - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve",
    "Answer_Options": "0=NO TO: Website / Online portal,1=Website / Online portal",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r6c3",
    "Description": "Q3r6c3: Other type of interaction, Specify: - Bristol-Myers Squibb (BMS) - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interacti",
    "Answer_Options": "0=NO TO: Other type of interaction, Specify:,1=Other type of interaction, Specify:",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r7c3",
    "Description": "Q3r7c3: Other type of interaction, Specify: - Bristol-Myers Squibb (BMS) - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interacti",
    "Answer_Options": "0=NO TO: Other type of interaction, Specify:,1=Other type of interaction, Specify:",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r1c4",
    "Description": "Q3r1c4: In person discussion (i.e. at practice setting) - Genentech / Roche - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL intera",
    "Answer_Options": "0=NO TO: In person discussion (i.e. at practice setting),1=In person discussion (i.e. at practice setting)",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r8c4",
    "Description": "Q3r8c4: Virtual detail / discussion - Genentech / Roche - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had",
    "Answer_Options": "0=NO TO: Virtual detail / discussion,1=Virtual detail / discussion",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r2c4",
    "Description": "Q3r2c4: Telephone call - Genentech / Roche - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had since October",
    "Answer_Options": "0=NO TO: Telephone call,1=Telephone call",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r3c4",
    "Description": "Q3r3c4: Email communication - Genentech / Roche - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had since Oc",
    "Answer_Options": "0=NO TO: Email communication,1=Email communication",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r4c4",
    "Description": "Q3r4c4: Conference discussion (e.g. booth visit, meeting) - Genentech / Roche - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL inte",
    "Answer_Options": "0=NO TO: Conference discussion (e.g. booth visit, meeting),1=Conference discussion (e.g. booth visit, meeting)",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r5c4",
    "Description": "Q3r5c4: Website / Online portal - Genentech / Roche - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had sinc",
    "Answer_Options": "0=NO TO: Website / Online portal,1=Website / Online portal",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r6c4",
    "Description": "Q3r6c4: Other type of interaction, Specify: - Genentech / Roche - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you",
    "Answer_Options": "0=NO TO: Other type of interaction, Specify:,1=Other type of interaction, Specify:",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r7c4",
    "Description": "Q3r7c4: Other type of interaction, Specify: - Genentech / Roche - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you",
    "Answer_Options": "0=NO TO: Other type of interaction, Specify:,1=Other type of interaction, Specify:",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r1c5",
    "Description": "Q3r1c5: In person discussion (i.e. at practice setting) - Pfizer - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you",
    "Answer_Options": "0=NO TO: In person discussion (i.e. at practice setting),1=In person discussion (i.e. at practice setting)",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r8c5",
    "Description": "Q3r8c5: Virtual detail / discussion - Pfizer - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had since Octob",
    "Answer_Options": "0=NO TO: Virtual detail / discussion,1=Virtual detail / discussion",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r2c5",
    "Description": "Q3r2c5: Telephone call - Pfizer - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had since October 2019.",
    "Answer_Options": "0=NO TO: Telephone call,1=Telephone call",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r3c5",
    "Description": "Q3r3c5: Email communication - Pfizer - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had since October 2019.",
    "Answer_Options": "0=NO TO: Email communication,1=Email communication",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r4c5",
    "Description": "Q3r4c5: Conference discussion (e.g. booth visit, meeting) - Pfizer - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions yo",
    "Answer_Options": "0=NO TO: Conference discussion (e.g. booth visit, meeting),1=Conference discussion (e.g. booth visit, meeting)",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r5c5",
    "Description": "Q3r5c5: Website / Online portal - Pfizer - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had since October 2",
    "Answer_Options": "0=NO TO: Website / Online portal,1=Website / Online portal",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r6c5",
    "Description": "Q3r6c5: Other type of interaction, Specify: - Pfizer - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had sin",
    "Answer_Options": "0=NO TO: Other type of interaction, Specify:,1=Other type of interaction, Specify:",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r7c5",
    "Description": "Q3r7c5: Other type of interaction, Specify: - Pfizer - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had sin",
    "Answer_Options": "0=NO TO: Other type of interaction, Specify:,1=Other type of interaction, Specify:",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r1c6",
    "Description": "Q3r1c6: In person discussion (i.e. at practice setting) - Janssen / Johnson & Johnson - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider",
    "Answer_Options": "0=NO TO: In person discussion (i.e. at practice setting),1=In person discussion (i.e. at practice setting)",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r8c6",
    "Description": "Q3r8c6: Virtual detail / discussion - Janssen / Johnson & Johnson - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you",
    "Answer_Options": "0=NO TO: Virtual detail / discussion,1=Virtual detail / discussion",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r2c6",
    "Description": "Q3r2c6: Telephone call - Janssen / Johnson & Johnson - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had sin",
    "Answer_Options": "0=NO TO: Telephone call,1=Telephone call",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r3c6",
    "Description": "Q3r3c6: Email communication - Janssen / Johnson & Johnson - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve ha",
    "Answer_Options": "0=NO TO: Email communication,1=Email communication",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r4c6",
    "Description": "Q3r4c6: Conference discussion (e.g. booth visit, meeting) - Janssen / Johnson & Johnson - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please conside",
    "Answer_Options": "0=NO TO: Conference discussion (e.g. booth visit, meeting),1=Conference discussion (e.g. booth visit, meeting)",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r5c6",
    "Description": "Q3r5c6: Website / Online portal - Janssen / Johnson & Johnson - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’v",
    "Answer_Options": "0=NO TO: Website / Online portal,1=Website / Online portal",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r6c6",
    "Description": "Q3r6c6: Other type of interaction, Specify: - Janssen / Johnson & Johnson - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interact",
    "Answer_Options": "0=NO TO: Other type of interaction, Specify:,1=Other type of interaction, Specify:",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r7c6",
    "Description": "Q3r7c6: Other type of interaction, Specify: - Janssen / Johnson & Johnson - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interact",
    "Answer_Options": "0=NO TO: Other type of interaction, Specify:,1=Other type of interaction, Specify:",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r1c7",
    "Description": "Q3r1c7: In person discussion (i.e. at practice setting) - Bayer - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you",
    "Answer_Options": "0=NO TO: In person discussion (i.e. at practice setting),1=In person discussion (i.e. at practice setting)",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r8c7",
    "Description": "Q3r8c7: Virtual detail / discussion - Bayer - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had since Octobe",
    "Answer_Options": "0=NO TO: Virtual detail / discussion,1=Virtual detail / discussion",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r2c7",
    "Description": "Q3r2c7: Telephone call - Bayer - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had since October 2019.",
    "Answer_Options": "0=NO TO: Telephone call,1=Telephone call",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r3c7",
    "Description": "Q3r3c7: Email communication - Bayer - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had since October 2019.",
    "Answer_Options": "0=NO TO: Email communication,1=Email communication",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r4c7",
    "Description": "Q3r4c7: Conference discussion (e.g. booth visit, meeting) - Bayer - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you",
    "Answer_Options": "0=NO TO: Conference discussion (e.g. booth visit, meeting),1=Conference discussion (e.g. booth visit, meeting)",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r5c7",
    "Description": "Q3r5c7: Website / Online portal - Bayer - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had since October 20",
    "Answer_Options": "0=NO TO: Website / Online portal,1=Website / Online portal",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r6c7",
    "Description": "Q3r6c7: Other type of interaction, Specify: - Bayer - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had sinc",
    "Answer_Options": "0=NO TO: Other type of interaction, Specify:,1=Other type of interaction, Specify:",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r7c7",
    "Description": "Q3r7c7: Other type of interaction, Specify: - Bayer - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had sinc",
    "Answer_Options": "0=NO TO: Other type of interaction, Specify:,1=Other type of interaction, Specify:",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r1c8",
    "Description": "Q3r1c8: In person discussion (i.e. at practice setting) - Abbvie - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you",
    "Answer_Options": "0=NO TO: In person discussion (i.e. at practice setting),1=In person discussion (i.e. at practice setting)",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r8c8",
    "Description": "Q3r8c8: Virtual detail / discussion - Abbvie - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had since Octob",
    "Answer_Options": "0=NO TO: Virtual detail / discussion,1=Virtual detail / discussion",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r2c8",
    "Description": "Q3r2c8: Telephone call - Abbvie - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had since October 2019.",
    "Answer_Options": "0=NO TO: Telephone call,1=Telephone call",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r3c8",
    "Description": "Q3r3c8: Email communication - Abbvie - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had since October 2019.",
    "Answer_Options": "0=NO TO: Email communication,1=Email communication",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r4c8",
    "Description": "Q3r4c8: Conference discussion (e.g. booth visit, meeting) - Abbvie - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions yo",
    "Answer_Options": "0=NO TO: Conference discussion (e.g. booth visit, meeting),1=Conference discussion (e.g. booth visit, meeting)",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r5c8",
    "Description": "Q3r5c8: Website / Online portal - Abbvie - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had since October 2",
    "Answer_Options": "0=NO TO: Website / Online portal,1=Website / Online portal",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r6c8",
    "Description": "Q3r6c8: Other type of interaction, Specify: - Abbvie - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had sin",
    "Answer_Options": "0=NO TO: Other type of interaction, Specify:,1=Other type of interaction, Specify:",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r7c8",
    "Description": "Q3r7c8: Other type of interaction, Specify: - Abbvie - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had sin",
    "Answer_Options": "0=NO TO: Other type of interaction, Specify:,1=Other type of interaction, Specify:",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r1c9",
    "Description": "Q3r1c9: In person discussion (i.e. at practice setting) - Sanofi - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you",
    "Answer_Options": "0=NO TO: In person discussion (i.e. at practice setting),1=In person discussion (i.e. at practice setting)",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r8c9",
    "Description": "Q3r8c9: Virtual detail / discussion - Sanofi - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had since Octob",
    "Answer_Options": "0=NO TO: Virtual detail / discussion,1=Virtual detail / discussion",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r2c9",
    "Description": "Q3r2c9: Telephone call - Sanofi - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had since October 2019.",
    "Answer_Options": "0=NO TO: Telephone call,1=Telephone call",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r3c9",
    "Description": "Q3r3c9: Email communication - Sanofi - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had since October 2019.",
    "Answer_Options": "0=NO TO: Email communication,1=Email communication",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r4c9",
    "Description": "Q3r4c9: Conference discussion (e.g. booth visit, meeting) - Sanofi - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions yo",
    "Answer_Options": "0=NO TO: Conference discussion (e.g. booth visit, meeting),1=Conference discussion (e.g. booth visit, meeting)",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r5c9",
    "Description": "Q3r5c9: Website / Online portal - Sanofi - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had since October 2",
    "Answer_Options": "0=NO TO: Website / Online portal,1=Website / Online portal",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r6c9",
    "Description": "Q3r6c9: Other type of interaction, Specify: - Sanofi - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had sin",
    "Answer_Options": "0=NO TO: Other type of interaction, Specify:,1=Other type of interaction, Specify:",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r7c9",
    "Description": "Q3r7c9: Other type of interaction, Specify: - Sanofi - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had sin",
    "Answer_Options": "0=NO TO: Other type of interaction, Specify:,1=Other type of interaction, Specify:",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r1c10",
    "Description": "Q3r1c10: In person discussion (i.e. at practice setting) - Lilly - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you",
    "Answer_Options": "0=NO TO: In person discussion (i.e. at practice setting),1=In person discussion (i.e. at practice setting)",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r8c10",
    "Description": "Q3r8c10: Virtual detail / discussion - Lilly - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had since Octob",
    "Answer_Options": "0=NO TO: Virtual detail / discussion,1=Virtual detail / discussion",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r2c10",
    "Description": "Q3r2c10: Telephone call - Lilly - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had since October 2019.",
    "Answer_Options": "0=NO TO: Telephone call,1=Telephone call",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r3c10",
    "Description": "Q3r3c10: Email communication - Lilly - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had since October 2019.",
    "Answer_Options": "0=NO TO: Email communication,1=Email communication",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r4c10",
    "Description": "Q3r4c10: Conference discussion (e.g. booth visit, meeting) - Lilly - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions yo",
    "Answer_Options": "0=NO TO: Conference discussion (e.g. booth visit, meeting),1=Conference discussion (e.g. booth visit, meeting)",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r5c10",
    "Description": "Q3r5c10: Website / Online portal - Lilly - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had since October 2",
    "Answer_Options": "0=NO TO: Website / Online portal,1=Website / Online portal",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r6c10",
    "Description": "Q3r6c10: Other type of interaction, Specify: - Lilly - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had sin",
    "Answer_Options": "0=NO TO: Other type of interaction, Specify:,1=Other type of interaction, Specify:",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r7c10",
    "Description": "Q3r7c10: Other type of interaction, Specify: - Lilly - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had sin",
    "Answer_Options": "0=NO TO: Other type of interaction, Specify:,1=Other type of interaction, Specify:",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r1c11",
    "Description": "Q3r1c11: In person discussion (i.e. at practice setting) - Novartis - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions y",
    "Answer_Options": "0=NO TO: In person discussion (i.e. at practice setting),1=In person discussion (i.e. at practice setting)",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r8c11",
    "Description": "Q3r8c11: Virtual detail / discussion - Novartis - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had since Oc",
    "Answer_Options": "0=NO TO: Virtual detail / discussion,1=Virtual detail / discussion",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r2c11",
    "Description": "Q3r2c11: Telephone call - Novartis - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had since October 2019.",
    "Answer_Options": "0=NO TO: Telephone call,1=Telephone call",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r3c11",
    "Description": "Q3r3c11: Email communication - Novartis - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had since October 20",
    "Answer_Options": "0=NO TO: Email communication,1=Email communication",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r4c11",
    "Description": "Q3r4c11: Conference discussion (e.g. booth visit, meeting) - Novartis - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions",
    "Answer_Options": "0=NO TO: Conference discussion (e.g. booth visit, meeting),1=Conference discussion (e.g. booth visit, meeting)",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r5c11",
    "Description": "Q3r5c11: Website / Online portal - Novartis - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had since Octobe",
    "Answer_Options": "0=NO TO: Website / Online portal,1=Website / Online portal",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r6c11",
    "Description": "Q3r6c11: Other type of interaction, Specify: - Novartis - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had",
    "Answer_Options": "0=NO TO: Other type of interaction, Specify:,1=Other type of interaction, Specify:",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r7c11",
    "Description": "Q3r7c11: Other type of interaction, Specify: - Novartis - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had",
    "Answer_Options": "0=NO TO: Other type of interaction, Specify:,1=Other type of interaction, Specify:",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r1c12",
    "Description": "Q3r1c12: In person discussion (i.e. at practice setting) - Daiichi-Sankyo - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interact",
    "Answer_Options": "0=NO TO: In person discussion (i.e. at practice setting),1=In person discussion (i.e. at practice setting)",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r8c12",
    "Description": "Q3r8c12: Virtual detail / discussion - Daiichi-Sankyo - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had si",
    "Answer_Options": "0=NO TO: Virtual detail / discussion,1=Virtual detail / discussion",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r2c12",
    "Description": "Q3r2c12: Telephone call - Daiichi-Sankyo - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had since October 2",
    "Answer_Options": "0=NO TO: Telephone call,1=Telephone call",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r3c12",
    "Description": "Q3r3c12: Email communication - Daiichi-Sankyo - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had since Octo",
    "Answer_Options": "0=NO TO: Email communication,1=Email communication",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r4c12",
    "Description": "Q3r4c12: Conference discussion (e.g. booth visit, meeting) - Daiichi-Sankyo - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL intera",
    "Answer_Options": "0=NO TO: Conference discussion (e.g. booth visit, meeting),1=Conference discussion (e.g. booth visit, meeting)",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r5c12",
    "Description": "Q3r5c12: Website / Online portal - Daiichi-Sankyo - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had since",
    "Answer_Options": "0=NO TO: Website / Online portal,1=Website / Online portal",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r6c12",
    "Description": "Q3r6c12: Other type of interaction, Specify: - Daiichi-Sankyo - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’v",
    "Answer_Options": "0=NO TO: Other type of interaction, Specify:,1=Other type of interaction, Specify:",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r7c12",
    "Description": "Q3r7c12: Other type of interaction, Specify: - Daiichi-Sankyo - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’v",
    "Answer_Options": "0=NO TO: Other type of interaction, Specify:,1=Other type of interaction, Specify:",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r1c13",
    "Description": "Q3r1c13: In person discussion (i.e. at practice setting) - Amgen - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you",
    "Answer_Options": "0=NO TO: In person discussion (i.e. at practice setting),1=In person discussion (i.e. at practice setting)",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r8c13",
    "Description": "Q3r8c13: Virtual detail / discussion - Amgen - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had since Octob",
    "Answer_Options": "0=NO TO: Virtual detail / discussion,1=Virtual detail / discussion",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r2c13",
    "Description": "Q3r2c13: Telephone call - Amgen - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had since October 2019.",
    "Answer_Options": "0=NO TO: Telephone call,1=Telephone call",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r3c13",
    "Description": "Q3r3c13: Email communication - Amgen - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had since October 2019.",
    "Answer_Options": "0=NO TO: Email communication,1=Email communication",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r4c13",
    "Description": "Q3r4c13: Conference discussion (e.g. booth visit, meeting) - Amgen - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions yo",
    "Answer_Options": "0=NO TO: Conference discussion (e.g. booth visit, meeting),1=Conference discussion (e.g. booth visit, meeting)",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r5c13",
    "Description": "Q3r5c13: Website / Online portal - Amgen - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had since October 2",
    "Answer_Options": "0=NO TO: Website / Online portal,1=Website / Online portal",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r6c13",
    "Description": "Q3r6c13: Other type of interaction, Specify: - Amgen - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had sin",
    "Answer_Options": "0=NO TO: Other type of interaction, Specify:,1=Other type of interaction, Specify:",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r7c13",
    "Description": "Q3r7c13: Other type of interaction, Specify: - Amgen - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had sin",
    "Answer_Options": "0=NO TO: Other type of interaction, Specify:,1=Other type of interaction, Specify:",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r1c14",
    "Description": "Q3r1c14: In person discussion (i.e. at practice setting) - Seattle Genetics - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL intera",
    "Answer_Options": "0=NO TO: In person discussion (i.e. at practice setting),1=In person discussion (i.e. at practice setting)",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r8c14",
    "Description": "Q3r8c14: Virtual detail / discussion - Seattle Genetics - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had",
    "Answer_Options": "0=NO TO: Virtual detail / discussion,1=Virtual detail / discussion",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r2c14",
    "Description": "Q3r2c14: Telephone call - Seattle Genetics - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had since October",
    "Answer_Options": "0=NO TO: Telephone call,1=Telephone call",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r3c14",
    "Description": "Q3r3c14: Email communication - Seattle Genetics - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had since Oc",
    "Answer_Options": "0=NO TO: Email communication,1=Email communication",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r4c14",
    "Description": "Q3r4c14: Conference discussion (e.g. booth visit, meeting) - Seattle Genetics - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL inte",
    "Answer_Options": "0=NO TO: Conference discussion (e.g. booth visit, meeting),1=Conference discussion (e.g. booth visit, meeting)",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r5c14",
    "Description": "Q3r5c14: Website / Online portal - Seattle Genetics - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had sinc",
    "Answer_Options": "0=NO TO: Website / Online portal,1=Website / Online portal",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r6c14",
    "Description": "Q3r6c14: Other type of interaction, Specify: - Seattle Genetics - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you",
    "Answer_Options": "0=NO TO: Other type of interaction, Specify:,1=Other type of interaction, Specify:",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r7c14",
    "Description": "Q3r7c14: Other type of interaction, Specify: - Seattle Genetics - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you",
    "Answer_Options": "0=NO TO: Other type of interaction, Specify:,1=Other type of interaction, Specify:",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r1c15",
    "Description": "Q3r1c15: In person discussion (i.e. at practice setting) - GSK - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’",
    "Answer_Options": "0=NO TO: In person discussion (i.e. at practice setting),1=In person discussion (i.e. at practice setting)",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r8c15",
    "Description": "Q3r8c15: Virtual detail / discussion - GSK - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had since October",
    "Answer_Options": "0=NO TO: Virtual detail / discussion,1=Virtual detail / discussion",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r2c15",
    "Description": "Q3r2c15: Telephone call - GSK - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had since October 2019.",
    "Answer_Options": "0=NO TO: Telephone call,1=Telephone call",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r3c15",
    "Description": "Q3r3c15: Email communication - GSK - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had since October 2019.",
    "Answer_Options": "0=NO TO: Email communication,1=Email communication",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r4c15",
    "Description": "Q3r4c15: Conference discussion (e.g. booth visit, meeting) - GSK - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you",
    "Answer_Options": "0=NO TO: Conference discussion (e.g. booth visit, meeting),1=Conference discussion (e.g. booth visit, meeting)",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r5c15",
    "Description": "Q3r5c15: Website / Online portal - GSK - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had since October 201",
    "Answer_Options": "0=NO TO: Website / Online portal,1=Website / Online portal",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r6c15",
    "Description": "Q3r6c15: Other type of interaction, Specify: - GSK - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had since",
    "Answer_Options": "0=NO TO: Other type of interaction, Specify:,1=Other type of interaction, Specify:",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r7c15",
    "Description": "Q3r7c15: Other type of interaction, Specify: - GSK - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had since",
    "Answer_Options": "0=NO TO: Other type of interaction, Specify:,1=Other type of interaction, Specify:",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r1c16",
    "Description": "Q3r1c16: In person discussion (i.e. at practice setting) - AstraZeneca - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interaction",
    "Answer_Options": "0=NO TO: In person discussion (i.e. at practice setting),1=In person discussion (i.e. at practice setting)",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r8c16",
    "Description": "Q3r8c16: Virtual detail / discussion - AstraZeneca - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had since",
    "Answer_Options": "0=NO TO: Virtual detail / discussion,1=Virtual detail / discussion",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r2c16",
    "Description": "Q3r2c16: Telephone call - AstraZeneca - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had since October 2019",
    "Answer_Options": "0=NO TO: Telephone call,1=Telephone call",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r3c16",
    "Description": "Q3r3c16: Email communication - AstraZeneca - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had since October",
    "Answer_Options": "0=NO TO: Email communication,1=Email communication",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r4c16",
    "Description": "Q3r4c16: Conference discussion (e.g. booth visit, meeting) - AstraZeneca - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interacti",
    "Answer_Options": "0=NO TO: Conference discussion (e.g. booth visit, meeting),1=Conference discussion (e.g. booth visit, meeting)",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r5c16",
    "Description": "Q3r5c16: Website / Online portal - AstraZeneca - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had since Oct",
    "Answer_Options": "0=NO TO: Website / Online portal,1=Website / Online portal",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r6c16",
    "Description": "Q3r6c16: Other type of interaction, Specify: - AstraZeneca - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve h",
    "Answer_Options": "0=NO TO: Other type of interaction, Specify:,1=Other type of interaction, Specify:",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r7c16",
    "Description": "Q3r7c16: Other type of interaction, Specify: - AstraZeneca - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve h",
    "Answer_Options": "0=NO TO: Other type of interaction, Specify:,1=Other type of interaction, Specify:",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r1c17",
    "Description": "Q3r1c17: In person discussion (i.e. at practice setting) - Immunomedics - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactio",
    "Answer_Options": "0=NO TO: In person discussion (i.e. at practice setting),1=In person discussion (i.e. at practice setting)",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r8c17",
    "Description": "Q3r8c17: Virtual detail / discussion - Immunomedics - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had sinc",
    "Answer_Options": "0=NO TO: Virtual detail / discussion,1=Virtual detail / discussion",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r2c17",
    "Description": "Q3r2c17: Telephone call - Immunomedics - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had since October 201",
    "Answer_Options": "0=NO TO: Telephone call,1=Telephone call",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r3c17",
    "Description": "Q3r3c17: Email communication - Immunomedics - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had since Octobe",
    "Answer_Options": "0=NO TO: Email communication,1=Email communication",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r4c17",
    "Description": "Q3r4c17: Conference discussion (e.g. booth visit, meeting) - Immunomedics - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interact",
    "Answer_Options": "0=NO TO: Conference discussion (e.g. booth visit, meeting),1=Conference discussion (e.g. booth visit, meeting)",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r5c17",
    "Description": "Q3r5c17: Website / Online portal - Immunomedics - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had since Oc",
    "Answer_Options": "0=NO TO: Website / Online portal,1=Website / Online portal",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r6c17",
    "Description": "Q3r6c17: Other type of interaction, Specify: - Immunomedics - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve",
    "Answer_Options": "0=NO TO: Other type of interaction, Specify:,1=Other type of interaction, Specify:",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r7c17",
    "Description": "Q3r7c17: Other type of interaction, Specify: - Immunomedics - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve",
    "Answer_Options": "0=NO TO: Other type of interaction, Specify:,1=Other type of interaction, Specify:",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r6oe",
    "Description": "Q3r6oe: Other type of interaction, Specify: - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had since Octobe",
    "Answer_Options": "NA",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3r7oe",
    "Description": "Q3r7oe: Other type of interaction, Specify: - For each of these companies, please indicate all the types of interactions you have had with them related to their oncology drugs in the past 6 months.Please consider ALL interactions you’ve had since Octobe",
    "Answer_Options": "NA",
    "ParentQuestion": "Q3"
  },
  {
    "Column": "Q3ar1c1",
    "Description": "Q3ar1c1: Product sales representative - Astellas - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncology drugs in the past 6 months.",
    "Answer_Options": "0=NO TO: Product sales representative,1=Product sales representative",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar2c1",
    "Description": "Q3ar2c1: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state) - Astellas - For each of these companies, to the best of your ability, please indicate all the types of personnel you have inter",
    "Answer_Options": "0=NO TO: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease st,1=Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar8c1",
    "Description": "Q3ar8c1: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but are NOT involved in day-to-day product sales) - Astellas - For each of these companies, to the best of your ability, please ind",
    "Answer_Options": "0=NO TO: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issue,1=Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but a",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar9c1",
    "Description": "Q3ar9c1: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement) - Astellas - For each of these companies, to the best of your ability, please indicate all the types of personnel you have inter",
    "Answer_Options": "0=NO TO: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursem,1=Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar3c1",
    "Description": "Q3ar3c1: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.) - Astellas - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interact",
    "Answer_Options": "0=NO TO: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.,1=Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar7c1",
    "Description": "Q3ar7c1: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor) - Astellas - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncology d",
    "Answer_Options": "0=NO TO: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor),1=Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar4c1",
    "Description": "Q3ar4c1: Other type of person (Specify): - Astellas - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncology drugs in the past 6 months.",
    "Answer_Options": "0=NO TO: Other type of person (Specify):,1=Other type of person (Specify):",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar5c1",
    "Description": "Q3ar5c1: Other type of person (Specify): - Astellas - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncology drugs in the past 6 months.",
    "Answer_Options": "0=NO TO: Other type of person (Specify):,1=Other type of person (Specify):",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar1c2",
    "Description": "Q3ar1c2: Product sales representative - Merck - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncology drugs in the past 6 months.",
    "Answer_Options": "0=NO TO: Product sales representative,1=Product sales representative",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar2c2",
    "Description": "Q3ar2c2: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state) - Merck - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interact",
    "Answer_Options": "0=NO TO: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease st,1=Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar8c2",
    "Description": "Q3ar8c2: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but are NOT involved in day-to-day product sales) - Merck - For each of these companies, to the best of your ability, please indica",
    "Answer_Options": "0=NO TO: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issue,1=Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but a",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar9c2",
    "Description": "Q3ar9c2: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement) - Merck - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interact",
    "Answer_Options": "0=NO TO: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursem,1=Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar3c2",
    "Description": "Q3ar3c2: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.) - Merck - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted",
    "Answer_Options": "0=NO TO: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.,1=Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar7c2",
    "Description": "Q3ar7c2: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor) - Merck - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncology drug",
    "Answer_Options": "0=NO TO: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor),1=Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar4c2",
    "Description": "Q3ar4c2: Other type of person (Specify): - Merck - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncology drugs in the past 6 months.",
    "Answer_Options": "0=NO TO: Other type of person (Specify):,1=Other type of person (Specify):",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar5c2",
    "Description": "Q3ar5c2: Other type of person (Specify): - Merck - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncology drugs in the past 6 months.",
    "Answer_Options": "0=NO TO: Other type of person (Specify):,1=Other type of person (Specify):",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar1c3",
    "Description": "Q3ar1c3: Product sales representative - Bristol-Myers Squibb (BMS) - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncology drugs in the past 6 months.",
    "Answer_Options": "0=NO TO: Product sales representative,1=Product sales representative",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar2c3",
    "Description": "Q3ar2c3: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state) - Bristol-Myers Squibb (BMS) - For each of these companies, to the best of your ability, please indicate all the types of person",
    "Answer_Options": "0=NO TO: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease st,1=Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar8c3",
    "Description": "Q3ar8c3: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but are NOT involved in day-to-day product sales) - Bristol-Myers Squibb (BMS) - For each of these companies, to the best of your a",
    "Answer_Options": "0=NO TO: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issue,1=Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but a",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar9c3",
    "Description": "Q3ar9c3: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement) - Bristol-Myers Squibb (BMS) - For each of these companies, to the best of your ability, please indicate all the types of person",
    "Answer_Options": "0=NO TO: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursem,1=Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar3c3",
    "Description": "Q3ar3c3: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.) - Bristol-Myers Squibb (BMS) - For each of these companies, to the best of your ability, please indicate all the types of personnel",
    "Answer_Options": "0=NO TO: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.,1=Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar7c3",
    "Description": "Q3ar7c3: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor) - Bristol-Myers Squibb (BMS) - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related t",
    "Answer_Options": "0=NO TO: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor),1=Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar4c3",
    "Description": "Q3ar4c3: Other type of person (Specify): - Bristol-Myers Squibb (BMS) - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncology drugs in the past 6 months.",
    "Answer_Options": "0=NO TO: Other type of person (Specify):,1=Other type of person (Specify):",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar5c3",
    "Description": "Q3ar5c3: Other type of person (Specify): - Bristol-Myers Squibb (BMS) - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncology drugs in the past 6 months.",
    "Answer_Options": "0=NO TO: Other type of person (Specify):,1=Other type of person (Specify):",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar1c4",
    "Description": "Q3ar1c4: Product sales representative - Genentech / Roche - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncology drugs in the past 6 months.",
    "Answer_Options": "0=NO TO: Product sales representative,1=Product sales representative",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar2c4",
    "Description": "Q3ar2c4: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state) - Genentech / Roche - For each of these companies, to the best of your ability, please indicate all the types of personnel you h",
    "Answer_Options": "0=NO TO: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease st,1=Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar8c4",
    "Description": "Q3ar8c4: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but are NOT involved in day-to-day product sales) - Genentech / Roche - For each of these companies, to the best of your ability, p",
    "Answer_Options": "0=NO TO: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issue,1=Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but a",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar9c4",
    "Description": "Q3ar9c4: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement) - Genentech / Roche - For each of these companies, to the best of your ability, please indicate all the types of personnel you h",
    "Answer_Options": "0=NO TO: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursem,1=Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar3c4",
    "Description": "Q3ar3c4: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.) - Genentech / Roche - For each of these companies, to the best of your ability, please indicate all the types of personnel you have",
    "Answer_Options": "0=NO TO: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.,1=Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar7c4",
    "Description": "Q3ar7c4: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor) - Genentech / Roche - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their o",
    "Answer_Options": "0=NO TO: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor),1=Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar4c4",
    "Description": "Q3ar4c4: Other type of person (Specify): - Genentech / Roche - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncology drugs in the past 6 months.",
    "Answer_Options": "0=NO TO: Other type of person (Specify):,1=Other type of person (Specify):",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar5c4",
    "Description": "Q3ar5c4: Other type of person (Specify): - Genentech / Roche - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncology drugs in the past 6 months.",
    "Answer_Options": "0=NO TO: Other type of person (Specify):,1=Other type of person (Specify):",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar1c5",
    "Description": "Q3ar1c5: Product sales representative - Pfizer - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncology drugs in the past 6 months.",
    "Answer_Options": "0=NO TO: Product sales representative,1=Product sales representative",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar2c5",
    "Description": "Q3ar2c5: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state) - Pfizer - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interac",
    "Answer_Options": "0=NO TO: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease st,1=Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar8c5",
    "Description": "Q3ar8c5: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but are NOT involved in day-to-day product sales) - Pfizer - For each of these companies, to the best of your ability, please indic",
    "Answer_Options": "0=NO TO: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issue,1=Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but a",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar9c5",
    "Description": "Q3ar9c5: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement) - Pfizer - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interac",
    "Answer_Options": "0=NO TO: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursem,1=Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar3c5",
    "Description": "Q3ar3c5: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.) - Pfizer - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted",
    "Answer_Options": "0=NO TO: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.,1=Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar7c5",
    "Description": "Q3ar7c5: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor) - Pfizer - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncology dru",
    "Answer_Options": "0=NO TO: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor),1=Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar4c5",
    "Description": "Q3ar4c5: Other type of person (Specify): - Pfizer - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncology drugs in the past 6 months.",
    "Answer_Options": "0=NO TO: Other type of person (Specify):,1=Other type of person (Specify):",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar5c5",
    "Description": "Q3ar5c5: Other type of person (Specify): - Pfizer - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncology drugs in the past 6 months.",
    "Answer_Options": "0=NO TO: Other type of person (Specify):,1=Other type of person (Specify):",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar1c6",
    "Description": "Q3ar1c6: Product sales representative - Janssen / Johnson & Johnson - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncology drugs in the past 6 months.",
    "Answer_Options": "0=NO TO: Product sales representative,1=Product sales representative",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar2c6",
    "Description": "Q3ar2c6: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state) - Janssen / Johnson & Johnson - For each of these companies, to the best of your ability, please indicate all the types of perso",
    "Answer_Options": "0=NO TO: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease st,1=Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar8c6",
    "Description": "Q3ar8c6: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but are NOT involved in day-to-day product sales) - Janssen / Johnson & Johnson - For each of these companies, to the best of your",
    "Answer_Options": "0=NO TO: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issue,1=Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but a",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar9c6",
    "Description": "Q3ar9c6: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement) - Janssen / Johnson & Johnson - For each of these companies, to the best of your ability, please indicate all the types of perso",
    "Answer_Options": "0=NO TO: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursem,1=Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar3c6",
    "Description": "Q3ar3c6: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.) - Janssen / Johnson & Johnson - For each of these companies, to the best of your ability, please indicate all the types of personne",
    "Answer_Options": "0=NO TO: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.,1=Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar7c6",
    "Description": "Q3ar7c6: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor) - Janssen / Johnson & Johnson - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related",
    "Answer_Options": "0=NO TO: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor),1=Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar4c6",
    "Description": "Q3ar4c6: Other type of person (Specify): - Janssen / Johnson & Johnson - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncology drugs in the past 6 months.",
    "Answer_Options": "0=NO TO: Other type of person (Specify):,1=Other type of person (Specify):",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar5c6",
    "Description": "Q3ar5c6: Other type of person (Specify): - Janssen / Johnson & Johnson - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncology drugs in the past 6 months.",
    "Answer_Options": "0=NO TO: Other type of person (Specify):,1=Other type of person (Specify):",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar1c7",
    "Description": "Q3ar1c7: Product sales representative - Bayer - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncology drugs in the past 6 months.",
    "Answer_Options": "0=NO TO: Product sales representative,1=Product sales representative",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar2c7",
    "Description": "Q3ar2c7: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state) - Bayer - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interact",
    "Answer_Options": "0=NO TO: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease st,1=Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar8c7",
    "Description": "Q3ar8c7: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but are NOT involved in day-to-day product sales) - Bayer - For each of these companies, to the best of your ability, please indica",
    "Answer_Options": "0=NO TO: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issue,1=Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but a",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar9c7",
    "Description": "Q3ar9c7: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement) - Bayer - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interact",
    "Answer_Options": "0=NO TO: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursem,1=Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar3c7",
    "Description": "Q3ar3c7: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.) - Bayer - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted",
    "Answer_Options": "0=NO TO: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.,1=Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar7c7",
    "Description": "Q3ar7c7: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor) - Bayer - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncology drug",
    "Answer_Options": "0=NO TO: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor),1=Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar4c7",
    "Description": "Q3ar4c7: Other type of person (Specify): - Bayer - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncology drugs in the past 6 months.",
    "Answer_Options": "0=NO TO: Other type of person (Specify):,1=Other type of person (Specify):",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar5c7",
    "Description": "Q3ar5c7: Other type of person (Specify): - Bayer - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncology drugs in the past 6 months.",
    "Answer_Options": "0=NO TO: Other type of person (Specify):,1=Other type of person (Specify):",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar1c8",
    "Description": "Q3ar1c8: Product sales representative - Abbvie - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncology drugs in the past 6 months.",
    "Answer_Options": "0=NO TO: Product sales representative,1=Product sales representative",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar2c8",
    "Description": "Q3ar2c8: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state) - Abbvie - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interac",
    "Answer_Options": "0=NO TO: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease st,1=Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar8c8",
    "Description": "Q3ar8c8: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but are NOT involved in day-to-day product sales) - Abbvie - For each of these companies, to the best of your ability, please indic",
    "Answer_Options": "0=NO TO: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issue,1=Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but a",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar9c8",
    "Description": "Q3ar9c8: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement) - Abbvie - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interac",
    "Answer_Options": "0=NO TO: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursem,1=Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar3c8",
    "Description": "Q3ar3c8: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.) - Abbvie - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted",
    "Answer_Options": "0=NO TO: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.,1=Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar7c8",
    "Description": "Q3ar7c8: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor) - Abbvie - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncology dru",
    "Answer_Options": "0=NO TO: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor),1=Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar4c8",
    "Description": "Q3ar4c8: Other type of person (Specify): - Abbvie - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncology drugs in the past 6 months.",
    "Answer_Options": "0=NO TO: Other type of person (Specify):,1=Other type of person (Specify):",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar5c8",
    "Description": "Q3ar5c8: Other type of person (Specify): - Abbvie - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncology drugs in the past 6 months.",
    "Answer_Options": "0=NO TO: Other type of person (Specify):,1=Other type of person (Specify):",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar1c9",
    "Description": "Q3ar1c9: Product sales representative - Sanofi - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncology drugs in the past 6 months.",
    "Answer_Options": "0=NO TO: Product sales representative,1=Product sales representative",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar2c9",
    "Description": "Q3ar2c9: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state) - Sanofi - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interac",
    "Answer_Options": "0=NO TO: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease st,1=Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar8c9",
    "Description": "Q3ar8c9: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but are NOT involved in day-to-day product sales) - Sanofi - For each of these companies, to the best of your ability, please indic",
    "Answer_Options": "0=NO TO: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issue,1=Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but a",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar9c9",
    "Description": "Q3ar9c9: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement) - Sanofi - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interac",
    "Answer_Options": "0=NO TO: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursem,1=Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar3c9",
    "Description": "Q3ar3c9: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.) - Sanofi - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted",
    "Answer_Options": "0=NO TO: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.,1=Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar7c9",
    "Description": "Q3ar7c9: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor) - Sanofi - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncology dru",
    "Answer_Options": "0=NO TO: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor),1=Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar4c9",
    "Description": "Q3ar4c9: Other type of person (Specify): - Sanofi - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncology drugs in the past 6 months.",
    "Answer_Options": "0=NO TO: Other type of person (Specify):,1=Other type of person (Specify):",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar5c9",
    "Description": "Q3ar5c9: Other type of person (Specify): - Sanofi - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncology drugs in the past 6 months.",
    "Answer_Options": "0=NO TO: Other type of person (Specify):,1=Other type of person (Specify):",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar1c10",
    "Description": "Q3ar1c10: Product sales representative - Lilly - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncology drugs in the past 6 months.",
    "Answer_Options": "0=NO TO: Product sales representative,1=Product sales representative",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar2c10",
    "Description": "Q3ar2c10: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state) - Lilly - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interac",
    "Answer_Options": "0=NO TO: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease st,1=Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar8c10",
    "Description": "Q3ar8c10: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but are NOT involved in day-to-day product sales) - Lilly - For each of these companies, to the best of your ability, please indic",
    "Answer_Options": "0=NO TO: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issue,1=Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but a",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar9c10",
    "Description": "Q3ar9c10: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement) - Lilly - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interac",
    "Answer_Options": "0=NO TO: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursem,1=Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar3c10",
    "Description": "Q3ar3c10: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.) - Lilly - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted",
    "Answer_Options": "0=NO TO: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.,1=Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar7c10",
    "Description": "Q3ar7c10: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor) - Lilly - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncology dru",
    "Answer_Options": "0=NO TO: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor),1=Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar4c10",
    "Description": "Q3ar4c10: Other type of person (Specify): - Lilly - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncology drugs in the past 6 months.",
    "Answer_Options": "0=NO TO: Other type of person (Specify):,1=Other type of person (Specify):",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar5c10",
    "Description": "Q3ar5c10: Other type of person (Specify): - Lilly - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncology drugs in the past 6 months.",
    "Answer_Options": "0=NO TO: Other type of person (Specify):,1=Other type of person (Specify):",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar1c11",
    "Description": "Q3ar1c11: Product sales representative - Novartis - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncology drugs in the past 6 months.",
    "Answer_Options": "0=NO TO: Product sales representative,1=Product sales representative",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar2c11",
    "Description": "Q3ar2c11: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state) - Novartis - For each of these companies, to the best of your ability, please indicate all the types of personnel you have inte",
    "Answer_Options": "0=NO TO: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease st,1=Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar8c11",
    "Description": "Q3ar8c11: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but are NOT involved in day-to-day product sales) - Novartis - For each of these companies, to the best of your ability, please in",
    "Answer_Options": "0=NO TO: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issue,1=Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but a",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar9c11",
    "Description": "Q3ar9c11: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement) - Novartis - For each of these companies, to the best of your ability, please indicate all the types of personnel you have inte",
    "Answer_Options": "0=NO TO: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursem,1=Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar3c11",
    "Description": "Q3ar3c11: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.) - Novartis - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interac",
    "Answer_Options": "0=NO TO: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.,1=Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar7c11",
    "Description": "Q3ar7c11: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor) - Novartis - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncology",
    "Answer_Options": "0=NO TO: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor),1=Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar4c11",
    "Description": "Q3ar4c11: Other type of person (Specify): - Novartis - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncology drugs in the past 6 months.",
    "Answer_Options": "0=NO TO: Other type of person (Specify):,1=Other type of person (Specify):",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar5c11",
    "Description": "Q3ar5c11: Other type of person (Specify): - Novartis - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncology drugs in the past 6 months.",
    "Answer_Options": "0=NO TO: Other type of person (Specify):,1=Other type of person (Specify):",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar1c12",
    "Description": "Q3ar1c12: Product sales representative - Daiichi-Sankyo - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncology drugs in the past 6 months.",
    "Answer_Options": "0=NO TO: Product sales representative,1=Product sales representative",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar2c12",
    "Description": "Q3ar2c12: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state) - Daiichi-Sankyo - For each of these companies, to the best of your ability, please indicate all the types of personnel you hav",
    "Answer_Options": "0=NO TO: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease st,1=Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar8c12",
    "Description": "Q3ar8c12: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but are NOT involved in day-to-day product sales) - Daiichi-Sankyo - For each of these companies, to the best of your ability, ple",
    "Answer_Options": "0=NO TO: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issue,1=Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but a",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar9c12",
    "Description": "Q3ar9c12: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement) - Daiichi-Sankyo - For each of these companies, to the best of your ability, please indicate all the types of personnel you hav",
    "Answer_Options": "0=NO TO: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursem,1=Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar3c12",
    "Description": "Q3ar3c12: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.) - Daiichi-Sankyo - For each of these companies, to the best of your ability, please indicate all the types of personnel you have i",
    "Answer_Options": "0=NO TO: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.,1=Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar7c12",
    "Description": "Q3ar7c12: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor) - Daiichi-Sankyo - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their onc",
    "Answer_Options": "0=NO TO: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor),1=Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar4c12",
    "Description": "Q3ar4c12: Other type of person (Specify): - Daiichi-Sankyo - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncology drugs in the past 6 months.",
    "Answer_Options": "0=NO TO: Other type of person (Specify):,1=Other type of person (Specify):",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar5c12",
    "Description": "Q3ar5c12: Other type of person (Specify): - Daiichi-Sankyo - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncology drugs in the past 6 months.",
    "Answer_Options": "0=NO TO: Other type of person (Specify):,1=Other type of person (Specify):",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar1c13",
    "Description": "Q3ar1c13: Product sales representative - Amgen - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncology drugs in the past 6 months.",
    "Answer_Options": "0=NO TO: Product sales representative,1=Product sales representative",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar2c13",
    "Description": "Q3ar2c13: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state) - Amgen - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interac",
    "Answer_Options": "0=NO TO: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease st,1=Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar8c13",
    "Description": "Q3ar8c13: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but are NOT involved in day-to-day product sales) - Amgen - For each of these companies, to the best of your ability, please indic",
    "Answer_Options": "0=NO TO: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issue,1=Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but a",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar9c13",
    "Description": "Q3ar9c13: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement) - Amgen - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interac",
    "Answer_Options": "0=NO TO: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursem,1=Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar3c13",
    "Description": "Q3ar3c13: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.) - Amgen - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted",
    "Answer_Options": "0=NO TO: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.,1=Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar7c13",
    "Description": "Q3ar7c13: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor) - Amgen - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncology dru",
    "Answer_Options": "0=NO TO: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor),1=Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar4c13",
    "Description": "Q3ar4c13: Other type of person (Specify): - Amgen - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncology drugs in the past 6 months.",
    "Answer_Options": "0=NO TO: Other type of person (Specify):,1=Other type of person (Specify):",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar5c13",
    "Description": "Q3ar5c13: Other type of person (Specify): - Amgen - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncology drugs in the past 6 months.",
    "Answer_Options": "0=NO TO: Other type of person (Specify):,1=Other type of person (Specify):",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar1c14",
    "Description": "Q3ar1c14: Product sales representative - Seattle Genetics - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncology drugs in the past 6 months.",
    "Answer_Options": "0=NO TO: Product sales representative,1=Product sales representative",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar2c14",
    "Description": "Q3ar2c14: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state) - Seattle Genetics - For each of these companies, to the best of your ability, please indicate all the types of personnel you h",
    "Answer_Options": "0=NO TO: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease st,1=Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar8c14",
    "Description": "Q3ar8c14: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but are NOT involved in day-to-day product sales) - Seattle Genetics - For each of these companies, to the best of your ability, p",
    "Answer_Options": "0=NO TO: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issue,1=Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but a",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar9c14",
    "Description": "Q3ar9c14: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement) - Seattle Genetics - For each of these companies, to the best of your ability, please indicate all the types of personnel you h",
    "Answer_Options": "0=NO TO: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursem,1=Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar3c14",
    "Description": "Q3ar3c14: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.) - Seattle Genetics - For each of these companies, to the best of your ability, please indicate all the types of personnel you have",
    "Answer_Options": "0=NO TO: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.,1=Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar7c14",
    "Description": "Q3ar7c14: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor) - Seattle Genetics - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their o",
    "Answer_Options": "0=NO TO: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor),1=Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar4c14",
    "Description": "Q3ar4c14: Other type of person (Specify): - Seattle Genetics - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncology drugs in the past 6 months.",
    "Answer_Options": "0=NO TO: Other type of person (Specify):,1=Other type of person (Specify):",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar5c14",
    "Description": "Q3ar5c14: Other type of person (Specify): - Seattle Genetics - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncology drugs in the past 6 months.",
    "Answer_Options": "0=NO TO: Other type of person (Specify):,1=Other type of person (Specify):",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar1c15",
    "Description": "Q3ar1c15: Product sales representative - GSK - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncology drugs in the past 6 months.",
    "Answer_Options": "0=NO TO: Product sales representative,1=Product sales representative",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar2c15",
    "Description": "Q3ar2c15: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state) - GSK - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacte",
    "Answer_Options": "0=NO TO: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease st,1=Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar8c15",
    "Description": "Q3ar8c15: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but are NOT involved in day-to-day product sales) - GSK - For each of these companies, to the best of your ability, please indicat",
    "Answer_Options": "0=NO TO: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issue,1=Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but a",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar9c15",
    "Description": "Q3ar9c15: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement) - GSK - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacte",
    "Answer_Options": "0=NO TO: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursem,1=Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar3c15",
    "Description": "Q3ar3c15: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.) - GSK - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted w",
    "Answer_Options": "0=NO TO: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.,1=Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar7c15",
    "Description": "Q3ar7c15: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor) - GSK - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncology drugs",
    "Answer_Options": "0=NO TO: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor),1=Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar4c15",
    "Description": "Q3ar4c15: Other type of person (Specify): - GSK - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncology drugs in the past 6 months.",
    "Answer_Options": "0=NO TO: Other type of person (Specify):,1=Other type of person (Specify):",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar5c15",
    "Description": "Q3ar5c15: Other type of person (Specify): - GSK - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncology drugs in the past 6 months.",
    "Answer_Options": "0=NO TO: Other type of person (Specify):,1=Other type of person (Specify):",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar1c16",
    "Description": "Q3ar1c16: Product sales representative - AstraZeneca - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncology drugs in the past 6 months.",
    "Answer_Options": "0=NO TO: Product sales representative,1=Product sales representative",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar2c16",
    "Description": "Q3ar2c16: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state) - AstraZeneca - For each of these companies, to the best of your ability, please indicate all the types of personnel you have i",
    "Answer_Options": "0=NO TO: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease st,1=Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar8c16",
    "Description": "Q3ar8c16: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but are NOT involved in day-to-day product sales) - AstraZeneca - For each of these companies, to the best of your ability, please",
    "Answer_Options": "0=NO TO: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issue,1=Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but a",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar9c16",
    "Description": "Q3ar9c16: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement) - AstraZeneca - For each of these companies, to the best of your ability, please indicate all the types of personnel you have i",
    "Answer_Options": "0=NO TO: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursem,1=Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar3c16",
    "Description": "Q3ar3c16: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.) - AstraZeneca - For each of these companies, to the best of your ability, please indicate all the types of personnel you have inte",
    "Answer_Options": "0=NO TO: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.,1=Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar7c16",
    "Description": "Q3ar7c16: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor) - AstraZeneca - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncolo",
    "Answer_Options": "0=NO TO: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor),1=Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar4c16",
    "Description": "Q3ar4c16: Other type of person (Specify): - AstraZeneca - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncology drugs in the past 6 months.",
    "Answer_Options": "0=NO TO: Other type of person (Specify):,1=Other type of person (Specify):",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar5c16",
    "Description": "Q3ar5c16: Other type of person (Specify): - AstraZeneca - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncology drugs in the past 6 months.",
    "Answer_Options": "0=NO TO: Other type of person (Specify):,1=Other type of person (Specify):",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar1c17",
    "Description": "Q3ar1c17: Product sales representative - Immunomedics - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncology drugs in the past 6 months.",
    "Answer_Options": "0=NO TO: Product sales representative,1=Product sales representative",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar2c17",
    "Description": "Q3ar2c17: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state) - Immunomedics - For each of these companies, to the best of your ability, please indicate all the types of personnel you have",
    "Answer_Options": "0=NO TO: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease st,1=Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar8c17",
    "Description": "Q3ar8c17: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but are NOT involved in day-to-day product sales) - Immunomedics - For each of these companies, to the best of your ability, pleas",
    "Answer_Options": "0=NO TO: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issue,1=Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but a",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar9c17",
    "Description": "Q3ar9c17: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement) - Immunomedics - For each of these companies, to the best of your ability, please indicate all the types of personnel you have",
    "Answer_Options": "0=NO TO: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursem,1=Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar3c17",
    "Description": "Q3ar3c17: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.) - Immunomedics - For each of these companies, to the best of your ability, please indicate all the types of personnel you have int",
    "Answer_Options": "0=NO TO: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.,1=Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar7c17",
    "Description": "Q3ar7c17: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor) - Immunomedics - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncol",
    "Answer_Options": "0=NO TO: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor),1=Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor)",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar4c17",
    "Description": "Q3ar4c17: Other type of person (Specify): - Immunomedics - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncology drugs in the past 6 months.",
    "Answer_Options": "0=NO TO: Other type of person (Specify):,1=Other type of person (Specify):",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar5c17",
    "Description": "Q3ar5c17: Other type of person (Specify): - Immunomedics - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncology drugs in the past 6 months.",
    "Answer_Options": "0=NO TO: Other type of person (Specify):,1=Other type of person (Specify):",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar4oe",
    "Description": "Q3ar4oe: Other type of person (Specify): - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncology drugs in the past 6 months.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q3ar5oe",
    "Description": "Q3ar5oe: Other type of person (Specify): - For each of these companies, to the best of your ability, please indicate all the types of personnel you have interacted with related to their oncology drugs in the past 6 months.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q3a"
  },
  {
    "Column": "Q4r1",
    "Description": "Q4r1: Is a company I trust - Please think about the pharmaceutical companies that you interact with most often for oncology drugs.Please indicate how important the following attributes are for a pharmaceutical company with oncology drugs. It is important",
    "Answer_Options": "1=Not at all Important1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Important10",
    "ParentQuestion": "Q4"
  },
  {
    "Column": "Q4r2",
    "Description": "Q4r2: Puts patients first - Please think about the pharmaceutical companies that you interact with most often for oncology drugs.Please indicate how important the following attributes are for a pharmaceutical company with oncology drugs. It is important t",
    "Answer_Options": "1=Not at all Important1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Important10",
    "ParentQuestion": "Q4"
  },
  {
    "Column": "Q4r3",
    "Description": "Q4r3: Enables timely and reliable access to medications - Please think about the pharmaceutical companies that you interact with most often for oncology drugs.Please indicate how important the following attributes are for a pharmaceutical company with onc",
    "Answer_Options": "1=Not at all Important1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Important10",
    "ParentQuestion": "Q4"
  },
  {
    "Column": "Q4r4",
    "Description": "Q4r4: Provides a breadth of financial assistance options for patients - Please think about the pharmaceutical companies that you interact with most often for oncology drugs.Please indicate how important the following attributes are for a pharmaceutical co",
    "Answer_Options": "1=Not at all Important1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Important10",
    "ParentQuestion": "Q4"
  },
  {
    "Column": "Q4r5",
    "Description": "Q4r5: Invests in oncology clinical trials/pipeline - Please think about the pharmaceutical companies that you interact with most often for oncology drugs.Please indicate how important the following attributes are for a pharmaceutical company with oncology",
    "Answer_Options": "1=Not at all Important1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Important10",
    "ParentQuestion": "Q4"
  },
  {
    "Column": "Q4r6",
    "Description": "Q4r6: [pipe: Q4_row6] - Please think about the pharmaceutical companies that you interact with most often for oncology drugs.Please indicate how important the following attributes are for a pharmaceutical company with oncology drugs. It is important that",
    "Answer_Options": "1=Not at all Important1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Important10",
    "ParentQuestion": "Q4"
  },
  {
    "Column": "Q4r7",
    "Description": "Q4r7: Provides support services (non-financial) to patients and caregivers - Please think about the pharmaceutical companies that you interact with most often for oncology drugs.Please indicate how important the following attributes are for a pharmaceutic",
    "Answer_Options": "1=Not at all Important1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Important10",
    "ParentQuestion": "Q4"
  },
  {
    "Column": "Q4r8",
    "Description": "Q4r8: Has a useful and easy-to-use website - Please think about the pharmaceutical companies that you interact with most often for oncology drugs.Please indicate how important the following attributes are for a pharmaceutical company with oncology drugs.",
    "Answer_Options": "1=Not at all Important1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Important10",
    "ParentQuestion": "Q4"
  },
  {
    "Column": "Q4a",
    "Description": "Q4a: And, of the attributes below, please indicate which ONE is most important to you when interacting with companies regarding their oncology drugs.",
    "Answer_Options": "1=Is a company I trust,2=Puts patients first,3=Enables timely and reliable access to medications,4=Provides a breadth of financial assistance options for patients,5=Invests in oncology clinical trials/pipeline,6=[pipe: Q4_row6],7=Provides support services (non-financial) to patients and caregivers,8=Has a useful and easy-to-use website"
  },
  {
    "Column": "Q5r1",
    "Description": "Q5r1: Have a presence in my practice/frequent office visits - Now please think about the personnel from these companies (including reps, account managers, MSLs, access/ reimbursement managers, and any other people that you might interact with). Please ind",
    "Answer_Options": "1=Not at all Important1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Important10",
    "ParentQuestion": "Q5"
  },
  {
    "Column": "Q5r2",
    "Description": "Q5r2: Demonstrate in-depth knowledge of treatment area - Now please think about the personnel from these companies (including reps, account managers, MSLs, access/ reimbursement managers, and any other people that you might interact with). Please indicate",
    "Answer_Options": "1=Not at all Important1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Important10",
    "ParentQuestion": "Q5"
  },
  {
    "Column": "Q5r3",
    "Description": "Q5r3: Deliver quality product information and education - Now please think about the personnel from these companies (including reps, account managers, MSLs, access/ reimbursement managers, and any other people that you might interact with). Please indicat",
    "Answer_Options": "1=Not at all Important1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Important10",
    "ParentQuestion": "Q5"
  },
  {
    "Column": "Q5r4",
    "Description": "Q5r4: Understand my practice - Now please think about the personnel from these companies (including reps, account managers, MSLs, access/ reimbursement managers, and any other people that you might interact with). Please indicate how important the followi",
    "Answer_Options": "1=Not at all Important1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Important10",
    "ParentQuestion": "Q5"
  },
  {
    "Column": "Q5r5",
    "Description": "Q5r5: Are responsive and dependable - Now please think about the personnel from these companies (including reps, account managers, MSLs, access/ reimbursement managers, and any other people that you might interact with). Please indicate how important the",
    "Answer_Options": "1=Not at all Important1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Important10",
    "ParentQuestion": "Q5"
  },
  {
    "Column": "Q5r6",
    "Description": "Q5r6: Are collaborative - Now please think about the personnel from these companies (including reps, account managers, MSLs, access/ reimbursement managers, and any other people that you might interact with). Please indicate how important the following at",
    "Answer_Options": "1=Not at all Important1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Important10",
    "ParentQuestion": "Q5"
  },
  {
    "Column": "Q5r7",
    "Description": "Q5r7: Are helpful in securing timely product access - Now please think about the personnel from these companies (including reps, account managers, MSLs, access/ reimbursement managers, and any other people that you might interact with). Please indicate ho",
    "Answer_Options": "1=Not at all Important1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Important10",
    "ParentQuestion": "Q5"
  },
  {
    "Column": "Q5r8",
    "Description": "Q5r8: Make my job easier by reducing hassles to prescribing - Now please think about the personnel from these companies (including reps, account managers, MSLs, access/ reimbursement managers, and any other people that you might interact with). Please ind",
    "Answer_Options": "1=Not at all Important1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Important10",
    "ParentQuestion": "Q5"
  },
  {
    "Column": "Q5r9",
    "Description": "Q5r9: Give me confidence I am making the right treatment decisions - Now please think about the personnel from these companies (including reps, account managers, MSLs, access/ reimbursement managers, and any other people that you might interact with). Ple",
    "Answer_Options": "1=Not at all Important1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Important10",
    "ParentQuestion": "Q5"
  },
  {
    "Column": "Q5r10",
    "Description": "Q5r10: Are warm and friendly - Now please think about the personnel from these companies (including reps, account managers, MSLs, access/ reimbursement managers, and any other people that you might interact with). Please indicate how important the followi",
    "Answer_Options": "1=Not at all Important1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Important10",
    "ParentQuestion": "Q5"
  },
  {
    "Column": "Q5a",
    "Description": "Q5a: And, of the attributes below, please indicate which ONE is most important to you when interacting with the people from a pharmaceutical company regarding their oncology drugs.",
    "Answer_Options": "1=Have a presence in my practice/frequent office visits,2=Demonstrate in-depth knowledge of treatment area,3=Deliver quality product information and education,4=Understand my practice,5=Are responsive and dependable,6=Are collaborative,7=Are helpful in securing timely product access,8=Make my job easier by reducing hassles to prescribing,9=Give me confidence I am making the right treatment decisions,10=Are warm and friendly"
  },
  {
    "Column": "Q6_Lr1r1",
    "Description": "Q6_Lr1r1: Is a company I trust - Now please rate your experience with Astellas on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr1"
  },
  {
    "Column": "Q6_Lr1r2",
    "Description": "Q6_Lr1r2: Puts patients first - Now please rate your experience with Astellas on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr1"
  },
  {
    "Column": "Q6_Lr1r3",
    "Description": "Q6_Lr1r3: Enables timely and reliable access to medications - Now please rate your experience with Astellas on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr1"
  },
  {
    "Column": "Q6_Lr1r4",
    "Description": "Q6_Lr1r4: Provides a variety of financial assistance options for patients - Now please rate your experience with Astellas on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr1"
  },
  {
    "Column": "Q6_Lr1r5",
    "Description": "Q6_Lr1r5: Invests in oncology clinical trials/pipeline - Now please rate your experience with Astellas on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr1"
  },
  {
    "Column": "Q6_Lr1r6",
    "Description": "Q6_Lr1r6: [pipe: Q4_row6] - Now please rate your experience with Astellas on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr1"
  },
  {
    "Column": "Q6_Lr1r7",
    "Description": "Q6_Lr1r7: Provides support services (non-financial) to patients and caregivers - Now please rate your experience with Astellas on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr1"
  },
  {
    "Column": "Q6_Lr1r8",
    "Description": "Q6_Lr1r8: Has a useful and easy-to-use website - Now please rate your experience with Astellas on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr1"
  },
  {
    "Column": "Q6_Lr2r1",
    "Description": "Q6_Lr2r1: Is a company I trust - Now please rate your experience with Merck on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr2"
  },
  {
    "Column": "Q6_Lr2r2",
    "Description": "Q6_Lr2r2: Puts patients first - Now please rate your experience with Merck on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr2"
  },
  {
    "Column": "Q6_Lr2r3",
    "Description": "Q6_Lr2r3: Enables timely and reliable access to medications - Now please rate your experience with Merck on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr2"
  },
  {
    "Column": "Q6_Lr2r4",
    "Description": "Q6_Lr2r4: Provides a variety of financial assistance options for patients - Now please rate your experience with Merck on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr2"
  },
  {
    "Column": "Q6_Lr2r5",
    "Description": "Q6_Lr2r5: Invests in oncology clinical trials/pipeline - Now please rate your experience with Merck on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr2"
  },
  {
    "Column": "Q6_Lr2r6",
    "Description": "Q6_Lr2r6: [pipe: Q4_row6] - Now please rate your experience with Merck on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr2"
  },
  {
    "Column": "Q6_Lr2r7",
    "Description": "Q6_Lr2r7: Provides support services (non-financial) to patients and caregivers - Now please rate your experience with Merck on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr2"
  },
  {
    "Column": "Q6_Lr2r8",
    "Description": "Q6_Lr2r8: Has a useful and easy-to-use website - Now please rate your experience with Merck on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr2"
  },
  {
    "Column": "Q6_Lr3r1",
    "Description": "Q6_Lr3r1: Is a company I trust - Now please rate your experience with Bristol-Myers Squibb (BMS) on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr3"
  },
  {
    "Column": "Q6_Lr3r2",
    "Description": "Q6_Lr3r2: Puts patients first - Now please rate your experience with Bristol-Myers Squibb (BMS) on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr3"
  },
  {
    "Column": "Q6_Lr3r3",
    "Description": "Q6_Lr3r3: Enables timely and reliable access to medications - Now please rate your experience with Bristol-Myers Squibb (BMS) on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr3"
  },
  {
    "Column": "Q6_Lr3r4",
    "Description": "Q6_Lr3r4: Provides a variety of financial assistance options for patients - Now please rate your experience with Bristol-Myers Squibb (BMS) on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr3"
  },
  {
    "Column": "Q6_Lr3r5",
    "Description": "Q6_Lr3r5: Invests in oncology clinical trials/pipeline - Now please rate your experience with Bristol-Myers Squibb (BMS) on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr3"
  },
  {
    "Column": "Q6_Lr3r6",
    "Description": "Q6_Lr3r6: [pipe: Q4_row6] - Now please rate your experience with Bristol-Myers Squibb (BMS) on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr3"
  },
  {
    "Column": "Q6_Lr3r7",
    "Description": "Q6_Lr3r7: Provides support services (non-financial) to patients and caregivers - Now please rate your experience with Bristol-Myers Squibb (BMS) on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr3"
  },
  {
    "Column": "Q6_Lr3r8",
    "Description": "Q6_Lr3r8: Has a useful and easy-to-use website - Now please rate your experience with Bristol-Myers Squibb (BMS) on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr3"
  },
  {
    "Column": "Q6_Lr4r1",
    "Description": "Q6_Lr4r1: Is a company I trust - Now please rate your experience with Genentech / Roche on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr4"
  },
  {
    "Column": "Q6_Lr4r2",
    "Description": "Q6_Lr4r2: Puts patients first - Now please rate your experience with Genentech / Roche on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr4"
  },
  {
    "Column": "Q6_Lr4r3",
    "Description": "Q6_Lr4r3: Enables timely and reliable access to medications - Now please rate your experience with Genentech / Roche on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr4"
  },
  {
    "Column": "Q6_Lr4r4",
    "Description": "Q6_Lr4r4: Provides a variety of financial assistance options for patients - Now please rate your experience with Genentech / Roche on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr4"
  },
  {
    "Column": "Q6_Lr4r5",
    "Description": "Q6_Lr4r5: Invests in oncology clinical trials/pipeline - Now please rate your experience with Genentech / Roche on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr4"
  },
  {
    "Column": "Q6_Lr4r6",
    "Description": "Q6_Lr4r6: [pipe: Q4_row6] - Now please rate your experience with Genentech / Roche on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr4"
  },
  {
    "Column": "Q6_Lr4r7",
    "Description": "Q6_Lr4r7: Provides support services (non-financial) to patients and caregivers - Now please rate your experience with Genentech / Roche on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr4"
  },
  {
    "Column": "Q6_Lr4r8",
    "Description": "Q6_Lr4r8: Has a useful and easy-to-use website - Now please rate your experience with Genentech / Roche on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr4"
  },
  {
    "Column": "Q6_Lr5r1",
    "Description": "Q6_Lr5r1: Is a company I trust - Now please rate your experience with Pfizer on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr5"
  },
  {
    "Column": "Q6_Lr5r2",
    "Description": "Q6_Lr5r2: Puts patients first - Now please rate your experience with Pfizer on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr5"
  },
  {
    "Column": "Q6_Lr5r3",
    "Description": "Q6_Lr5r3: Enables timely and reliable access to medications - Now please rate your experience with Pfizer on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr5"
  },
  {
    "Column": "Q6_Lr5r4",
    "Description": "Q6_Lr5r4: Provides a variety of financial assistance options for patients - Now please rate your experience with Pfizer on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr5"
  },
  {
    "Column": "Q6_Lr5r5",
    "Description": "Q6_Lr5r5: Invests in oncology clinical trials/pipeline - Now please rate your experience with Pfizer on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr5"
  },
  {
    "Column": "Q6_Lr5r6",
    "Description": "Q6_Lr5r6: [pipe: Q4_row6] - Now please rate your experience with Pfizer on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr5"
  },
  {
    "Column": "Q6_Lr5r7",
    "Description": "Q6_Lr5r7: Provides support services (non-financial) to patients and caregivers - Now please rate your experience with Pfizer on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr5"
  },
  {
    "Column": "Q6_Lr5r8",
    "Description": "Q6_Lr5r8: Has a useful and easy-to-use website - Now please rate your experience with Pfizer on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr5"
  },
  {
    "Column": "Q6_Lr6r1",
    "Description": "Q6_Lr6r1: Is a company I trust - Now please rate your experience with Janssen / Johnson & Johnson on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr6"
  },
  {
    "Column": "Q6_Lr6r2",
    "Description": "Q6_Lr6r2: Puts patients first - Now please rate your experience with Janssen / Johnson & Johnson on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr6"
  },
  {
    "Column": "Q6_Lr6r3",
    "Description": "Q6_Lr6r3: Enables timely and reliable access to medications - Now please rate your experience with Janssen / Johnson & Johnson on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr6"
  },
  {
    "Column": "Q6_Lr6r4",
    "Description": "Q6_Lr6r4: Provides a variety of financial assistance options for patients - Now please rate your experience with Janssen / Johnson & Johnson on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr6"
  },
  {
    "Column": "Q6_Lr6r5",
    "Description": "Q6_Lr6r5: Invests in oncology clinical trials/pipeline - Now please rate your experience with Janssen / Johnson & Johnson on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr6"
  },
  {
    "Column": "Q6_Lr6r6",
    "Description": "Q6_Lr6r6: [pipe: Q4_row6] - Now please rate your experience with Janssen / Johnson & Johnson on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr6"
  },
  {
    "Column": "Q6_Lr6r7",
    "Description": "Q6_Lr6r7: Provides support services (non-financial) to patients and caregivers - Now please rate your experience with Janssen / Johnson & Johnson on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr6"
  },
  {
    "Column": "Q6_Lr6r8",
    "Description": "Q6_Lr6r8: Has a useful and easy-to-use website - Now please rate your experience with Janssen / Johnson & Johnson on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr6"
  },
  {
    "Column": "Q6_Lr7r1",
    "Description": "Q6_Lr7r1: Is a company I trust - Now please rate your experience with Bayer on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr7"
  },
  {
    "Column": "Q6_Lr7r2",
    "Description": "Q6_Lr7r2: Puts patients first - Now please rate your experience with Bayer on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr7"
  },
  {
    "Column": "Q6_Lr7r3",
    "Description": "Q6_Lr7r3: Enables timely and reliable access to medications - Now please rate your experience with Bayer on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr7"
  },
  {
    "Column": "Q6_Lr7r4",
    "Description": "Q6_Lr7r4: Provides a variety of financial assistance options for patients - Now please rate your experience with Bayer on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr7"
  },
  {
    "Column": "Q6_Lr7r5",
    "Description": "Q6_Lr7r5: Invests in oncology clinical trials/pipeline - Now please rate your experience with Bayer on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr7"
  },
  {
    "Column": "Q6_Lr7r6",
    "Description": "Q6_Lr7r6: [pipe: Q4_row6] - Now please rate your experience with Bayer on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr7"
  },
  {
    "Column": "Q6_Lr7r7",
    "Description": "Q6_Lr7r7: Provides support services (non-financial) to patients and caregivers - Now please rate your experience with Bayer on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr7"
  },
  {
    "Column": "Q6_Lr7r8",
    "Description": "Q6_Lr7r8: Has a useful and easy-to-use website - Now please rate your experience with Bayer on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr7"
  },
  {
    "Column": "Q6_Lr8r1",
    "Description": "Q6_Lr8r1: Is a company I trust - Now please rate your experience with Abbvie on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr8"
  },
  {
    "Column": "Q6_Lr8r2",
    "Description": "Q6_Lr8r2: Puts patients first - Now please rate your experience with Abbvie on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr8"
  },
  {
    "Column": "Q6_Lr8r3",
    "Description": "Q6_Lr8r3: Enables timely and reliable access to medications - Now please rate your experience with Abbvie on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr8"
  },
  {
    "Column": "Q6_Lr8r4",
    "Description": "Q6_Lr8r4: Provides a variety of financial assistance options for patients - Now please rate your experience with Abbvie on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr8"
  },
  {
    "Column": "Q6_Lr8r5",
    "Description": "Q6_Lr8r5: Invests in oncology clinical trials/pipeline - Now please rate your experience with Abbvie on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr8"
  },
  {
    "Column": "Q6_Lr8r6",
    "Description": "Q6_Lr8r6: [pipe: Q4_row6] - Now please rate your experience with Abbvie on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr8"
  },
  {
    "Column": "Q6_Lr8r7",
    "Description": "Q6_Lr8r7: Provides support services (non-financial) to patients and caregivers - Now please rate your experience with Abbvie on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr8"
  },
  {
    "Column": "Q6_Lr8r8",
    "Description": "Q6_Lr8r8: Has a useful and easy-to-use website - Now please rate your experience with Abbvie on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr8"
  },
  {
    "Column": "Q6_Lr9r1",
    "Description": "Q6_Lr9r1: Is a company I trust - Now please rate your experience with Sanofi on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr9"
  },
  {
    "Column": "Q6_Lr9r2",
    "Description": "Q6_Lr9r2: Puts patients first - Now please rate your experience with Sanofi on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr9"
  },
  {
    "Column": "Q6_Lr9r3",
    "Description": "Q6_Lr9r3: Enables timely and reliable access to medications - Now please rate your experience with Sanofi on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr9"
  },
  {
    "Column": "Q6_Lr9r4",
    "Description": "Q6_Lr9r4: Provides a variety of financial assistance options for patients - Now please rate your experience with Sanofi on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr9"
  },
  {
    "Column": "Q6_Lr9r5",
    "Description": "Q6_Lr9r5: Invests in oncology clinical trials/pipeline - Now please rate your experience with Sanofi on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr9"
  },
  {
    "Column": "Q6_Lr9r6",
    "Description": "Q6_Lr9r6: [pipe: Q4_row6] - Now please rate your experience with Sanofi on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr9"
  },
  {
    "Column": "Q6_Lr9r7",
    "Description": "Q6_Lr9r7: Provides support services (non-financial) to patients and caregivers - Now please rate your experience with Sanofi on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr9"
  },
  {
    "Column": "Q6_Lr9r8",
    "Description": "Q6_Lr9r8: Has a useful and easy-to-use website - Now please rate your experience with Sanofi on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr9"
  },
  {
    "Column": "Q6_Lr10r1",
    "Description": "Q6_Lr10r1: Is a company I trust - Now please rate your experience with Lilly on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr10"
  },
  {
    "Column": "Q6_Lr10r2",
    "Description": "Q6_Lr10r2: Puts patients first - Now please rate your experience with Lilly on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr10"
  },
  {
    "Column": "Q6_Lr10r3",
    "Description": "Q6_Lr10r3: Enables timely and reliable access to medications - Now please rate your experience with Lilly on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr10"
  },
  {
    "Column": "Q6_Lr10r4",
    "Description": "Q6_Lr10r4: Provides a variety of financial assistance options for patients - Now please rate your experience with Lilly on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr10"
  },
  {
    "Column": "Q6_Lr10r5",
    "Description": "Q6_Lr10r5: Invests in oncology clinical trials/pipeline - Now please rate your experience with Lilly on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr10"
  },
  {
    "Column": "Q6_Lr10r6",
    "Description": "Q6_Lr10r6: [pipe: Q4_row6] - Now please rate your experience with Lilly on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr10"
  },
  {
    "Column": "Q6_Lr10r7",
    "Description": "Q6_Lr10r7: Provides support services (non-financial) to patients and caregivers - Now please rate your experience with Lilly on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr10"
  },
  {
    "Column": "Q6_Lr10r8",
    "Description": "Q6_Lr10r8: Has a useful and easy-to-use website - Now please rate your experience with Lilly on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr10"
  },
  {
    "Column": "Q6_Lr11r1",
    "Description": "Q6_Lr11r1: Is a company I trust - Now please rate your experience with Novartis on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr11"
  },
  {
    "Column": "Q6_Lr11r2",
    "Description": "Q6_Lr11r2: Puts patients first - Now please rate your experience with Novartis on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr11"
  },
  {
    "Column": "Q6_Lr11r3",
    "Description": "Q6_Lr11r3: Enables timely and reliable access to medications - Now please rate your experience with Novartis on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr11"
  },
  {
    "Column": "Q6_Lr11r4",
    "Description": "Q6_Lr11r4: Provides a variety of financial assistance options for patients - Now please rate your experience with Novartis on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr11"
  },
  {
    "Column": "Q6_Lr11r5",
    "Description": "Q6_Lr11r5: Invests in oncology clinical trials/pipeline - Now please rate your experience with Novartis on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr11"
  },
  {
    "Column": "Q6_Lr11r6",
    "Description": "Q6_Lr11r6: [pipe: Q4_row6] - Now please rate your experience with Novartis on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr11"
  },
  {
    "Column": "Q6_Lr11r7",
    "Description": "Q6_Lr11r7: Provides support services (non-financial) to patients and caregivers - Now please rate your experience with Novartis on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr11"
  },
  {
    "Column": "Q6_Lr11r8",
    "Description": "Q6_Lr11r8: Has a useful and easy-to-use website - Now please rate your experience with Novartis on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr11"
  },
  {
    "Column": "Q6_Lr12r1",
    "Description": "Q6_Lr12r1: Is a company I trust - Now please rate your experience with Daiichi-Sankyo on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr12"
  },
  {
    "Column": "Q6_Lr12r2",
    "Description": "Q6_Lr12r2: Puts patients first - Now please rate your experience with Daiichi-Sankyo on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr12"
  },
  {
    "Column": "Q6_Lr12r3",
    "Description": "Q6_Lr12r3: Enables timely and reliable access to medications - Now please rate your experience with Daiichi-Sankyo on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr12"
  },
  {
    "Column": "Q6_Lr12r4",
    "Description": "Q6_Lr12r4: Provides a variety of financial assistance options for patients - Now please rate your experience with Daiichi-Sankyo on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr12"
  },
  {
    "Column": "Q6_Lr12r5",
    "Description": "Q6_Lr12r5: Invests in oncology clinical trials/pipeline - Now please rate your experience with Daiichi-Sankyo on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr12"
  },
  {
    "Column": "Q6_Lr12r6",
    "Description": "Q6_Lr12r6: [pipe: Q4_row6] - Now please rate your experience with Daiichi-Sankyo on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr12"
  },
  {
    "Column": "Q6_Lr12r7",
    "Description": "Q6_Lr12r7: Provides support services (non-financial) to patients and caregivers - Now please rate your experience with Daiichi-Sankyo on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr12"
  },
  {
    "Column": "Q6_Lr12r8",
    "Description": "Q6_Lr12r8: Has a useful and easy-to-use website - Now please rate your experience with Daiichi-Sankyo on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr12"
  },
  {
    "Column": "Q6_Lr13r1",
    "Description": "Q6_Lr13r1: Is a company I trust - Now please rate your experience with Amgen on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr13"
  },
  {
    "Column": "Q6_Lr13r2",
    "Description": "Q6_Lr13r2: Puts patients first - Now please rate your experience with Amgen on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr13"
  },
  {
    "Column": "Q6_Lr13r3",
    "Description": "Q6_Lr13r3: Enables timely and reliable access to medications - Now please rate your experience with Amgen on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr13"
  },
  {
    "Column": "Q6_Lr13r4",
    "Description": "Q6_Lr13r4: Provides a variety of financial assistance options for patients - Now please rate your experience with Amgen on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr13"
  },
  {
    "Column": "Q6_Lr13r5",
    "Description": "Q6_Lr13r5: Invests in oncology clinical trials/pipeline - Now please rate your experience with Amgen on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr13"
  },
  {
    "Column": "Q6_Lr13r6",
    "Description": "Q6_Lr13r6: [pipe: Q4_row6] - Now please rate your experience with Amgen on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr13"
  },
  {
    "Column": "Q6_Lr13r7",
    "Description": "Q6_Lr13r7: Provides support services (non-financial) to patients and caregivers - Now please rate your experience with Amgen on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr13"
  },
  {
    "Column": "Q6_Lr13r8",
    "Description": "Q6_Lr13r8: Has a useful and easy-to-use website - Now please rate your experience with Amgen on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr13"
  },
  {
    "Column": "Q6_Lr14r1",
    "Description": "Q6_Lr14r1: Is a company I trust - Now please rate your experience with Seattle Genetics on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr14"
  },
  {
    "Column": "Q6_Lr14r2",
    "Description": "Q6_Lr14r2: Puts patients first - Now please rate your experience with Seattle Genetics on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr14"
  },
  {
    "Column": "Q6_Lr14r3",
    "Description": "Q6_Lr14r3: Enables timely and reliable access to medications - Now please rate your experience with Seattle Genetics on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr14"
  },
  {
    "Column": "Q6_Lr14r4",
    "Description": "Q6_Lr14r4: Provides a variety of financial assistance options for patients - Now please rate your experience with Seattle Genetics on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr14"
  },
  {
    "Column": "Q6_Lr14r5",
    "Description": "Q6_Lr14r5: Invests in oncology clinical trials/pipeline - Now please rate your experience with Seattle Genetics on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr14"
  },
  {
    "Column": "Q6_Lr14r6",
    "Description": "Q6_Lr14r6: [pipe: Q4_row6] - Now please rate your experience with Seattle Genetics on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr14"
  },
  {
    "Column": "Q6_Lr14r7",
    "Description": "Q6_Lr14r7: Provides support services (non-financial) to patients and caregivers - Now please rate your experience with Seattle Genetics on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr14"
  },
  {
    "Column": "Q6_Lr14r8",
    "Description": "Q6_Lr14r8: Has a useful and easy-to-use website - Now please rate your experience with Seattle Genetics on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr14"
  },
  {
    "Column": "Q6_Lr15r1",
    "Description": "Q6_Lr15r1: Is a company I trust - Now please rate your experience with GSK on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr15"
  },
  {
    "Column": "Q6_Lr15r2",
    "Description": "Q6_Lr15r2: Puts patients first - Now please rate your experience with GSK on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr15"
  },
  {
    "Column": "Q6_Lr15r3",
    "Description": "Q6_Lr15r3: Enables timely and reliable access to medications - Now please rate your experience with GSK on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr15"
  },
  {
    "Column": "Q6_Lr15r4",
    "Description": "Q6_Lr15r4: Provides a variety of financial assistance options for patients - Now please rate your experience with GSK on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr15"
  },
  {
    "Column": "Q6_Lr15r5",
    "Description": "Q6_Lr15r5: Invests in oncology clinical trials/pipeline - Now please rate your experience with GSK on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr15"
  },
  {
    "Column": "Q6_Lr15r6",
    "Description": "Q6_Lr15r6: [pipe: Q4_row6] - Now please rate your experience with GSK on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr15"
  },
  {
    "Column": "Q6_Lr15r7",
    "Description": "Q6_Lr15r7: Provides support services (non-financial) to patients and caregivers - Now please rate your experience with GSK on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr15"
  },
  {
    "Column": "Q6_Lr15r8",
    "Description": "Q6_Lr15r8: Has a useful and easy-to-use website - Now please rate your experience with GSK on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr15"
  },
  {
    "Column": "Q6_Lr16r1",
    "Description": "Q6_Lr16r1: Is a company I trust - Now please rate your experience with AstraZeneca on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr16"
  },
  {
    "Column": "Q6_Lr16r2",
    "Description": "Q6_Lr16r2: Puts patients first - Now please rate your experience with AstraZeneca on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr16"
  },
  {
    "Column": "Q6_Lr16r3",
    "Description": "Q6_Lr16r3: Enables timely and reliable access to medications - Now please rate your experience with AstraZeneca on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr16"
  },
  {
    "Column": "Q6_Lr16r4",
    "Description": "Q6_Lr16r4: Provides a variety of financial assistance options for patients - Now please rate your experience with AstraZeneca on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr16"
  },
  {
    "Column": "Q6_Lr16r5",
    "Description": "Q6_Lr16r5: Invests in oncology clinical trials/pipeline - Now please rate your experience with AstraZeneca on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr16"
  },
  {
    "Column": "Q6_Lr16r6",
    "Description": "Q6_Lr16r6: [pipe: Q4_row6] - Now please rate your experience with AstraZeneca on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr16"
  },
  {
    "Column": "Q6_Lr16r7",
    "Description": "Q6_Lr16r7: Provides support services (non-financial) to patients and caregivers - Now please rate your experience with AstraZeneca on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr16"
  },
  {
    "Column": "Q6_Lr16r8",
    "Description": "Q6_Lr16r8: Has a useful and easy-to-use website - Now please rate your experience with AstraZeneca on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr16"
  },
  {
    "Column": "Q6_Lr17r1",
    "Description": "Q6_Lr17r1: Is a company I trust - Now please rate your experience with Immunomedics on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr17"
  },
  {
    "Column": "Q6_Lr17r2",
    "Description": "Q6_Lr17r2: Puts patients first - Now please rate your experience with Immunomedics on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr17"
  },
  {
    "Column": "Q6_Lr17r3",
    "Description": "Q6_Lr17r3: Enables timely and reliable access to medications - Now please rate your experience with Immunomedics on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr17"
  },
  {
    "Column": "Q6_Lr17r4",
    "Description": "Q6_Lr17r4: Provides a variety of financial assistance options for patients - Now please rate your experience with Immunomedics on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr17"
  },
  {
    "Column": "Q6_Lr17r5",
    "Description": "Q6_Lr17r5: Invests in oncology clinical trials/pipeline - Now please rate your experience with Immunomedics on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr17"
  },
  {
    "Column": "Q6_Lr17r6",
    "Description": "Q6_Lr17r6: [pipe: Q4_row6] - Now please rate your experience with Immunomedics on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr17"
  },
  {
    "Column": "Q6_Lr17r7",
    "Description": "Q6_Lr17r7: Provides support services (non-financial) to patients and caregivers - Now please rate your experience with Immunomedics on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr17"
  },
  {
    "Column": "Q6_Lr17r8",
    "Description": "Q6_Lr17r8: Has a useful and easy-to-use website - Now please rate your experience with Immunomedics on the following attributes.",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q6_Lr17"
  },
  {
    "Column": "Q7_Lr1r1",
    "Description": "Q7_Lr1r1: Have a presence in my practice/frequent office visits - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Astellas on the following attributes. These can be reps, account managers",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr1"
  },
  {
    "Column": "Q7_Lr1r2",
    "Description": "Q7_Lr1r2: Demonstrate in-depth knowledge of treatment area - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Astellas on the following attributes. These can be reps, account managers, MSL",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr1"
  },
  {
    "Column": "Q7_Lr1r3",
    "Description": "Q7_Lr1r3: Deliver quality product information and education - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Astellas on the following attributes. These can be reps, account managers, MS",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr1"
  },
  {
    "Column": "Q7_Lr1r4",
    "Description": "Q7_Lr1r4: Understand my practice - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Astellas on the following attributes. These can be reps, account managers, MSLs, access/ reimbursement m",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr1"
  },
  {
    "Column": "Q7_Lr1r5",
    "Description": "Q7_Lr1r5: Are responsive and dependable - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Astellas on the following attributes. These can be reps, account managers, MSLs, access/ reimburs",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr1"
  },
  {
    "Column": "Q7_Lr1r6",
    "Description": "Q7_Lr1r6: Are collaborative - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Astellas on the following attributes. These can be reps, account managers, MSLs, access/ reimbursement manage",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr1"
  },
  {
    "Column": "Q7_Lr1r7",
    "Description": "Q7_Lr1r7: Are helpful in securing timely product access - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Astellas on the following attributes. These can be reps, account managers, MSLs,",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr1"
  },
  {
    "Column": "Q7_Lr1r8",
    "Description": "Q7_Lr1r8: Make my job easier by reducing hassles to prescribing - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Astellas on the following attributes. These can be reps, account managers",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr1"
  },
  {
    "Column": "Q7_Lr1r9",
    "Description": "Q7_Lr1r9: Give me confidence I am making the right treatment decisions - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Astellas on the following attributes. These can be reps, account m",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr1"
  },
  {
    "Column": "Q7_Lr1r10",
    "Description": "Q7_Lr1r10: Are warm and friendly - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Astellas on the following attributes. These can be reps, account managers, MSLs, access/ reimbursement m",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr1"
  },
  {
    "Column": "Q7_Lr2r1",
    "Description": "Q7_Lr2r1: Have a presence in my practice/frequent office visits - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Merck on the following attributes. These can be reps, account managers, M",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr2"
  },
  {
    "Column": "Q7_Lr2r2",
    "Description": "Q7_Lr2r2: Demonstrate in-depth knowledge of treatment area - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Merck on the following attributes. These can be reps, account managers, MSLs,",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr2"
  },
  {
    "Column": "Q7_Lr2r3",
    "Description": "Q7_Lr2r3: Deliver quality product information and education - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Merck on the following attributes. These can be reps, account managers, MSLs,",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr2"
  },
  {
    "Column": "Q7_Lr2r4",
    "Description": "Q7_Lr2r4: Understand my practice - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Merck on the following attributes. These can be reps, account managers, MSLs, access/ reimbursement mana",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr2"
  },
  {
    "Column": "Q7_Lr2r5",
    "Description": "Q7_Lr2r5: Are responsive and dependable - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Merck on the following attributes. These can be reps, account managers, MSLs, access/ reimburseme",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr2"
  },
  {
    "Column": "Q7_Lr2r6",
    "Description": "Q7_Lr2r6: Are collaborative - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Merck on the following attributes. These can be reps, account managers, MSLs, access/ reimbursement managers,",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr2"
  },
  {
    "Column": "Q7_Lr2r7",
    "Description": "Q7_Lr2r7: Are helpful in securing timely product access - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Merck on the following attributes. These can be reps, account managers, MSLs, acc",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr2"
  },
  {
    "Column": "Q7_Lr2r8",
    "Description": "Q7_Lr2r8: Make my job easier by reducing hassles to prescribing - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Merck on the following attributes. These can be reps, account managers, M",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr2"
  },
  {
    "Column": "Q7_Lr2r9",
    "Description": "Q7_Lr2r9: Give me confidence I am making the right treatment decisions - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Merck on the following attributes. These can be reps, account mana",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr2"
  },
  {
    "Column": "Q7_Lr2r10",
    "Description": "Q7_Lr2r10: Are warm and friendly - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Merck on the following attributes. These can be reps, account managers, MSLs, access/ reimbursement mana",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr2"
  },
  {
    "Column": "Q7_Lr3r1",
    "Description": "Q7_Lr3r1: Have a presence in my practice/frequent office visits - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Bristol-Myers Squibb (BMS) on the following attributes. These can be reps",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr3"
  },
  {
    "Column": "Q7_Lr3r2",
    "Description": "Q7_Lr3r2: Demonstrate in-depth knowledge of treatment area - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Bristol-Myers Squibb (BMS) on the following attributes. These can be reps, acc",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr3"
  },
  {
    "Column": "Q7_Lr3r3",
    "Description": "Q7_Lr3r3: Deliver quality product information and education - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Bristol-Myers Squibb (BMS) on the following attributes. These can be reps, ac",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr3"
  },
  {
    "Column": "Q7_Lr3r4",
    "Description": "Q7_Lr3r4: Understand my practice - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Bristol-Myers Squibb (BMS) on the following attributes. These can be reps, account managers, MSLs, acces",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr3"
  },
  {
    "Column": "Q7_Lr3r5",
    "Description": "Q7_Lr3r5: Are responsive and dependable - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Bristol-Myers Squibb (BMS) on the following attributes. These can be reps, account managers, MSLs",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr3"
  },
  {
    "Column": "Q7_Lr3r6",
    "Description": "Q7_Lr3r6: Are collaborative - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Bristol-Myers Squibb (BMS) on the following attributes. These can be reps, account managers, MSLs, access/ re",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr3"
  },
  {
    "Column": "Q7_Lr3r7",
    "Description": "Q7_Lr3r7: Are helpful in securing timely product access - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Bristol-Myers Squibb (BMS) on the following attributes. These can be reps, accoun",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr3"
  },
  {
    "Column": "Q7_Lr3r8",
    "Description": "Q7_Lr3r8: Make my job easier by reducing hassles to prescribing - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Bristol-Myers Squibb (BMS) on the following attributes. These can be reps",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr3"
  },
  {
    "Column": "Q7_Lr3r9",
    "Description": "Q7_Lr3r9: Give me confidence I am making the right treatment decisions - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Bristol-Myers Squibb (BMS) on the following attributes. These can",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr3"
  },
  {
    "Column": "Q7_Lr3r10",
    "Description": "Q7_Lr3r10: Are warm and friendly - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Bristol-Myers Squibb (BMS) on the following attributes. These can be reps, account managers, MSLs, acces",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr3"
  },
  {
    "Column": "Q7_Lr4r1",
    "Description": "Q7_Lr4r1: Have a presence in my practice/frequent office visits - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Genentech / Roche on the following attributes. These can be reps, account",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr4"
  },
  {
    "Column": "Q7_Lr4r2",
    "Description": "Q7_Lr4r2: Demonstrate in-depth knowledge of treatment area - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Genentech / Roche on the following attributes. These can be reps, account mana",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr4"
  },
  {
    "Column": "Q7_Lr4r3",
    "Description": "Q7_Lr4r3: Deliver quality product information and education - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Genentech / Roche on the following attributes. These can be reps, account man",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr4"
  },
  {
    "Column": "Q7_Lr4r4",
    "Description": "Q7_Lr4r4: Understand my practice - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Genentech / Roche on the following attributes. These can be reps, account managers, MSLs, access/ reimbu",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr4"
  },
  {
    "Column": "Q7_Lr4r5",
    "Description": "Q7_Lr4r5: Are responsive and dependable - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Genentech / Roche on the following attributes. These can be reps, account managers, MSLs, access/",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr4"
  },
  {
    "Column": "Q7_Lr4r6",
    "Description": "Q7_Lr4r6: Are collaborative - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Genentech / Roche on the following attributes. These can be reps, account managers, MSLs, access/ reimburseme",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr4"
  },
  {
    "Column": "Q7_Lr4r7",
    "Description": "Q7_Lr4r7: Are helpful in securing timely product access - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Genentech / Roche on the following attributes. These can be reps, account manager",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr4"
  },
  {
    "Column": "Q7_Lr4r8",
    "Description": "Q7_Lr4r8: Make my job easier by reducing hassles to prescribing - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Genentech / Roche on the following attributes. These can be reps, account",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr4"
  },
  {
    "Column": "Q7_Lr4r9",
    "Description": "Q7_Lr4r9: Give me confidence I am making the right treatment decisions - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Genentech / Roche on the following attributes. These can be reps,",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr4"
  },
  {
    "Column": "Q7_Lr4r10",
    "Description": "Q7_Lr4r10: Are warm and friendly - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Genentech / Roche on the following attributes. These can be reps, account managers, MSLs, access/ reimbu",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr4"
  },
  {
    "Column": "Q7_Lr5r1",
    "Description": "Q7_Lr5r1: Have a presence in my practice/frequent office visits - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Pfizer on the following attributes. These can be reps, account managers,",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr5"
  },
  {
    "Column": "Q7_Lr5r2",
    "Description": "Q7_Lr5r2: Demonstrate in-depth knowledge of treatment area - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Pfizer on the following attributes. These can be reps, account managers, MSLs,",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr5"
  },
  {
    "Column": "Q7_Lr5r3",
    "Description": "Q7_Lr5r3: Deliver quality product information and education - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Pfizer on the following attributes. These can be reps, account managers, MSLs",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr5"
  },
  {
    "Column": "Q7_Lr5r4",
    "Description": "Q7_Lr5r4: Understand my practice - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Pfizer on the following attributes. These can be reps, account managers, MSLs, access/ reimbursement man",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr5"
  },
  {
    "Column": "Q7_Lr5r5",
    "Description": "Q7_Lr5r5: Are responsive and dependable - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Pfizer on the following attributes. These can be reps, account managers, MSLs, access/ reimbursem",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr5"
  },
  {
    "Column": "Q7_Lr5r6",
    "Description": "Q7_Lr5r6: Are collaborative - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Pfizer on the following attributes. These can be reps, account managers, MSLs, access/ reimbursement managers",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr5"
  },
  {
    "Column": "Q7_Lr5r7",
    "Description": "Q7_Lr5r7: Are helpful in securing timely product access - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Pfizer on the following attributes. These can be reps, account managers, MSLs, ac",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr5"
  },
  {
    "Column": "Q7_Lr5r8",
    "Description": "Q7_Lr5r8: Make my job easier by reducing hassles to prescribing - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Pfizer on the following attributes. These can be reps, account managers,",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr5"
  },
  {
    "Column": "Q7_Lr5r9",
    "Description": "Q7_Lr5r9: Give me confidence I am making the right treatment decisions - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Pfizer on the following attributes. These can be reps, account man",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr5"
  },
  {
    "Column": "Q7_Lr5r10",
    "Description": "Q7_Lr5r10: Are warm and friendly - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Pfizer on the following attributes. These can be reps, account managers, MSLs, access/ reimbursement man",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr5"
  },
  {
    "Column": "Q7_Lr6r1",
    "Description": "Q7_Lr6r1: Have a presence in my practice/frequent office visits - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Janssen / Johnson & Johnson on the following attributes. These can be rep",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr6"
  },
  {
    "Column": "Q7_Lr6r2",
    "Description": "Q7_Lr6r2: Demonstrate in-depth knowledge of treatment area - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Janssen / Johnson & Johnson on the following attributes. These can be reps, ac",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr6"
  },
  {
    "Column": "Q7_Lr6r3",
    "Description": "Q7_Lr6r3: Deliver quality product information and education - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Janssen / Johnson & Johnson on the following attributes. These can be reps, a",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr6"
  },
  {
    "Column": "Q7_Lr6r4",
    "Description": "Q7_Lr6r4: Understand my practice - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Janssen / Johnson & Johnson on the following attributes. These can be reps, account managers, MSLs, acce",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr6"
  },
  {
    "Column": "Q7_Lr6r5",
    "Description": "Q7_Lr6r5: Are responsive and dependable - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Janssen / Johnson & Johnson on the following attributes. These can be reps, account managers, MSL",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr6"
  },
  {
    "Column": "Q7_Lr6r6",
    "Description": "Q7_Lr6r6: Are collaborative - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Janssen / Johnson & Johnson on the following attributes. These can be reps, account managers, MSLs, access/ r",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr6"
  },
  {
    "Column": "Q7_Lr6r7",
    "Description": "Q7_Lr6r7: Are helpful in securing timely product access - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Janssen / Johnson & Johnson on the following attributes. These can be reps, accou",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr6"
  },
  {
    "Column": "Q7_Lr6r8",
    "Description": "Q7_Lr6r8: Make my job easier by reducing hassles to prescribing - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Janssen / Johnson & Johnson on the following attributes. These can be rep",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr6"
  },
  {
    "Column": "Q7_Lr6r9",
    "Description": "Q7_Lr6r9: Give me confidence I am making the right treatment decisions - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Janssen / Johnson & Johnson on the following attributes. These can",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr6"
  },
  {
    "Column": "Q7_Lr6r10",
    "Description": "Q7_Lr6r10: Are warm and friendly - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Janssen / Johnson & Johnson on the following attributes. These can be reps, account managers, MSLs, acce",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr6"
  },
  {
    "Column": "Q7_Lr7r1",
    "Description": "Q7_Lr7r1: Have a presence in my practice/frequent office visits - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Bayer on the following attributes. These can be reps, account managers, M",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr7"
  },
  {
    "Column": "Q7_Lr7r2",
    "Description": "Q7_Lr7r2: Demonstrate in-depth knowledge of treatment area - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Bayer on the following attributes. These can be reps, account managers, MSLs,",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr7"
  },
  {
    "Column": "Q7_Lr7r3",
    "Description": "Q7_Lr7r3: Deliver quality product information and education - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Bayer on the following attributes. These can be reps, account managers, MSLs,",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr7"
  },
  {
    "Column": "Q7_Lr7r4",
    "Description": "Q7_Lr7r4: Understand my practice - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Bayer on the following attributes. These can be reps, account managers, MSLs, access/ reimbursement mana",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr7"
  },
  {
    "Column": "Q7_Lr7r5",
    "Description": "Q7_Lr7r5: Are responsive and dependable - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Bayer on the following attributes. These can be reps, account managers, MSLs, access/ reimburseme",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr7"
  },
  {
    "Column": "Q7_Lr7r6",
    "Description": "Q7_Lr7r6: Are collaborative - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Bayer on the following attributes. These can be reps, account managers, MSLs, access/ reimbursement managers,",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr7"
  },
  {
    "Column": "Q7_Lr7r7",
    "Description": "Q7_Lr7r7: Are helpful in securing timely product access - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Bayer on the following attributes. These can be reps, account managers, MSLs, acc",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr7"
  },
  {
    "Column": "Q7_Lr7r8",
    "Description": "Q7_Lr7r8: Make my job easier by reducing hassles to prescribing - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Bayer on the following attributes. These can be reps, account managers, M",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr7"
  },
  {
    "Column": "Q7_Lr7r9",
    "Description": "Q7_Lr7r9: Give me confidence I am making the right treatment decisions - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Bayer on the following attributes. These can be reps, account mana",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr7"
  },
  {
    "Column": "Q7_Lr7r10",
    "Description": "Q7_Lr7r10: Are warm and friendly - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Bayer on the following attributes. These can be reps, account managers, MSLs, access/ reimbursement mana",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr7"
  },
  {
    "Column": "Q7_Lr8r1",
    "Description": "Q7_Lr8r1: Have a presence in my practice/frequent office visits - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Abbvie on the following attributes. These can be reps, account managers,",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr8"
  },
  {
    "Column": "Q7_Lr8r2",
    "Description": "Q7_Lr8r2: Demonstrate in-depth knowledge of treatment area - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Abbvie on the following attributes. These can be reps, account managers, MSLs,",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr8"
  },
  {
    "Column": "Q7_Lr8r3",
    "Description": "Q7_Lr8r3: Deliver quality product information and education - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Abbvie on the following attributes. These can be reps, account managers, MSLs",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr8"
  },
  {
    "Column": "Q7_Lr8r4",
    "Description": "Q7_Lr8r4: Understand my practice - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Abbvie on the following attributes. These can be reps, account managers, MSLs, access/ reimbursement man",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr8"
  },
  {
    "Column": "Q7_Lr8r5",
    "Description": "Q7_Lr8r5: Are responsive and dependable - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Abbvie on the following attributes. These can be reps, account managers, MSLs, access/ reimbursem",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr8"
  },
  {
    "Column": "Q7_Lr8r6",
    "Description": "Q7_Lr8r6: Are collaborative - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Abbvie on the following attributes. These can be reps, account managers, MSLs, access/ reimbursement managers",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr8"
  },
  {
    "Column": "Q7_Lr8r7",
    "Description": "Q7_Lr8r7: Are helpful in securing timely product access - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Abbvie on the following attributes. These can be reps, account managers, MSLs, ac",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr8"
  },
  {
    "Column": "Q7_Lr8r8",
    "Description": "Q7_Lr8r8: Make my job easier by reducing hassles to prescribing - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Abbvie on the following attributes. These can be reps, account managers,",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr8"
  },
  {
    "Column": "Q7_Lr8r9",
    "Description": "Q7_Lr8r9: Give me confidence I am making the right treatment decisions - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Abbvie on the following attributes. These can be reps, account man",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr8"
  },
  {
    "Column": "Q7_Lr8r10",
    "Description": "Q7_Lr8r10: Are warm and friendly - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Abbvie on the following attributes. These can be reps, account managers, MSLs, access/ reimbursement man",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr8"
  },
  {
    "Column": "Q7_Lr9r1",
    "Description": "Q7_Lr9r1: Have a presence in my practice/frequent office visits - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Sanofi on the following attributes. These can be reps, account managers,",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr9"
  },
  {
    "Column": "Q7_Lr9r2",
    "Description": "Q7_Lr9r2: Demonstrate in-depth knowledge of treatment area - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Sanofi on the following attributes. These can be reps, account managers, MSLs,",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr9"
  },
  {
    "Column": "Q7_Lr9r3",
    "Description": "Q7_Lr9r3: Deliver quality product information and education - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Sanofi on the following attributes. These can be reps, account managers, MSLs",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr9"
  },
  {
    "Column": "Q7_Lr9r4",
    "Description": "Q7_Lr9r4: Understand my practice - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Sanofi on the following attributes. These can be reps, account managers, MSLs, access/ reimbursement man",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr9"
  },
  {
    "Column": "Q7_Lr9r5",
    "Description": "Q7_Lr9r5: Are responsive and dependable - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Sanofi on the following attributes. These can be reps, account managers, MSLs, access/ reimbursem",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr9"
  },
  {
    "Column": "Q7_Lr9r6",
    "Description": "Q7_Lr9r6: Are collaborative - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Sanofi on the following attributes. These can be reps, account managers, MSLs, access/ reimbursement managers",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr9"
  },
  {
    "Column": "Q7_Lr9r7",
    "Description": "Q7_Lr9r7: Are helpful in securing timely product access - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Sanofi on the following attributes. These can be reps, account managers, MSLs, ac",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr9"
  },
  {
    "Column": "Q7_Lr9r8",
    "Description": "Q7_Lr9r8: Make my job easier by reducing hassles to prescribing - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Sanofi on the following attributes. These can be reps, account managers,",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr9"
  },
  {
    "Column": "Q7_Lr9r9",
    "Description": "Q7_Lr9r9: Give me confidence I am making the right treatment decisions - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Sanofi on the following attributes. These can be reps, account man",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr9"
  },
  {
    "Column": "Q7_Lr9r10",
    "Description": "Q7_Lr9r10: Are warm and friendly - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Sanofi on the following attributes. These can be reps, account managers, MSLs, access/ reimbursement man",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr9"
  },
  {
    "Column": "Q7_Lr10r1",
    "Description": "Q7_Lr10r1: Have a presence in my practice/frequent office visits - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Lilly on the following attributes. These can be reps, account managers,",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr10"
  },
  {
    "Column": "Q7_Lr10r2",
    "Description": "Q7_Lr10r2: Demonstrate in-depth knowledge of treatment area - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Lilly on the following attributes. These can be reps, account managers, MSLs,",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr10"
  },
  {
    "Column": "Q7_Lr10r3",
    "Description": "Q7_Lr10r3: Deliver quality product information and education - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Lilly on the following attributes. These can be reps, account managers, MSLs",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr10"
  },
  {
    "Column": "Q7_Lr10r4",
    "Description": "Q7_Lr10r4: Understand my practice - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Lilly on the following attributes. These can be reps, account managers, MSLs, access/ reimbursement man",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr10"
  },
  {
    "Column": "Q7_Lr10r5",
    "Description": "Q7_Lr10r5: Are responsive and dependable - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Lilly on the following attributes. These can be reps, account managers, MSLs, access/ reimbursem",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr10"
  },
  {
    "Column": "Q7_Lr10r6",
    "Description": "Q7_Lr10r6: Are collaborative - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Lilly on the following attributes. These can be reps, account managers, MSLs, access/ reimbursement managers",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr10"
  },
  {
    "Column": "Q7_Lr10r7",
    "Description": "Q7_Lr10r7: Are helpful in securing timely product access - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Lilly on the following attributes. These can be reps, account managers, MSLs, ac",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr10"
  },
  {
    "Column": "Q7_Lr10r8",
    "Description": "Q7_Lr10r8: Make my job easier by reducing hassles to prescribing - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Lilly on the following attributes. These can be reps, account managers,",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr10"
  },
  {
    "Column": "Q7_Lr10r9",
    "Description": "Q7_Lr10r9: Give me confidence I am making the right treatment decisions - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Lilly on the following attributes. These can be reps, account man",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr10"
  },
  {
    "Column": "Q7_Lr10r10",
    "Description": "Q7_Lr10r10: Are warm and friendly - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Lilly on the following attributes. These can be reps, account managers, MSLs, access/ reimbursement man",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr10"
  },
  {
    "Column": "Q7_Lr11r1",
    "Description": "Q7_Lr11r1: Have a presence in my practice/frequent office visits - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Novartis on the following attributes. These can be reps, account manager",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr11"
  },
  {
    "Column": "Q7_Lr11r2",
    "Description": "Q7_Lr11r2: Demonstrate in-depth knowledge of treatment area - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Novartis on the following attributes. These can be reps, account managers, MS",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr11"
  },
  {
    "Column": "Q7_Lr11r3",
    "Description": "Q7_Lr11r3: Deliver quality product information and education - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Novartis on the following attributes. These can be reps, account managers, M",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr11"
  },
  {
    "Column": "Q7_Lr11r4",
    "Description": "Q7_Lr11r4: Understand my practice - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Novartis on the following attributes. These can be reps, account managers, MSLs, access/ reimbursement",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr11"
  },
  {
    "Column": "Q7_Lr11r5",
    "Description": "Q7_Lr11r5: Are responsive and dependable - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Novartis on the following attributes. These can be reps, account managers, MSLs, access/ reimbur",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr11"
  },
  {
    "Column": "Q7_Lr11r6",
    "Description": "Q7_Lr11r6: Are collaborative - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Novartis on the following attributes. These can be reps, account managers, MSLs, access/ reimbursement manag",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr11"
  },
  {
    "Column": "Q7_Lr11r7",
    "Description": "Q7_Lr11r7: Are helpful in securing timely product access - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Novartis on the following attributes. These can be reps, account managers, MSLs,",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr11"
  },
  {
    "Column": "Q7_Lr11r8",
    "Description": "Q7_Lr11r8: Make my job easier by reducing hassles to prescribing - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Novartis on the following attributes. These can be reps, account manager",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr11"
  },
  {
    "Column": "Q7_Lr11r9",
    "Description": "Q7_Lr11r9: Give me confidence I am making the right treatment decisions - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Novartis on the following attributes. These can be reps, account",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr11"
  },
  {
    "Column": "Q7_Lr11r10",
    "Description": "Q7_Lr11r10: Are warm and friendly - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Novartis on the following attributes. These can be reps, account managers, MSLs, access/ reimbursement",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr11"
  },
  {
    "Column": "Q7_Lr12r1",
    "Description": "Q7_Lr12r1: Have a presence in my practice/frequent office visits - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Daiichi-Sankyo on the following attributes. These can be reps, account m",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr12"
  },
  {
    "Column": "Q7_Lr12r2",
    "Description": "Q7_Lr12r2: Demonstrate in-depth knowledge of treatment area - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Daiichi-Sankyo on the following attributes. These can be reps, account manage",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr12"
  },
  {
    "Column": "Q7_Lr12r3",
    "Description": "Q7_Lr12r3: Deliver quality product information and education - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Daiichi-Sankyo on the following attributes. These can be reps, account manag",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr12"
  },
  {
    "Column": "Q7_Lr12r4",
    "Description": "Q7_Lr12r4: Understand my practice - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Daiichi-Sankyo on the following attributes. These can be reps, account managers, MSLs, access/ reimburs",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr12"
  },
  {
    "Column": "Q7_Lr12r5",
    "Description": "Q7_Lr12r5: Are responsive and dependable - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Daiichi-Sankyo on the following attributes. These can be reps, account managers, MSLs, access/ r",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr12"
  },
  {
    "Column": "Q7_Lr12r6",
    "Description": "Q7_Lr12r6: Are collaborative - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Daiichi-Sankyo on the following attributes. These can be reps, account managers, MSLs, access/ reimbursement",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr12"
  },
  {
    "Column": "Q7_Lr12r7",
    "Description": "Q7_Lr12r7: Are helpful in securing timely product access - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Daiichi-Sankyo on the following attributes. These can be reps, account managers,",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr12"
  },
  {
    "Column": "Q7_Lr12r8",
    "Description": "Q7_Lr12r8: Make my job easier by reducing hassles to prescribing - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Daiichi-Sankyo on the following attributes. These can be reps, account m",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr12"
  },
  {
    "Column": "Q7_Lr12r9",
    "Description": "Q7_Lr12r9: Give me confidence I am making the right treatment decisions - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Daiichi-Sankyo on the following attributes. These can be reps, ac",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr12"
  },
  {
    "Column": "Q7_Lr12r10",
    "Description": "Q7_Lr12r10: Are warm and friendly - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Daiichi-Sankyo on the following attributes. These can be reps, account managers, MSLs, access/ reimburs",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr12"
  },
  {
    "Column": "Q7_Lr13r1",
    "Description": "Q7_Lr13r1: Have a presence in my practice/frequent office visits - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Amgen on the following attributes. These can be reps, account managers,",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr13"
  },
  {
    "Column": "Q7_Lr13r2",
    "Description": "Q7_Lr13r2: Demonstrate in-depth knowledge of treatment area - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Amgen on the following attributes. These can be reps, account managers, MSLs,",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr13"
  },
  {
    "Column": "Q7_Lr13r3",
    "Description": "Q7_Lr13r3: Deliver quality product information and education - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Amgen on the following attributes. These can be reps, account managers, MSLs",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr13"
  },
  {
    "Column": "Q7_Lr13r4",
    "Description": "Q7_Lr13r4: Understand my practice - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Amgen on the following attributes. These can be reps, account managers, MSLs, access/ reimbursement man",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr13"
  },
  {
    "Column": "Q7_Lr13r5",
    "Description": "Q7_Lr13r5: Are responsive and dependable - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Amgen on the following attributes. These can be reps, account managers, MSLs, access/ reimbursem",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr13"
  },
  {
    "Column": "Q7_Lr13r6",
    "Description": "Q7_Lr13r6: Are collaborative - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Amgen on the following attributes. These can be reps, account managers, MSLs, access/ reimbursement managers",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr13"
  },
  {
    "Column": "Q7_Lr13r7",
    "Description": "Q7_Lr13r7: Are helpful in securing timely product access - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Amgen on the following attributes. These can be reps, account managers, MSLs, ac",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr13"
  },
  {
    "Column": "Q7_Lr13r8",
    "Description": "Q7_Lr13r8: Make my job easier by reducing hassles to prescribing - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Amgen on the following attributes. These can be reps, account managers,",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr13"
  },
  {
    "Column": "Q7_Lr13r9",
    "Description": "Q7_Lr13r9: Give me confidence I am making the right treatment decisions - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Amgen on the following attributes. These can be reps, account man",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr13"
  },
  {
    "Column": "Q7_Lr13r10",
    "Description": "Q7_Lr13r10: Are warm and friendly - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Amgen on the following attributes. These can be reps, account managers, MSLs, access/ reimbursement man",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr13"
  },
  {
    "Column": "Q7_Lr14r1",
    "Description": "Q7_Lr14r1: Have a presence in my practice/frequent office visits - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Seattle Genetics on the following attributes. These can be reps, account",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr14"
  },
  {
    "Column": "Q7_Lr14r2",
    "Description": "Q7_Lr14r2: Demonstrate in-depth knowledge of treatment area - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Seattle Genetics on the following attributes. These can be reps, account mana",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr14"
  },
  {
    "Column": "Q7_Lr14r3",
    "Description": "Q7_Lr14r3: Deliver quality product information and education - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Seattle Genetics on the following attributes. These can be reps, account man",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr14"
  },
  {
    "Column": "Q7_Lr14r4",
    "Description": "Q7_Lr14r4: Understand my practice - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Seattle Genetics on the following attributes. These can be reps, account managers, MSLs, access/ reimbu",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr14"
  },
  {
    "Column": "Q7_Lr14r5",
    "Description": "Q7_Lr14r5: Are responsive and dependable - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Seattle Genetics on the following attributes. These can be reps, account managers, MSLs, access/",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr14"
  },
  {
    "Column": "Q7_Lr14r6",
    "Description": "Q7_Lr14r6: Are collaborative - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Seattle Genetics on the following attributes. These can be reps, account managers, MSLs, access/ reimburseme",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr14"
  },
  {
    "Column": "Q7_Lr14r7",
    "Description": "Q7_Lr14r7: Are helpful in securing timely product access - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Seattle Genetics on the following attributes. These can be reps, account manager",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr14"
  },
  {
    "Column": "Q7_Lr14r8",
    "Description": "Q7_Lr14r8: Make my job easier by reducing hassles to prescribing - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Seattle Genetics on the following attributes. These can be reps, account",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr14"
  },
  {
    "Column": "Q7_Lr14r9",
    "Description": "Q7_Lr14r9: Give me confidence I am making the right treatment decisions - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Seattle Genetics on the following attributes. These can be reps,",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr14"
  },
  {
    "Column": "Q7_Lr14r10",
    "Description": "Q7_Lr14r10: Are warm and friendly - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Seattle Genetics on the following attributes. These can be reps, account managers, MSLs, access/ reimbu",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr14"
  },
  {
    "Column": "Q7_Lr15r1",
    "Description": "Q7_Lr15r1: Have a presence in my practice/frequent office visits - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from GSK on the following attributes. These can be reps, account managers, MS",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr15"
  },
  {
    "Column": "Q7_Lr15r2",
    "Description": "Q7_Lr15r2: Demonstrate in-depth knowledge of treatment area - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from GSK on the following attributes. These can be reps, account managers, MSLs, a",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr15"
  },
  {
    "Column": "Q7_Lr15r3",
    "Description": "Q7_Lr15r3: Deliver quality product information and education - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from GSK on the following attributes. These can be reps, account managers, MSLs,",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr15"
  },
  {
    "Column": "Q7_Lr15r4",
    "Description": "Q7_Lr15r4: Understand my practice - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from GSK on the following attributes. These can be reps, account managers, MSLs, access/ reimbursement manag",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr15"
  },
  {
    "Column": "Q7_Lr15r5",
    "Description": "Q7_Lr15r5: Are responsive and dependable - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from GSK on the following attributes. These can be reps, account managers, MSLs, access/ reimbursemen",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr15"
  },
  {
    "Column": "Q7_Lr15r6",
    "Description": "Q7_Lr15r6: Are collaborative - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from GSK on the following attributes. These can be reps, account managers, MSLs, access/ reimbursement managers,",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr15"
  },
  {
    "Column": "Q7_Lr15r7",
    "Description": "Q7_Lr15r7: Are helpful in securing timely product access - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from GSK on the following attributes. These can be reps, account managers, MSLs, acce",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr15"
  },
  {
    "Column": "Q7_Lr15r8",
    "Description": "Q7_Lr15r8: Make my job easier by reducing hassles to prescribing - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from GSK on the following attributes. These can be reps, account managers, MS",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr15"
  },
  {
    "Column": "Q7_Lr15r9",
    "Description": "Q7_Lr15r9: Give me confidence I am making the right treatment decisions - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from GSK on the following attributes. These can be reps, account manag",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr15"
  },
  {
    "Column": "Q7_Lr15r10",
    "Description": "Q7_Lr15r10: Are warm and friendly - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from GSK on the following attributes. These can be reps, account managers, MSLs, access/ reimbursement manag",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr15"
  },
  {
    "Column": "Q7_Lr16r1",
    "Description": "Q7_Lr16r1: Have a presence in my practice/frequent office visits - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from AstraZeneca on the following attributes. These can be reps, account mana",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr16"
  },
  {
    "Column": "Q7_Lr16r2",
    "Description": "Q7_Lr16r2: Demonstrate in-depth knowledge of treatment area - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from AstraZeneca on the following attributes. These can be reps, account managers,",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr16"
  },
  {
    "Column": "Q7_Lr16r3",
    "Description": "Q7_Lr16r3: Deliver quality product information and education - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from AstraZeneca on the following attributes. These can be reps, account managers",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr16"
  },
  {
    "Column": "Q7_Lr16r4",
    "Description": "Q7_Lr16r4: Understand my practice - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from AstraZeneca on the following attributes. These can be reps, account managers, MSLs, access/ reimburseme",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr16"
  },
  {
    "Column": "Q7_Lr16r5",
    "Description": "Q7_Lr16r5: Are responsive and dependable - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from AstraZeneca on the following attributes. These can be reps, account managers, MSLs, access/ reim",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr16"
  },
  {
    "Column": "Q7_Lr16r6",
    "Description": "Q7_Lr16r6: Are collaborative - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from AstraZeneca on the following attributes. These can be reps, account managers, MSLs, access/ reimbursement ma",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr16"
  },
  {
    "Column": "Q7_Lr16r7",
    "Description": "Q7_Lr16r7: Are helpful in securing timely product access - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from AstraZeneca on the following attributes. These can be reps, account managers, MS",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr16"
  },
  {
    "Column": "Q7_Lr16r8",
    "Description": "Q7_Lr16r8: Make my job easier by reducing hassles to prescribing - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from AstraZeneca on the following attributes. These can be reps, account mana",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr16"
  },
  {
    "Column": "Q7_Lr16r9",
    "Description": "Q7_Lr16r9: Give me confidence I am making the right treatment decisions - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from AstraZeneca on the following attributes. These can be reps, accou",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr16"
  },
  {
    "Column": "Q7_Lr16r10",
    "Description": "Q7_Lr16r10: Are warm and friendly - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from AstraZeneca on the following attributes. These can be reps, account managers, MSLs, access/ reimburseme",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr16"
  },
  {
    "Column": "Q7_Lr17r1",
    "Description": "Q7_Lr17r1: Have a presence in my practice/frequent office visits - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Immunomedics on the following attributes. These can be reps, account man",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr17"
  },
  {
    "Column": "Q7_Lr17r2",
    "Description": "Q7_Lr17r2: Demonstrate in-depth knowledge of treatment area - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Immunomedics on the following attributes. These can be reps, account managers",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr17"
  },
  {
    "Column": "Q7_Lr17r3",
    "Description": "Q7_Lr17r3: Deliver quality product information and education - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Immunomedics on the following attributes. These can be reps, account manager",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr17"
  },
  {
    "Column": "Q7_Lr17r4",
    "Description": "Q7_Lr17r4: Understand my practice - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Immunomedics on the following attributes. These can be reps, account managers, MSLs, access/ reimbursem",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr17"
  },
  {
    "Column": "Q7_Lr17r5",
    "Description": "Q7_Lr17r5: Are responsive and dependable - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Immunomedics on the following attributes. These can be reps, account managers, MSLs, access/ rei",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr17"
  },
  {
    "Column": "Q7_Lr17r6",
    "Description": "Q7_Lr17r6: Are collaborative - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Immunomedics on the following attributes. These can be reps, account managers, MSLs, access/ reimbursement m",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr17"
  },
  {
    "Column": "Q7_Lr17r7",
    "Description": "Q7_Lr17r7: Are helpful in securing timely product access - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Immunomedics on the following attributes. These can be reps, account managers, M",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr17"
  },
  {
    "Column": "Q7_Lr17r8",
    "Description": "Q7_Lr17r8: Make my job easier by reducing hassles to prescribing - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Immunomedics on the following attributes. These can be reps, account man",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr17"
  },
  {
    "Column": "Q7_Lr17r9",
    "Description": "Q7_Lr17r9: Give me confidence I am making the right treatment decisions - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Immunomedics on the following attributes. These can be reps, acco",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr17"
  },
  {
    "Column": "Q7_Lr17r10",
    "Description": "Q7_Lr17r10: Are warm and friendly - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Immunomedics on the following attributes. These can be reps, account managers, MSLs, access/ reimbursem",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely10",
    "ParentQuestion": "Q7_Lr17"
  },
  {
    "Column": "Q8r1",
    "Description": "Q8r1: Astellas - For each of the following companies, please indicate your satisfaction with your overall relationship with the company in oncology:",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10",
    "ParentQuestion": "Q8"
  },
  {
    "Column": "Q8r2",
    "Description": "Q8r2: Merck - For each of the following companies, please indicate your satisfaction with your overall relationship with the company in oncology:",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10",
    "ParentQuestion": "Q8"
  },
  {
    "Column": "Q8r3",
    "Description": "Q8r3: Bristol-Myers Squibb (BMS) - For each of the following companies, please indicate your satisfaction with your overall relationship with the company in oncology:",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10",
    "ParentQuestion": "Q8"
  },
  {
    "Column": "Q8r4",
    "Description": "Q8r4: Genentech / Roche - For each of the following companies, please indicate your satisfaction with your overall relationship with the company in oncology:",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10",
    "ParentQuestion": "Q8"
  },
  {
    "Column": "Q8r5",
    "Description": "Q8r5: Pfizer - For each of the following companies, please indicate your satisfaction with your overall relationship with the company in oncology:",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10",
    "ParentQuestion": "Q8"
  },
  {
    "Column": "Q8r6",
    "Description": "Q8r6: Janssen / Johnson & Johnson - For each of the following companies, please indicate your satisfaction with your overall relationship with the company in oncology:",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10",
    "ParentQuestion": "Q8"
  },
  {
    "Column": "Q8r7",
    "Description": "Q8r7: Bayer - For each of the following companies, please indicate your satisfaction with your overall relationship with the company in oncology:",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10",
    "ParentQuestion": "Q8"
  },
  {
    "Column": "Q8r8",
    "Description": "Q8r8: Abbvie - For each of the following companies, please indicate your satisfaction with your overall relationship with the company in oncology:",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10",
    "ParentQuestion": "Q8"
  },
  {
    "Column": "Q8r9",
    "Description": "Q8r9: Sanofi - For each of the following companies, please indicate your satisfaction with your overall relationship with the company in oncology:",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10",
    "ParentQuestion": "Q8"
  },
  {
    "Column": "Q8r10",
    "Description": "Q8r10: Lilly - For each of the following companies, please indicate your satisfaction with your overall relationship with the company in oncology:",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10",
    "ParentQuestion": "Q8"
  },
  {
    "Column": "Q8r11",
    "Description": "Q8r11: Novartis - For each of the following companies, please indicate your satisfaction with your overall relationship with the company in oncology:",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10",
    "ParentQuestion": "Q8"
  },
  {
    "Column": "Q8r12",
    "Description": "Q8r12: Daiichi-Sankyo - For each of the following companies, please indicate your satisfaction with your overall relationship with the company in oncology:",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10",
    "ParentQuestion": "Q8"
  },
  {
    "Column": "Q8r13",
    "Description": "Q8r13: Amgen - For each of the following companies, please indicate your satisfaction with your overall relationship with the company in oncology:",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10",
    "ParentQuestion": "Q8"
  },
  {
    "Column": "Q8r14",
    "Description": "Q8r14: Seattle Genetics - For each of the following companies, please indicate your satisfaction with your overall relationship with the company in oncology:",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10",
    "ParentQuestion": "Q8"
  },
  {
    "Column": "Q8r15",
    "Description": "Q8r15: GSK - For each of the following companies, please indicate your satisfaction with your overall relationship with the company in oncology:",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10",
    "ParentQuestion": "Q8"
  },
  {
    "Column": "Q8r16",
    "Description": "Q8r16: AstraZeneca - For each of the following companies, please indicate your satisfaction with your overall relationship with the company in oncology:",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10",
    "ParentQuestion": "Q8"
  },
  {
    "Column": "Q8r17",
    "Description": "Q8r17: Immunomedics - For each of the following companies, please indicate your satisfaction with your overall relationship with the company in oncology:",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10",
    "ParentQuestion": "Q8"
  },
  {
    "Column": "Q9c1",
    "Description": "Q9c1: Best experience related to oncology overall - Which pharmaceutical company do you consider to be the best in terms of your overall experiences with them specifically related to oncology?",
    "Answer_Options": "1=Astellas,2=Merck,3=Bristol-Myers Squibb (BMS),4=Genentech / Roche,5=Pfizer,6=Janssen / Johnson & Johnson,7=Bayer,8=Abbvie,9=Sanofi,10=Lilly,11=Novartis,12=Daiichi-Sankyo,13=Amgen,14=Seattle Genetics,15=GSK,16=AstraZeneca,17=Immunomedics,18=Other, Specify:",
    "ParentQuestion": "Q9"
  },
  {
    "Column": "Q9r18oe",
    "Description": "Q9r18oe: Which pharmaceutical company do you consider to be the best in terms of your overall experiences with them specifically related to oncology? - Other, Specify:",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9"
  },
  {
    "Column": "Q9a_Hc1",
    "Description": "Q9a_Hc1: Best experience related to AML - And, which do you consider to be the best in terms of your overall experiences specifically related to AML?",
    "Answer_Options": "1=Astellas,2=Merck,3=Bristol-Myers Squibb (BMS),4=Genentech / Roche,5=Pfizer,6=Janssen / Johnson & Johnson,7=Bayer,8=Abbvie,9=Sanofi,10=Lilly,11=Novartis,12=Daiichi-Sankyo,13=Amgen,14=Seattle Genetics,15=GSK,16=AstraZeneca,17=Immunomedics,18=Other, Specify:",
    "ParentQuestion": "Q9a_H"
  },
  {
    "Column": "Q9a_Hr18oe",
    "Description": "Q9a_Hr18oe: And, which do you consider to be the best in terms of your overall experiences specifically related to AML? - Other, Specify:",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9a_H"
  },
  {
    "Column": "Q9a_O_Uc1",
    "Description": "Q9a_O_Uc1: Best experience related to prostate cancer - And, which do you consider to be the best in terms of your overall experiences specifically related to prostate cancer?",
    "Answer_Options": "1=Astellas,2=Merck,3=Bristol-Myers Squibb (BMS),4=Genentech / Roche,5=Pfizer,6=Janssen / Johnson & Johnson,7=Bayer,8=Abbvie,9=Sanofi,10=Lilly,11=Novartis,12=Daiichi-Sankyo,13=Amgen,14=Seattle Genetics,15=GSK,16=AstraZeneca,17=Immunomedics,18=Other, Specify:",
    "ParentQuestion": "Q9a_O_U"
  },
  {
    "Column": "Q9a_O_Ur18oe",
    "Description": "Q9a_O_Ur18oe: And, which do you consider to be the best in terms of your overall experiences specifically related to prostate cancer? - Other, Specify:",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9a_O_U"
  },
  {
    "Column": "x9aOBc1",
    "Description": "x9aOBc1: Best experience related to bladder cancer - And, which do you consider to be the best in terms of your overall experiences specifically related to bladder cancer?",
    "Answer_Options": "1=Astellas,2=Merck,3=Bristol-Myers Squibb (BMS),4=Genentech / Roche,5=Pfizer,6=Janssen / Johnson & Johnson,7=Bayer,8=Abbvie,9=Sanofi,10=Lilly,11=Novartis,12=Daiichi-Sankyo,13=Amgen,14=Seattle Genetics,15=GSK,16=AstraZeneca,17=Immunomedics,18=Other, Specify:",
    "ParentQuestion": "x9aOB"
  },
  {
    "Column": "x9aOBr18oe",
    "Description": "x9aOBr18oe: And, which do you consider to be the best in terms of your overall experiences specifically related to bladder cancer? - Other, Specify:",
    "Answer_Options": "NA",
    "ParentQuestion": "x9aOB"
  },
  {
    "Column": "Q9b",
    "Description": "Q9b: Why do you consider the best in terms of your overall experiences specifically related to oncology?",
    "Answer_Options": "NA"
  },
  {
    "Column": "S9_LFr1",
    "Description": "S9_LFr1: Astellas - Listfill for S9",
    "Answer_Options": "0=NO TO: Astellas,1=Astellas",
    "ParentQuestion": "S9_LF"
  },
  {
    "Column": "S9_LFr2",
    "Description": "S9_LFr2: Merck - Listfill for S9",
    "Answer_Options": "0=NO TO: Merck,1=Merck",
    "ParentQuestion": "S9_LF"
  },
  {
    "Column": "S9_LFr3",
    "Description": "S9_LFr3: Bristol-Myers Squibb (BMS) - Listfill for S9",
    "Answer_Options": "0=NO TO: Bristol-Myers Squibb (BMS),1=Bristol-Myers Squibb (BMS)",
    "ParentQuestion": "S9_LF"
  },
  {
    "Column": "S9_LFr4",
    "Description": "S9_LFr4: Genentech / Roche - Listfill for S9",
    "Answer_Options": "0=NO TO: Genentech / Roche,1=Genentech / Roche",
    "ParentQuestion": "S9_LF"
  },
  {
    "Column": "S9_LFr5",
    "Description": "S9_LFr5: Pfizer - Listfill for S9",
    "Answer_Options": "0=NO TO: Pfizer,1=Pfizer",
    "ParentQuestion": "S9_LF"
  },
  {
    "Column": "S9_LFr6",
    "Description": "S9_LFr6: Janssen / Johnson & Johnson - Listfill for S9",
    "Answer_Options": "0=NO TO: Janssen / Johnson & Johnson,1=Janssen / Johnson & Johnson",
    "ParentQuestion": "S9_LF"
  },
  {
    "Column": "S9_LFr7",
    "Description": "S9_LFr7: Bayer - Listfill for S9",
    "Answer_Options": "0=NO TO: Bayer,1=Bayer",
    "ParentQuestion": "S9_LF"
  },
  {
    "Column": "S9_LFr8",
    "Description": "S9_LFr8: Abbvie - Listfill for S9",
    "Answer_Options": "0=NO TO: Abbvie,1=Abbvie",
    "ParentQuestion": "S9_LF"
  },
  {
    "Column": "S9_LFr9",
    "Description": "S9_LFr9: Sanofi - Listfill for S9",
    "Answer_Options": "0=NO TO: Sanofi,1=Sanofi",
    "ParentQuestion": "S9_LF"
  },
  {
    "Column": "S9_LFr10",
    "Description": "S9_LFr10: Lilly - Listfill for S9",
    "Answer_Options": "0=NO TO: Lilly,1=Lilly",
    "ParentQuestion": "S9_LF"
  },
  {
    "Column": "S9_LFr11",
    "Description": "S9_LFr11: Novartis - Listfill for S9",
    "Answer_Options": "0=NO TO: Novartis,1=Novartis",
    "ParentQuestion": "S9_LF"
  },
  {
    "Column": "S9_LFr12",
    "Description": "S9_LFr12: Daiichi-Sankyo - Listfill for S9",
    "Answer_Options": "0=NO TO: Daiichi-Sankyo,1=Daiichi-Sankyo",
    "ParentQuestion": "S9_LF"
  },
  {
    "Column": "S9_LFr13",
    "Description": "S9_LFr13: Amgen - Listfill for S9",
    "Answer_Options": "0=NO TO: Amgen,1=Amgen",
    "ParentQuestion": "S9_LF"
  },
  {
    "Column": "S9_LFr14",
    "Description": "S9_LFr14: Seattle Genetics - Listfill for S9",
    "Answer_Options": "0=NO TO: Seattle Genetics,1=Seattle Genetics",
    "ParentQuestion": "S9_LF"
  },
  {
    "Column": "S9_LFr15",
    "Description": "S9_LFr15: GSK - Listfill for S9",
    "Answer_Options": "0=NO TO: GSK,1=GSK",
    "ParentQuestion": "S9_LF"
  },
  {
    "Column": "S9_LFr16",
    "Description": "S9_LFr16: AstraZeneca - Listfill for S9",
    "Answer_Options": "0=NO TO: AstraZeneca,1=AstraZeneca",
    "ParentQuestion": "S9_LF"
  },
  {
    "Column": "S9_LFr17",
    "Description": "S9_LFr17: Immunomedics - Listfill for S9",
    "Answer_Options": "0=NO TO: Immunomedics,1=Immunomedics",
    "ParentQuestion": "S9_LF"
  },
  {
    "Column": "Q9cc1",
    "Description": "Q9cc1: Astellas - For each of company below, please indicate the MOST RECENT type of interaction you have had with them related to their oncology drugs.",
    "Answer_Options": "1=In person discussion (i.e. at practice setting),2=Virtual detail / discussion,3=Telephone call,4=Email communication,5=Conference discussion (e.g. booth visit, meeting),6=Website / Online portal,7=Other type of interaction (Specify:),8=Unsure / I don’t remember",
    "ParentQuestion": "Q9c"
  },
  {
    "Column": "Q9cc2",
    "Description": "Q9cc2: Merck - For each of company below, please indicate the MOST RECENT type of interaction you have had with them related to their oncology drugs.",
    "Answer_Options": "1=In person discussion (i.e. at practice setting),2=Virtual detail / discussion,3=Telephone call,4=Email communication,5=Conference discussion (e.g. booth visit, meeting),6=Website / Online portal,7=Other type of interaction (Specify:),8=Unsure / I don’t remember",
    "ParentQuestion": "Q9c"
  },
  {
    "Column": "Q9cc3",
    "Description": "Q9cc3: Bristol-Myers Squibb (BMS) - For each of company below, please indicate the MOST RECENT type of interaction you have had with them related to their oncology drugs.",
    "Answer_Options": "1=In person discussion (i.e. at practice setting),2=Virtual detail / discussion,3=Telephone call,4=Email communication,5=Conference discussion (e.g. booth visit, meeting),6=Website / Online portal,7=Other type of interaction (Specify:),8=Unsure / I don’t remember",
    "ParentQuestion": "Q9c"
  },
  {
    "Column": "Q9cc4",
    "Description": "Q9cc4: Genentech / Roche - For each of company below, please indicate the MOST RECENT type of interaction you have had with them related to their oncology drugs.",
    "Answer_Options": "1=In person discussion (i.e. at practice setting),2=Virtual detail / discussion,3=Telephone call,4=Email communication,5=Conference discussion (e.g. booth visit, meeting),6=Website / Online portal,7=Other type of interaction (Specify:),8=Unsure / I don’t remember",
    "ParentQuestion": "Q9c"
  },
  {
    "Column": "Q9cc5",
    "Description": "Q9cc5: Pfizer - For each of company below, please indicate the MOST RECENT type of interaction you have had with them related to their oncology drugs.",
    "Answer_Options": "1=In person discussion (i.e. at practice setting),2=Virtual detail / discussion,3=Telephone call,4=Email communication,5=Conference discussion (e.g. booth visit, meeting),6=Website / Online portal,7=Other type of interaction (Specify:),8=Unsure / I don’t remember",
    "ParentQuestion": "Q9c"
  },
  {
    "Column": "Q9cc6",
    "Description": "Q9cc6: Janssen / Johnson & Johnson - For each of company below, please indicate the MOST RECENT type of interaction you have had with them related to their oncology drugs.",
    "Answer_Options": "1=In person discussion (i.e. at practice setting),2=Virtual detail / discussion,3=Telephone call,4=Email communication,5=Conference discussion (e.g. booth visit, meeting),6=Website / Online portal,7=Other type of interaction (Specify:),8=Unsure / I don’t remember",
    "ParentQuestion": "Q9c"
  },
  {
    "Column": "Q9cc7",
    "Description": "Q9cc7: Bayer - For each of company below, please indicate the MOST RECENT type of interaction you have had with them related to their oncology drugs.",
    "Answer_Options": "1=In person discussion (i.e. at practice setting),2=Virtual detail / discussion,3=Telephone call,4=Email communication,5=Conference discussion (e.g. booth visit, meeting),6=Website / Online portal,7=Other type of interaction (Specify:),8=Unsure / I don’t remember",
    "ParentQuestion": "Q9c"
  },
  {
    "Column": "Q9cc8",
    "Description": "Q9cc8: Abbvie - For each of company below, please indicate the MOST RECENT type of interaction you have had with them related to their oncology drugs.",
    "Answer_Options": "1=In person discussion (i.e. at practice setting),2=Virtual detail / discussion,3=Telephone call,4=Email communication,5=Conference discussion (e.g. booth visit, meeting),6=Website / Online portal,7=Other type of interaction (Specify:),8=Unsure / I don’t remember",
    "ParentQuestion": "Q9c"
  },
  {
    "Column": "Q9cc9",
    "Description": "Q9cc9: Sanofi - For each of company below, please indicate the MOST RECENT type of interaction you have had with them related to their oncology drugs.",
    "Answer_Options": "1=In person discussion (i.e. at practice setting),2=Virtual detail / discussion,3=Telephone call,4=Email communication,5=Conference discussion (e.g. booth visit, meeting),6=Website / Online portal,7=Other type of interaction (Specify:),8=Unsure / I don’t remember",
    "ParentQuestion": "Q9c"
  },
  {
    "Column": "Q9cc10",
    "Description": "Q9cc10: Lilly - For each of company below, please indicate the MOST RECENT type of interaction you have had with them related to their oncology drugs.",
    "Answer_Options": "1=In person discussion (i.e. at practice setting),2=Virtual detail / discussion,3=Telephone call,4=Email communication,5=Conference discussion (e.g. booth visit, meeting),6=Website / Online portal,7=Other type of interaction (Specify:),8=Unsure / I don’t remember",
    "ParentQuestion": "Q9c"
  },
  {
    "Column": "Q9cc11",
    "Description": "Q9cc11: Novartis - For each of company below, please indicate the MOST RECENT type of interaction you have had with them related to their oncology drugs.",
    "Answer_Options": "1=In person discussion (i.e. at practice setting),2=Virtual detail / discussion,3=Telephone call,4=Email communication,5=Conference discussion (e.g. booth visit, meeting),6=Website / Online portal,7=Other type of interaction (Specify:),8=Unsure / I don’t remember",
    "ParentQuestion": "Q9c"
  },
  {
    "Column": "Q9cc12",
    "Description": "Q9cc12: Daiichi-Sankyo - For each of company below, please indicate the MOST RECENT type of interaction you have had with them related to their oncology drugs.",
    "Answer_Options": "1=In person discussion (i.e. at practice setting),2=Virtual detail / discussion,3=Telephone call,4=Email communication,5=Conference discussion (e.g. booth visit, meeting),6=Website / Online portal,7=Other type of interaction (Specify:),8=Unsure / I don’t remember",
    "ParentQuestion": "Q9c"
  },
  {
    "Column": "Q9cc13",
    "Description": "Q9cc13: Amgen - For each of company below, please indicate the MOST RECENT type of interaction you have had with them related to their oncology drugs.",
    "Answer_Options": "1=In person discussion (i.e. at practice setting),2=Virtual detail / discussion,3=Telephone call,4=Email communication,5=Conference discussion (e.g. booth visit, meeting),6=Website / Online portal,7=Other type of interaction (Specify:),8=Unsure / I don’t remember",
    "ParentQuestion": "Q9c"
  },
  {
    "Column": "Q9cc14",
    "Description": "Q9cc14: Seattle Genetics - For each of company below, please indicate the MOST RECENT type of interaction you have had with them related to their oncology drugs.",
    "Answer_Options": "1=In person discussion (i.e. at practice setting),2=Virtual detail / discussion,3=Telephone call,4=Email communication,5=Conference discussion (e.g. booth visit, meeting),6=Website / Online portal,7=Other type of interaction (Specify:),8=Unsure / I don’t remember",
    "ParentQuestion": "Q9c"
  },
  {
    "Column": "Q9cc15",
    "Description": "Q9cc15: GSK - For each of company below, please indicate the MOST RECENT type of interaction you have had with them related to their oncology drugs.",
    "Answer_Options": "1=In person discussion (i.e. at practice setting),2=Virtual detail / discussion,3=Telephone call,4=Email communication,5=Conference discussion (e.g. booth visit, meeting),6=Website / Online portal,7=Other type of interaction (Specify:),8=Unsure / I don’t remember",
    "ParentQuestion": "Q9c"
  },
  {
    "Column": "Q9cc16",
    "Description": "Q9cc16: AstraZeneca - For each of company below, please indicate the MOST RECENT type of interaction you have had with them related to their oncology drugs.",
    "Answer_Options": "1=In person discussion (i.e. at practice setting),2=Virtual detail / discussion,3=Telephone call,4=Email communication,5=Conference discussion (e.g. booth visit, meeting),6=Website / Online portal,7=Other type of interaction (Specify:),8=Unsure / I don’t remember",
    "ParentQuestion": "Q9c"
  },
  {
    "Column": "Q9cc17",
    "Description": "Q9cc17: Immunomedics - For each of company below, please indicate the MOST RECENT type of interaction you have had with them related to their oncology drugs.",
    "Answer_Options": "1=In person discussion (i.e. at practice setting),2=Virtual detail / discussion,3=Telephone call,4=Email communication,5=Conference discussion (e.g. booth visit, meeting),6=Website / Online portal,7=Other type of interaction (Specify:),8=Unsure / I don’t remember",
    "ParentQuestion": "Q9c"
  },
  {
    "Column": "Q9cr6oe",
    "Description": "Q9cr6oe: For each of company below, please indicate the MOST RECENT type of interaction you have had with them related to their oncology drugs. - Other type of interaction (Specify:)",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9c"
  },
  {
    "Column": "Q9dr1c1",
    "Description": "Q9dr1c1: Product sales representative - Astellas - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Product sales representative,1=Product sales representative",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr2c1",
    "Description": "Q9dr2c1: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state) - Astellas - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease st,1=Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr8c1",
    "Description": "Q9dr8c1: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but are NOT involved in day-to-day product sales) - Astellas - For this MOST RECENT interaction, what type of personnel did you int",
    "Answer_Options": "0=NO TO: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issue,1=Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but a",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr9c1",
    "Description": "Q9dr9c1: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement) - Astellas - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursem,1=Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr3c1",
    "Description": "Q9dr3c1: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.) - Astellas - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.,1=Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr7c1",
    "Description": "Q9dr7c1: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor) - Astellas - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor),1=Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr4c1",
    "Description": "Q9dr4c1: Other type of person (Specify:) - Astellas - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Other type of person (Specify:),1=Other type of person (Specify:)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr5c1",
    "Description": "Q9dr5c1: Did not directly interact with personnel - Astellas - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Did not directly interact with personnel,1=Did not directly interact with personnel",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr6c1",
    "Description": "Q9dr6c1: Unsure / I don’t remember - Astellas - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Unsure / I don’t remember,1=Unsure / I don’t remember",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr1c2",
    "Description": "Q9dr1c2: Product sales representative - Merck - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Product sales representative,1=Product sales representative",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr2c2",
    "Description": "Q9dr2c2: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state) - Merck - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease st,1=Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr8c2",
    "Description": "Q9dr8c2: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but are NOT involved in day-to-day product sales) - Merck - For this MOST RECENT interaction, what type of personnel did you intera",
    "Answer_Options": "0=NO TO: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issue,1=Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but a",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr9c2",
    "Description": "Q9dr9c2: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement) - Merck - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursem,1=Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr3c2",
    "Description": "Q9dr3c2: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.) - Merck - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.,1=Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr7c2",
    "Description": "Q9dr7c2: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor) - Merck - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor),1=Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr4c2",
    "Description": "Q9dr4c2: Other type of person (Specify:) - Merck - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Other type of person (Specify:),1=Other type of person (Specify:)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr5c2",
    "Description": "Q9dr5c2: Did not directly interact with personnel - Merck - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Did not directly interact with personnel,1=Did not directly interact with personnel",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr6c2",
    "Description": "Q9dr6c2: Unsure / I don’t remember - Merck - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Unsure / I don’t remember,1=Unsure / I don’t remember",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr1c3",
    "Description": "Q9dr1c3: Product sales representative - Bristol-Myers Squibb (BMS) - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Product sales representative,1=Product sales representative",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr2c3",
    "Description": "Q9dr2c3: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state) - Bristol-Myers Squibb (BMS) - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease st,1=Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr8c3",
    "Description": "Q9dr8c3: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but are NOT involved in day-to-day product sales) - Bristol-Myers Squibb (BMS) - For this MOST RECENT interaction, what type of per",
    "Answer_Options": "0=NO TO: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issue,1=Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but a",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr9c3",
    "Description": "Q9dr9c3: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement) - Bristol-Myers Squibb (BMS) - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursem,1=Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr3c3",
    "Description": "Q9dr3c3: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.) - Bristol-Myers Squibb (BMS) - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.,1=Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr7c3",
    "Description": "Q9dr7c3: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor) - Bristol-Myers Squibb (BMS) - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor),1=Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr4c3",
    "Description": "Q9dr4c3: Other type of person (Specify:) - Bristol-Myers Squibb (BMS) - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Other type of person (Specify:),1=Other type of person (Specify:)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr5c3",
    "Description": "Q9dr5c3: Did not directly interact with personnel - Bristol-Myers Squibb (BMS) - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Did not directly interact with personnel,1=Did not directly interact with personnel",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr6c3",
    "Description": "Q9dr6c3: Unsure / I don’t remember - Bristol-Myers Squibb (BMS) - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Unsure / I don’t remember,1=Unsure / I don’t remember",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr1c4",
    "Description": "Q9dr1c4: Product sales representative - Genentech / Roche - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Product sales representative,1=Product sales representative",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr2c4",
    "Description": "Q9dr2c4: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state) - Genentech / Roche - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease st,1=Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr8c4",
    "Description": "Q9dr8c4: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but are NOT involved in day-to-day product sales) - Genentech / Roche - For this MOST RECENT interaction, what type of personnel di",
    "Answer_Options": "0=NO TO: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issue,1=Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but a",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr9c4",
    "Description": "Q9dr9c4: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement) - Genentech / Roche - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursem,1=Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr3c4",
    "Description": "Q9dr3c4: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.) - Genentech / Roche - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.,1=Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr7c4",
    "Description": "Q9dr7c4: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor) - Genentech / Roche - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor),1=Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr4c4",
    "Description": "Q9dr4c4: Other type of person (Specify:) - Genentech / Roche - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Other type of person (Specify:),1=Other type of person (Specify:)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr5c4",
    "Description": "Q9dr5c4: Did not directly interact with personnel - Genentech / Roche - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Did not directly interact with personnel,1=Did not directly interact with personnel",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr6c4",
    "Description": "Q9dr6c4: Unsure / I don’t remember - Genentech / Roche - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Unsure / I don’t remember,1=Unsure / I don’t remember",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr1c5",
    "Description": "Q9dr1c5: Product sales representative - Pfizer - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Product sales representative,1=Product sales representative",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr2c5",
    "Description": "Q9dr2c5: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state) - Pfizer - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease st,1=Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr8c5",
    "Description": "Q9dr8c5: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but are NOT involved in day-to-day product sales) - Pfizer - For this MOST RECENT interaction, what type of personnel did you inter",
    "Answer_Options": "0=NO TO: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issue,1=Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but a",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr9c5",
    "Description": "Q9dr9c5: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement) - Pfizer - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursem,1=Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr3c5",
    "Description": "Q9dr3c5: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.) - Pfizer - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.,1=Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr7c5",
    "Description": "Q9dr7c5: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor) - Pfizer - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor),1=Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr4c5",
    "Description": "Q9dr4c5: Other type of person (Specify:) - Pfizer - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Other type of person (Specify:),1=Other type of person (Specify:)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr5c5",
    "Description": "Q9dr5c5: Did not directly interact with personnel - Pfizer - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Did not directly interact with personnel,1=Did not directly interact with personnel",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr6c5",
    "Description": "Q9dr6c5: Unsure / I don’t remember - Pfizer - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Unsure / I don’t remember,1=Unsure / I don’t remember",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr1c6",
    "Description": "Q9dr1c6: Product sales representative - Janssen / Johnson & Johnson - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Product sales representative,1=Product sales representative",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr2c6",
    "Description": "Q9dr2c6: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state) - Janssen / Johnson & Johnson - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease st,1=Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr8c6",
    "Description": "Q9dr8c6: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but are NOT involved in day-to-day product sales) - Janssen / Johnson & Johnson - For this MOST RECENT interaction, what type of pe",
    "Answer_Options": "0=NO TO: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issue,1=Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but a",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr9c6",
    "Description": "Q9dr9c6: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement) - Janssen / Johnson & Johnson - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursem,1=Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr3c6",
    "Description": "Q9dr3c6: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.) - Janssen / Johnson & Johnson - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.,1=Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr7c6",
    "Description": "Q9dr7c6: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor) - Janssen / Johnson & Johnson - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor),1=Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr4c6",
    "Description": "Q9dr4c6: Other type of person (Specify:) - Janssen / Johnson & Johnson - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Other type of person (Specify:),1=Other type of person (Specify:)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr5c6",
    "Description": "Q9dr5c6: Did not directly interact with personnel - Janssen / Johnson & Johnson - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Did not directly interact with personnel,1=Did not directly interact with personnel",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr6c6",
    "Description": "Q9dr6c6: Unsure / I don’t remember - Janssen / Johnson & Johnson - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Unsure / I don’t remember,1=Unsure / I don’t remember",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr1c7",
    "Description": "Q9dr1c7: Product sales representative - Bayer - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Product sales representative,1=Product sales representative",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr2c7",
    "Description": "Q9dr2c7: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state) - Bayer - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease st,1=Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr8c7",
    "Description": "Q9dr8c7: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but are NOT involved in day-to-day product sales) - Bayer - For this MOST RECENT interaction, what type of personnel did you intera",
    "Answer_Options": "0=NO TO: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issue,1=Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but a",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr9c7",
    "Description": "Q9dr9c7: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement) - Bayer - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursem,1=Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr3c7",
    "Description": "Q9dr3c7: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.) - Bayer - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.,1=Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr7c7",
    "Description": "Q9dr7c7: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor) - Bayer - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor),1=Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr4c7",
    "Description": "Q9dr4c7: Other type of person (Specify:) - Bayer - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Other type of person (Specify:),1=Other type of person (Specify:)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr5c7",
    "Description": "Q9dr5c7: Did not directly interact with personnel - Bayer - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Did not directly interact with personnel,1=Did not directly interact with personnel",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr6c7",
    "Description": "Q9dr6c7: Unsure / I don’t remember - Bayer - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Unsure / I don’t remember,1=Unsure / I don’t remember",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr1c8",
    "Description": "Q9dr1c8: Product sales representative - Abbvie - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Product sales representative,1=Product sales representative",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr2c8",
    "Description": "Q9dr2c8: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state) - Abbvie - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease st,1=Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr8c8",
    "Description": "Q9dr8c8: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but are NOT involved in day-to-day product sales) - Abbvie - For this MOST RECENT interaction, what type of personnel did you inter",
    "Answer_Options": "0=NO TO: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issue,1=Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but a",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr9c8",
    "Description": "Q9dr9c8: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement) - Abbvie - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursem,1=Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr3c8",
    "Description": "Q9dr3c8: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.) - Abbvie - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.,1=Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr7c8",
    "Description": "Q9dr7c8: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor) - Abbvie - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor),1=Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr4c8",
    "Description": "Q9dr4c8: Other type of person (Specify:) - Abbvie - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Other type of person (Specify:),1=Other type of person (Specify:)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr5c8",
    "Description": "Q9dr5c8: Did not directly interact with personnel - Abbvie - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Did not directly interact with personnel,1=Did not directly interact with personnel",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr6c8",
    "Description": "Q9dr6c8: Unsure / I don’t remember - Abbvie - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Unsure / I don’t remember,1=Unsure / I don’t remember",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr1c9",
    "Description": "Q9dr1c9: Product sales representative - Sanofi - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Product sales representative,1=Product sales representative",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr2c9",
    "Description": "Q9dr2c9: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state) - Sanofi - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease st,1=Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr8c9",
    "Description": "Q9dr8c9: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but are NOT involved in day-to-day product sales) - Sanofi - For this MOST RECENT interaction, what type of personnel did you inter",
    "Answer_Options": "0=NO TO: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issue,1=Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but a",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr9c9",
    "Description": "Q9dr9c9: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement) - Sanofi - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursem,1=Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr3c9",
    "Description": "Q9dr3c9: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.) - Sanofi - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.,1=Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr7c9",
    "Description": "Q9dr7c9: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor) - Sanofi - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor),1=Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr4c9",
    "Description": "Q9dr4c9: Other type of person (Specify:) - Sanofi - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Other type of person (Specify:),1=Other type of person (Specify:)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr5c9",
    "Description": "Q9dr5c9: Did not directly interact with personnel - Sanofi - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Did not directly interact with personnel,1=Did not directly interact with personnel",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr6c9",
    "Description": "Q9dr6c9: Unsure / I don’t remember - Sanofi - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Unsure / I don’t remember,1=Unsure / I don’t remember",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr1c10",
    "Description": "Q9dr1c10: Product sales representative - Lilly - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Product sales representative,1=Product sales representative",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr2c10",
    "Description": "Q9dr2c10: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state) - Lilly - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease st,1=Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr8c10",
    "Description": "Q9dr8c10: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but are NOT involved in day-to-day product sales) - Lilly - For this MOST RECENT interaction, what type of personnel did you inter",
    "Answer_Options": "0=NO TO: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issue,1=Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but a",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr9c10",
    "Description": "Q9dr9c10: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement) - Lilly - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursem,1=Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr3c10",
    "Description": "Q9dr3c10: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.) - Lilly - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.,1=Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr7c10",
    "Description": "Q9dr7c10: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor) - Lilly - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor),1=Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr4c10",
    "Description": "Q9dr4c10: Other type of person (Specify:) - Lilly - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Other type of person (Specify:),1=Other type of person (Specify:)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr5c10",
    "Description": "Q9dr5c10: Did not directly interact with personnel - Lilly - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Did not directly interact with personnel,1=Did not directly interact with personnel",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr6c10",
    "Description": "Q9dr6c10: Unsure / I don’t remember - Lilly - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Unsure / I don’t remember,1=Unsure / I don’t remember",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr1c11",
    "Description": "Q9dr1c11: Product sales representative - Novartis - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Product sales representative,1=Product sales representative",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr2c11",
    "Description": "Q9dr2c11: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state) - Novartis - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease st,1=Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr8c11",
    "Description": "Q9dr8c11: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but are NOT involved in day-to-day product sales) - Novartis - For this MOST RECENT interaction, what type of personnel did you in",
    "Answer_Options": "0=NO TO: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issue,1=Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but a",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr9c11",
    "Description": "Q9dr9c11: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement) - Novartis - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursem,1=Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr3c11",
    "Description": "Q9dr3c11: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.) - Novartis - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.,1=Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr7c11",
    "Description": "Q9dr7c11: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor) - Novartis - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor),1=Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr4c11",
    "Description": "Q9dr4c11: Other type of person (Specify:) - Novartis - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Other type of person (Specify:),1=Other type of person (Specify:)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr5c11",
    "Description": "Q9dr5c11: Did not directly interact with personnel - Novartis - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Did not directly interact with personnel,1=Did not directly interact with personnel",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr6c11",
    "Description": "Q9dr6c11: Unsure / I don’t remember - Novartis - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Unsure / I don’t remember,1=Unsure / I don’t remember",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr1c12",
    "Description": "Q9dr1c12: Product sales representative - Daiichi-Sankyo - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Product sales representative,1=Product sales representative",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr2c12",
    "Description": "Q9dr2c12: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state) - Daiichi-Sankyo - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease st,1=Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr8c12",
    "Description": "Q9dr8c12: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but are NOT involved in day-to-day product sales) - Daiichi-Sankyo - For this MOST RECENT interaction, what type of personnel did",
    "Answer_Options": "0=NO TO: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issue,1=Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but a",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr9c12",
    "Description": "Q9dr9c12: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement) - Daiichi-Sankyo - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursem,1=Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr3c12",
    "Description": "Q9dr3c12: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.) - Daiichi-Sankyo - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.,1=Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr7c12",
    "Description": "Q9dr7c12: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor) - Daiichi-Sankyo - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor),1=Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr4c12",
    "Description": "Q9dr4c12: Other type of person (Specify:) - Daiichi-Sankyo - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Other type of person (Specify:),1=Other type of person (Specify:)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr5c12",
    "Description": "Q9dr5c12: Did not directly interact with personnel - Daiichi-Sankyo - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Did not directly interact with personnel,1=Did not directly interact with personnel",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr6c12",
    "Description": "Q9dr6c12: Unsure / I don’t remember - Daiichi-Sankyo - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Unsure / I don’t remember,1=Unsure / I don’t remember",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr1c13",
    "Description": "Q9dr1c13: Product sales representative - Amgen - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Product sales representative,1=Product sales representative",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr2c13",
    "Description": "Q9dr2c13: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state) - Amgen - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease st,1=Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr8c13",
    "Description": "Q9dr8c13: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but are NOT involved in day-to-day product sales) - Amgen - For this MOST RECENT interaction, what type of personnel did you inter",
    "Answer_Options": "0=NO TO: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issue,1=Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but a",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr9c13",
    "Description": "Q9dr9c13: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement) - Amgen - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursem,1=Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr3c13",
    "Description": "Q9dr3c13: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.) - Amgen - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.,1=Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr7c13",
    "Description": "Q9dr7c13: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor) - Amgen - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor),1=Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr4c13",
    "Description": "Q9dr4c13: Other type of person (Specify:) - Amgen - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Other type of person (Specify:),1=Other type of person (Specify:)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr5c13",
    "Description": "Q9dr5c13: Did not directly interact with personnel - Amgen - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Did not directly interact with personnel,1=Did not directly interact with personnel",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr6c13",
    "Description": "Q9dr6c13: Unsure / I don’t remember - Amgen - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Unsure / I don’t remember,1=Unsure / I don’t remember",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr1c14",
    "Description": "Q9dr1c14: Product sales representative - Seattle Genetics - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Product sales representative,1=Product sales representative",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr2c14",
    "Description": "Q9dr2c14: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state) - Seattle Genetics - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease st,1=Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr8c14",
    "Description": "Q9dr8c14: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but are NOT involved in day-to-day product sales) - Seattle Genetics - For this MOST RECENT interaction, what type of personnel di",
    "Answer_Options": "0=NO TO: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issue,1=Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but a",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr9c14",
    "Description": "Q9dr9c14: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement) - Seattle Genetics - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursem,1=Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr3c14",
    "Description": "Q9dr3c14: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.) - Seattle Genetics - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.,1=Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr7c14",
    "Description": "Q9dr7c14: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor) - Seattle Genetics - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor),1=Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr4c14",
    "Description": "Q9dr4c14: Other type of person (Specify:) - Seattle Genetics - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Other type of person (Specify:),1=Other type of person (Specify:)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr5c14",
    "Description": "Q9dr5c14: Did not directly interact with personnel - Seattle Genetics - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Did not directly interact with personnel,1=Did not directly interact with personnel",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr6c14",
    "Description": "Q9dr6c14: Unsure / I don’t remember - Seattle Genetics - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Unsure / I don’t remember,1=Unsure / I don’t remember",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr1c15",
    "Description": "Q9dr1c15: Product sales representative - GSK - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Product sales representative,1=Product sales representative",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr2c15",
    "Description": "Q9dr2c15: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state) - GSK - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease st,1=Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr8c15",
    "Description": "Q9dr8c15: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but are NOT involved in day-to-day product sales) - GSK - For this MOST RECENT interaction, what type of personnel did you interac",
    "Answer_Options": "0=NO TO: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issue,1=Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but a",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr9c15",
    "Description": "Q9dr9c15: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement) - GSK - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursem,1=Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr3c15",
    "Description": "Q9dr3c15: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.) - GSK - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.,1=Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr7c15",
    "Description": "Q9dr7c15: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor) - GSK - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor),1=Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr4c15",
    "Description": "Q9dr4c15: Other type of person (Specify:) - GSK - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Other type of person (Specify:),1=Other type of person (Specify:)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr5c15",
    "Description": "Q9dr5c15: Did not directly interact with personnel - GSK - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Did not directly interact with personnel,1=Did not directly interact with personnel",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr6c15",
    "Description": "Q9dr6c15: Unsure / I don’t remember - GSK - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Unsure / I don’t remember,1=Unsure / I don’t remember",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr1c16",
    "Description": "Q9dr1c16: Product sales representative - AstraZeneca - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Product sales representative,1=Product sales representative",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr2c16",
    "Description": "Q9dr2c16: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state) - AstraZeneca - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease st,1=Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr8c16",
    "Description": "Q9dr8c16: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but are NOT involved in day-to-day product sales) - AstraZeneca - For this MOST RECENT interaction, what type of personnel did you",
    "Answer_Options": "0=NO TO: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issue,1=Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but a",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr9c16",
    "Description": "Q9dr9c16: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement) - AstraZeneca - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursem,1=Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr3c16",
    "Description": "Q9dr3c16: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.) - AstraZeneca - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.,1=Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr7c16",
    "Description": "Q9dr7c16: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor) - AstraZeneca - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor),1=Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr4c16",
    "Description": "Q9dr4c16: Other type of person (Specify:) - AstraZeneca - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Other type of person (Specify:),1=Other type of person (Specify:)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr5c16",
    "Description": "Q9dr5c16: Did not directly interact with personnel - AstraZeneca - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Did not directly interact with personnel,1=Did not directly interact with personnel",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr6c16",
    "Description": "Q9dr6c16: Unsure / I don’t remember - AstraZeneca - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Unsure / I don’t remember,1=Unsure / I don’t remember",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr1c17",
    "Description": "Q9dr1c17: Product sales representative - Immunomedics - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Product sales representative,1=Product sales representative",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr2c17",
    "Description": "Q9dr2c17: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state) - Immunomedics - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease st,1=Medical science liaison (MSL) (i.e. personnel who specializes in knowledge of the therapeutic area and disease state)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr8c17",
    "Description": "Q9dr8c17: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but are NOT involved in day-to-day product sales) - Immunomedics - For this MOST RECENT interaction, what type of personnel did yo",
    "Answer_Options": "0=NO TO: Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issue,1=Account manager (i.e. pharmaceutical company professionals that support your organization on more strategic issues but a",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr9c17",
    "Description": "Q9dr9c17: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement) - Immunomedics - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursem,1=Access / reimbursement manager (i.e. personnel who specializes in providing support for patient access/reimbursement)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr3c17",
    "Description": "Q9dr3c17: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.) - Immunomedics - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.,1=Other company employee (e.g. reimbursement hub representative, phone representative in corporate department, etc.)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr7c17",
    "Description": "Q9dr7c17: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor) - Immunomedics - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor),1=Third party affiliated with company (e.g. specialty pharmacy, GPO, distributor)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr4c17",
    "Description": "Q9dr4c17: Other type of person (Specify:) - Immunomedics - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Other type of person (Specify:),1=Other type of person (Specify:)",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr5c17",
    "Description": "Q9dr5c17: Did not directly interact with personnel - Immunomedics - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Did not directly interact with personnel,1=Did not directly interact with personnel",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr6c17",
    "Description": "Q9dr6c17: Unsure / I don’t remember - Immunomedics - For this MOST RECENT interaction, what type of personnel did you interact with?",
    "Answer_Options": "0=NO TO: Unsure / I don’t remember,1=Unsure / I don’t remember",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9dr4oe",
    "Description": "Q9dr4oe: For this MOST RECENT interaction, what type of personnel did you interact with? - Other type of person (Specify:)",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9d"
  },
  {
    "Column": "Q9er1",
    "Description": "Q9er1: Astellas - How satisfied were you with the MOST RECENT interaction?",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10",
    "ParentQuestion": "Q9e"
  },
  {
    "Column": "Q9er2",
    "Description": "Q9er2: Merck - How satisfied were you with the MOST RECENT interaction?",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10",
    "ParentQuestion": "Q9e"
  },
  {
    "Column": "Q9er3",
    "Description": "Q9er3: Bristol-Myers Squibb (BMS) - How satisfied were you with the MOST RECENT interaction?",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10",
    "ParentQuestion": "Q9e"
  },
  {
    "Column": "Q9er4",
    "Description": "Q9er4: Genentech / Roche - How satisfied were you with the MOST RECENT interaction?",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10",
    "ParentQuestion": "Q9e"
  },
  {
    "Column": "Q9er5",
    "Description": "Q9er5: Pfizer - How satisfied were you with the MOST RECENT interaction?",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10",
    "ParentQuestion": "Q9e"
  },
  {
    "Column": "Q9er6",
    "Description": "Q9er6: Janssen / Johnson & Johnson - How satisfied were you with the MOST RECENT interaction?",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10",
    "ParentQuestion": "Q9e"
  },
  {
    "Column": "Q9er7",
    "Description": "Q9er7: Bayer - How satisfied were you with the MOST RECENT interaction?",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10",
    "ParentQuestion": "Q9e"
  },
  {
    "Column": "Q9er8",
    "Description": "Q9er8: Abbvie - How satisfied were you with the MOST RECENT interaction?",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10",
    "ParentQuestion": "Q9e"
  },
  {
    "Column": "Q9er9",
    "Description": "Q9er9: Sanofi - How satisfied were you with the MOST RECENT interaction?",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10",
    "ParentQuestion": "Q9e"
  },
  {
    "Column": "Q9er10",
    "Description": "Q9er10: Lilly - How satisfied were you with the MOST RECENT interaction?",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10",
    "ParentQuestion": "Q9e"
  },
  {
    "Column": "Q9er11",
    "Description": "Q9er11: Novartis - How satisfied were you with the MOST RECENT interaction?",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10",
    "ParentQuestion": "Q9e"
  },
  {
    "Column": "Q9er12",
    "Description": "Q9er12: Daiichi-Sankyo - How satisfied were you with the MOST RECENT interaction?",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10",
    "ParentQuestion": "Q9e"
  },
  {
    "Column": "Q9er13",
    "Description": "Q9er13: Amgen - How satisfied were you with the MOST RECENT interaction?",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10",
    "ParentQuestion": "Q9e"
  },
  {
    "Column": "Q9er14",
    "Description": "Q9er14: Seattle Genetics - How satisfied were you with the MOST RECENT interaction?",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10",
    "ParentQuestion": "Q9e"
  },
  {
    "Column": "Q9er15",
    "Description": "Q9er15: GSK - How satisfied were you with the MOST RECENT interaction?",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10",
    "ParentQuestion": "Q9e"
  },
  {
    "Column": "Q9er16",
    "Description": "Q9er16: AstraZeneca - How satisfied were you with the MOST RECENT interaction?",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10",
    "ParentQuestion": "Q9e"
  },
  {
    "Column": "Q9er17",
    "Description": "Q9er17: Immunomedics - How satisfied were you with the MOST RECENT interaction?",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10",
    "ParentQuestion": "Q9e"
  },
  {
    "Column": "Q9f_Lr1r1",
    "Description": "Q9f_Lr1r1: Why did you give that rating for Astellas?",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9f_Lr1"
  },
  {
    "Column": "Q9f_Lr2r1",
    "Description": "Q9f_Lr2r1: Why did you give that rating for Merck?",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9f_Lr2"
  },
  {
    "Column": "Q9f_Lr3r1",
    "Description": "Q9f_Lr3r1: Why did you give that rating for Bristol-Myers Squibb (BMS)?",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9f_Lr3"
  },
  {
    "Column": "Q9f_Lr4r1",
    "Description": "Q9f_Lr4r1: Why did you give that rating for Genentech / Roche?",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9f_Lr4"
  },
  {
    "Column": "Q9f_Lr5r1",
    "Description": "Q9f_Lr5r1: Why did you give that rating for Pfizer?",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9f_Lr5"
  },
  {
    "Column": "Q9f_Lr6r1",
    "Description": "Q9f_Lr6r1: Why did you give that rating for Janssen / Johnson & Johnson?",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9f_Lr6"
  },
  {
    "Column": "Q9f_Lr7r1",
    "Description": "Q9f_Lr7r1: Why did you give that rating for Bayer?",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9f_Lr7"
  },
  {
    "Column": "Q9f_Lr8r1",
    "Description": "Q9f_Lr8r1: Why did you give that rating for Abbvie?",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9f_Lr8"
  },
  {
    "Column": "Q9f_Lr9r1",
    "Description": "Q9f_Lr9r1: Why did you give that rating for Sanofi?",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9f_Lr9"
  },
  {
    "Column": "Q9f_Lr10r1",
    "Description": "Q9f_Lr10r1: Why did you give that rating for Lilly?",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9f_Lr10"
  },
  {
    "Column": "Q9f_Lr11r1",
    "Description": "Q9f_Lr11r1: Why did you give that rating for Novartis?",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9f_Lr11"
  },
  {
    "Column": "Q9f_Lr12r1",
    "Description": "Q9f_Lr12r1: Why did you give that rating for Daiichi-Sankyo?",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9f_Lr12"
  },
  {
    "Column": "Q9f_Lr13r1",
    "Description": "Q9f_Lr13r1: Why did you give that rating for Amgen?",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9f_Lr13"
  },
  {
    "Column": "Q9f_Lr14r1",
    "Description": "Q9f_Lr14r1: Why did you give that rating for Seattle Genetics?",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9f_Lr14"
  },
  {
    "Column": "Q9f_Lr15r1",
    "Description": "Q9f_Lr15r1: Why did you give that rating for GSK?",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9f_Lr15"
  },
  {
    "Column": "Q9f_Lr16r1",
    "Description": "Q9f_Lr16r1: Why did you give that rating for AstraZeneca?",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9f_Lr16"
  },
  {
    "Column": "Q9f_Lr17r1",
    "Description": "Q9f_Lr17r1: Why did you give that rating for Immunomedics?",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9f_Lr17"
  },
  {
    "Column": "Q9gr1",
    "Description": "Q9gr1: Understands our practice’s interests (e.g. provides information based on what would be valuable for us) - Earlier you rated your experience with the personnel you interact with most frequently related to oncology drugs from several companies on t",
    "Answer_Options": "1=1,2=2,3=3",
    "ParentQuestion": "Q9g"
  },
  {
    "Column": "Q9gr2",
    "Description": "Q9gr2: Understands our practice’s patient population (e.g. understands which drugs are relevant, our coverage needs) - Earlier you rated your experience with the personnel you interact with most frequently related to oncology drugs from several companie",
    "Answer_Options": "1=1,2=2,3=3",
    "ParentQuestion": "Q9g"
  },
  {
    "Column": "Q9gr3",
    "Description": "Q9gr3: Understands our practice’s logistics/preferences (e.g. understands who to speak to, when/how to reach out) - Earlier you rated your experience with the personnel you interact with most frequently related to oncology drugs from several companies o",
    "Answer_Options": "1=1,2=2,3=3",
    "ParentQuestion": "Q9g"
  },
  {
    "Column": "Q9gr4",
    "Description": "Q9gr4: Other - Earlier you rated your experience with the personnel you interact with most frequently related to oncology drugs from several companies on the attribute of “Understands my practice.” In general, what is most important to you when thinki",
    "Answer_Options": "1=1,2=2,3=3",
    "ParentQuestion": "Q9g"
  },
  {
    "Column": "Q9G_OEr1",
    "Description": "Q9G_OEr1: You mentioned “other” in ranking personnel “understanding your practice”. What specifically were you thinking of?",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9G_OE"
  },
  {
    "Column": "Q9h_Lr1r1",
    "Description": "Q9h_Lr1r1: Understands our practice’s interests (e.g. provides information based on what would be valuable for us) - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Astellas on the attr",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr1"
  },
  {
    "Column": "Q9h_Lr1r2",
    "Description": "Q9h_Lr1r2: Understands our practice’s patient population (e.g. understands which drugs are relevant, our coverage needs) - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Astellas on th",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr1"
  },
  {
    "Column": "Q9h_Lr1r3",
    "Description": "Q9h_Lr1r3: Understands our practice’s logistics/preferences (e.g. understands who to speak to, when/how to reach out) - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Astellas on the a",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr1"
  },
  {
    "Column": "Q9h_Lr1r4",
    "Description": "Q9h_Lr1r4: $ {Q9G_OE.r1.val} - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Astellas on the attributes relating to “Understanding your practice”.These can be reps, account managers",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr1"
  },
  {
    "Column": "Q9h_Lr2r1",
    "Description": "Q9h_Lr2r1: Understands our practice’s interests (e.g. provides information based on what would be valuable for us) - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Merck on the attribu",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr2"
  },
  {
    "Column": "Q9h_Lr2r2",
    "Description": "Q9h_Lr2r2: Understands our practice’s patient population (e.g. understands which drugs are relevant, our coverage needs) - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Merck on the a",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr2"
  },
  {
    "Column": "Q9h_Lr2r3",
    "Description": "Q9h_Lr2r3: Understands our practice’s logistics/preferences (e.g. understands who to speak to, when/how to reach out) - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Merck on the attr",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr2"
  },
  {
    "Column": "Q9h_Lr2r4",
    "Description": "Q9h_Lr2r4: $ {Q9G_OE.r1.val} - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Merck on the attributes relating to “Understanding your practice”.These can be reps, account managers, M",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr2"
  },
  {
    "Column": "Q9h_Lr3r1",
    "Description": "Q9h_Lr3r1: Understands our practice’s interests (e.g. provides information based on what would be valuable for us) - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Bristol-Myers Squibb",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr3"
  },
  {
    "Column": "Q9h_Lr3r2",
    "Description": "Q9h_Lr3r2: Understands our practice’s patient population (e.g. understands which drugs are relevant, our coverage needs) - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Bristol-Myers",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr3"
  },
  {
    "Column": "Q9h_Lr3r3",
    "Description": "Q9h_Lr3r3: Understands our practice’s logistics/preferences (e.g. understands who to speak to, when/how to reach out) - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Bristol-Myers Squ",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr3"
  },
  {
    "Column": "Q9h_Lr3r4",
    "Description": "Q9h_Lr3r4: $ {Q9G_OE.r1.val} - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Bristol-Myers Squibb (BMS) on the attributes relating to “Understanding your practice”.These can be reps",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr3"
  },
  {
    "Column": "Q9h_Lr4r1",
    "Description": "Q9h_Lr4r1: Understands our practice’s interests (e.g. provides information based on what would be valuable for us) - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Genentech / Roche on",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr4"
  },
  {
    "Column": "Q9h_Lr4r2",
    "Description": "Q9h_Lr4r2: Understands our practice’s patient population (e.g. understands which drugs are relevant, our coverage needs) - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Genentech / Ro",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr4"
  },
  {
    "Column": "Q9h_Lr4r3",
    "Description": "Q9h_Lr4r3: Understands our practice’s logistics/preferences (e.g. understands who to speak to, when/how to reach out) - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Genentech / Roche",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr4"
  },
  {
    "Column": "Q9h_Lr4r4",
    "Description": "Q9h_Lr4r4: $ {Q9G_OE.r1.val} - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Genentech / Roche on the attributes relating to “Understanding your practice”.These can be reps, account",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr4"
  },
  {
    "Column": "Q9h_Lr5r1",
    "Description": "Q9h_Lr5r1: Understands our practice’s interests (e.g. provides information based on what would be valuable for us) - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Pfizer on the attrib",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr5"
  },
  {
    "Column": "Q9h_Lr5r2",
    "Description": "Q9h_Lr5r2: Understands our practice’s patient population (e.g. understands which drugs are relevant, our coverage needs) - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Pfizer on the",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr5"
  },
  {
    "Column": "Q9h_Lr5r3",
    "Description": "Q9h_Lr5r3: Understands our practice’s logistics/preferences (e.g. understands who to speak to, when/how to reach out) - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Pfizer on the att",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr5"
  },
  {
    "Column": "Q9h_Lr5r4",
    "Description": "Q9h_Lr5r4: $ {Q9G_OE.r1.val} - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Pfizer on the attributes relating to “Understanding your practice”.These can be reps, account managers,",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr5"
  },
  {
    "Column": "Q9h_Lr6r1",
    "Description": "Q9h_Lr6r1: Understands our practice’s interests (e.g. provides information based on what would be valuable for us) - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Janssen / Johnson &",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr6"
  },
  {
    "Column": "Q9h_Lr6r2",
    "Description": "Q9h_Lr6r2: Understands our practice’s patient population (e.g. understands which drugs are relevant, our coverage needs) - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Janssen / John",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr6"
  },
  {
    "Column": "Q9h_Lr6r3",
    "Description": "Q9h_Lr6r3: Understands our practice’s logistics/preferences (e.g. understands who to speak to, when/how to reach out) - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Janssen / Johnson",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr6"
  },
  {
    "Column": "Q9h_Lr6r4",
    "Description": "Q9h_Lr6r4: $ {Q9G_OE.r1.val} - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Janssen / Johnson & Johnson on the attributes relating to “Understanding your practice”.These can be rep",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr6"
  },
  {
    "Column": "Q9h_Lr7r1",
    "Description": "Q9h_Lr7r1: Understands our practice’s interests (e.g. provides information based on what would be valuable for us) - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Bayer on the attribu",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr7"
  },
  {
    "Column": "Q9h_Lr7r2",
    "Description": "Q9h_Lr7r2: Understands our practice’s patient population (e.g. understands which drugs are relevant, our coverage needs) - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Bayer on the a",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr7"
  },
  {
    "Column": "Q9h_Lr7r3",
    "Description": "Q9h_Lr7r3: Understands our practice’s logistics/preferences (e.g. understands who to speak to, when/how to reach out) - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Bayer on the attr",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr7"
  },
  {
    "Column": "Q9h_Lr7r4",
    "Description": "Q9h_Lr7r4: $ {Q9G_OE.r1.val} - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Bayer on the attributes relating to “Understanding your practice”.These can be reps, account managers, M",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr7"
  },
  {
    "Column": "Q9h_Lr8r1",
    "Description": "Q9h_Lr8r1: Understands our practice’s interests (e.g. provides information based on what would be valuable for us) - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Abbvie on the attrib",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr8"
  },
  {
    "Column": "Q9h_Lr8r2",
    "Description": "Q9h_Lr8r2: Understands our practice’s patient population (e.g. understands which drugs are relevant, our coverage needs) - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Abbvie on the",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr8"
  },
  {
    "Column": "Q9h_Lr8r3",
    "Description": "Q9h_Lr8r3: Understands our practice’s logistics/preferences (e.g. understands who to speak to, when/how to reach out) - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Abbvie on the att",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr8"
  },
  {
    "Column": "Q9h_Lr8r4",
    "Description": "Q9h_Lr8r4: $ {Q9G_OE.r1.val} - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Abbvie on the attributes relating to “Understanding your practice”.These can be reps, account managers,",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr8"
  },
  {
    "Column": "Q9h_Lr9r1",
    "Description": "Q9h_Lr9r1: Understands our practice’s interests (e.g. provides information based on what would be valuable for us) - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Sanofi on the attrib",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr9"
  },
  {
    "Column": "Q9h_Lr9r2",
    "Description": "Q9h_Lr9r2: Understands our practice’s patient population (e.g. understands which drugs are relevant, our coverage needs) - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Sanofi on the",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr9"
  },
  {
    "Column": "Q9h_Lr9r3",
    "Description": "Q9h_Lr9r3: Understands our practice’s logistics/preferences (e.g. understands who to speak to, when/how to reach out) - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Sanofi on the att",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr9"
  },
  {
    "Column": "Q9h_Lr9r4",
    "Description": "Q9h_Lr9r4: $ {Q9G_OE.r1.val} - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Sanofi on the attributes relating to “Understanding your practice”.These can be reps, account managers,",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr9"
  },
  {
    "Column": "Q9h_Lr10r1",
    "Description": "Q9h_Lr10r1: Understands our practice’s interests (e.g. provides information based on what would be valuable for us) - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Lilly on the attrib",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr10"
  },
  {
    "Column": "Q9h_Lr10r2",
    "Description": "Q9h_Lr10r2: Understands our practice’s patient population (e.g. understands which drugs are relevant, our coverage needs) - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Lilly on the",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr10"
  },
  {
    "Column": "Q9h_Lr10r3",
    "Description": "Q9h_Lr10r3: Understands our practice’s logistics/preferences (e.g. understands who to speak to, when/how to reach out) - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Lilly on the att",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr10"
  },
  {
    "Column": "Q9h_Lr10r4",
    "Description": "Q9h_Lr10r4: $ {Q9G_OE.r1.val} - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Lilly on the attributes relating to “Understanding your practice”.These can be reps, account managers,",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr10"
  },
  {
    "Column": "Q9h_Lr11r1",
    "Description": "Q9h_Lr11r1: Understands our practice’s interests (e.g. provides information based on what would be valuable for us) - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Novartis on the att",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr11"
  },
  {
    "Column": "Q9h_Lr11r2",
    "Description": "Q9h_Lr11r2: Understands our practice’s patient population (e.g. understands which drugs are relevant, our coverage needs) - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Novartis on t",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr11"
  },
  {
    "Column": "Q9h_Lr11r3",
    "Description": "Q9h_Lr11r3: Understands our practice’s logistics/preferences (e.g. understands who to speak to, when/how to reach out) - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Novartis on the",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr11"
  },
  {
    "Column": "Q9h_Lr11r4",
    "Description": "Q9h_Lr11r4: $ {Q9G_OE.r1.val} - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Novartis on the attributes relating to “Understanding your practice”.These can be reps, account manager",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr11"
  },
  {
    "Column": "Q9h_Lr12r1",
    "Description": "Q9h_Lr12r1: Understands our practice’s interests (e.g. provides information based on what would be valuable for us) - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Daiichi-Sankyo on t",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr12"
  },
  {
    "Column": "Q9h_Lr12r2",
    "Description": "Q9h_Lr12r2: Understands our practice’s patient population (e.g. understands which drugs are relevant, our coverage needs) - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Daiichi-Sanky",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr12"
  },
  {
    "Column": "Q9h_Lr12r3",
    "Description": "Q9h_Lr12r3: Understands our practice’s logistics/preferences (e.g. understands who to speak to, when/how to reach out) - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Daiichi-Sankyo o",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr12"
  },
  {
    "Column": "Q9h_Lr12r4",
    "Description": "Q9h_Lr12r4: $ {Q9G_OE.r1.val} - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Daiichi-Sankyo on the attributes relating to “Understanding your practice”.These can be reps, account m",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr12"
  },
  {
    "Column": "Q9h_Lr13r1",
    "Description": "Q9h_Lr13r1: Understands our practice’s interests (e.g. provides information based on what would be valuable for us) - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Amgen on the attrib",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr13"
  },
  {
    "Column": "Q9h_Lr13r2",
    "Description": "Q9h_Lr13r2: Understands our practice’s patient population (e.g. understands which drugs are relevant, our coverage needs) - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Amgen on the",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr13"
  },
  {
    "Column": "Q9h_Lr13r3",
    "Description": "Q9h_Lr13r3: Understands our practice’s logistics/preferences (e.g. understands who to speak to, when/how to reach out) - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Amgen on the att",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr13"
  },
  {
    "Column": "Q9h_Lr13r4",
    "Description": "Q9h_Lr13r4: $ {Q9G_OE.r1.val} - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Amgen on the attributes relating to “Understanding your practice”.These can be reps, account managers,",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr13"
  },
  {
    "Column": "Q9h_Lr14r1",
    "Description": "Q9h_Lr14r1: Understands our practice’s interests (e.g. provides information based on what would be valuable for us) - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Seattle Genetics on",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr14"
  },
  {
    "Column": "Q9h_Lr14r2",
    "Description": "Q9h_Lr14r2: Understands our practice’s patient population (e.g. understands which drugs are relevant, our coverage needs) - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Seattle Genet",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr14"
  },
  {
    "Column": "Q9h_Lr14r3",
    "Description": "Q9h_Lr14r3: Understands our practice’s logistics/preferences (e.g. understands who to speak to, when/how to reach out) - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Seattle Genetics",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr14"
  },
  {
    "Column": "Q9h_Lr14r4",
    "Description": "Q9h_Lr14r4: $ {Q9G_OE.r1.val} - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Seattle Genetics on the attributes relating to “Understanding your practice”.These can be reps, account",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr14"
  },
  {
    "Column": "Q9h_Lr15r1",
    "Description": "Q9h_Lr15r1: Understands our practice’s interests (e.g. provides information based on what would be valuable for us) - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from GSK on the attribut",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr15"
  },
  {
    "Column": "Q9h_Lr15r2",
    "Description": "Q9h_Lr15r2: Understands our practice’s patient population (e.g. understands which drugs are relevant, our coverage needs) - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from GSK on the at",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr15"
  },
  {
    "Column": "Q9h_Lr15r3",
    "Description": "Q9h_Lr15r3: Understands our practice’s logistics/preferences (e.g. understands who to speak to, when/how to reach out) - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from GSK on the attri",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr15"
  },
  {
    "Column": "Q9h_Lr15r4",
    "Description": "Q9h_Lr15r4: $ {Q9G_OE.r1.val} - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from GSK on the attributes relating to “Understanding your practice”.These can be reps, account managers, MS",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr15"
  },
  {
    "Column": "Q9h_Lr16r1",
    "Description": "Q9h_Lr16r1: Understands our practice’s interests (e.g. provides information based on what would be valuable for us) - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from AstraZeneca on the",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr16"
  },
  {
    "Column": "Q9h_Lr16r2",
    "Description": "Q9h_Lr16r2: Understands our practice’s patient population (e.g. understands which drugs are relevant, our coverage needs) - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from AstraZeneca o",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr16"
  },
  {
    "Column": "Q9h_Lr16r3",
    "Description": "Q9h_Lr16r3: Understands our practice’s logistics/preferences (e.g. understands who to speak to, when/how to reach out) - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from AstraZeneca on t",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr16"
  },
  {
    "Column": "Q9h_Lr16r4",
    "Description": "Q9h_Lr16r4: $ {Q9G_OE.r1.val} - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from AstraZeneca on the attributes relating to “Understanding your practice”.These can be reps, account mana",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr16"
  },
  {
    "Column": "Q9h_Lr17r1",
    "Description": "Q9h_Lr17r1: Understands our practice’s interests (e.g. provides information based on what would be valuable for us) - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Immunomedics on the",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr17"
  },
  {
    "Column": "Q9h_Lr17r2",
    "Description": "Q9h_Lr17r2: Understands our practice’s patient population (e.g. understands which drugs are relevant, our coverage needs) - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Immunomedics",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr17"
  },
  {
    "Column": "Q9h_Lr17r3",
    "Description": "Q9h_Lr17r3: Understands our practice’s logistics/preferences (e.g. understands who to speak to, when/how to reach out) - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Immunomedics on",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr17"
  },
  {
    "Column": "Q9h_Lr17r4",
    "Description": "Q9h_Lr17r4: $ {Q9G_OE.r1.val} - Now please rate your experience with the personnel you interact with most frequently related to oncology drugs from Immunomedics on the attributes relating to “Understanding your practice”.These can be reps, account man",
    "Answer_Options": "1=Does Not Describe at all1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Describes Completely 10",
    "ParentQuestion": "Q9h_Lr17"
  },
  {
    "Column": "Q9Ir1c1",
    "Description": "Q9Ir1c1: Astellas - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir1c2",
    "Description": "Q9Ir1c2: Merck - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir1c3",
    "Description": "Q9Ir1c3: Bristol-Myers Squibb (BMS) - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir1c4",
    "Description": "Q9Ir1c4: Genentech / Roche - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir1c5",
    "Description": "Q9Ir1c5: Pfizer - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir1c6",
    "Description": "Q9Ir1c6: Janssen / Johnson & Johnson - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir1c7",
    "Description": "Q9Ir1c7: Bayer - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir1c8",
    "Description": "Q9Ir1c8: Abbvie - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir1c9",
    "Description": "Q9Ir1c9: Sanofi - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir1c10",
    "Description": "Q9Ir1c10: Lilly - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir1c11",
    "Description": "Q9Ir1c11: Novartis - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir1c12",
    "Description": "Q9Ir1c12: Daiichi-Sankyo - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir1c13",
    "Description": "Q9Ir1c13: Amgen - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir1c14",
    "Description": "Q9Ir1c14: Seattle Genetics - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir1c15",
    "Description": "Q9Ir1c15: GSK - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir1c16",
    "Description": "Q9Ir1c16: AstraZeneca - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir1c17",
    "Description": "Q9Ir1c17: Immunomedics - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir2c1",
    "Description": "Q9Ir2c1: Astellas - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir2c2",
    "Description": "Q9Ir2c2: Merck - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir2c3",
    "Description": "Q9Ir2c3: Bristol-Myers Squibb (BMS) - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir2c4",
    "Description": "Q9Ir2c4: Genentech / Roche - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir2c5",
    "Description": "Q9Ir2c5: Pfizer - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir2c6",
    "Description": "Q9Ir2c6: Janssen / Johnson & Johnson - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir2c7",
    "Description": "Q9Ir2c7: Bayer - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir2c8",
    "Description": "Q9Ir2c8: Abbvie - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir2c9",
    "Description": "Q9Ir2c9: Sanofi - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir2c10",
    "Description": "Q9Ir2c10: Lilly - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir2c11",
    "Description": "Q9Ir2c11: Novartis - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir2c12",
    "Description": "Q9Ir2c12: Daiichi-Sankyo - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir2c13",
    "Description": "Q9Ir2c13: Amgen - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir2c14",
    "Description": "Q9Ir2c14: Seattle Genetics - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir2c15",
    "Description": "Q9Ir2c15: GSK - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir2c16",
    "Description": "Q9Ir2c16: AstraZeneca - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir2c17",
    "Description": "Q9Ir2c17: Immunomedics - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir3c1",
    "Description": "Q9Ir3c1: Astellas - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir3c2",
    "Description": "Q9Ir3c2: Merck - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir3c3",
    "Description": "Q9Ir3c3: Bristol-Myers Squibb (BMS) - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir3c4",
    "Description": "Q9Ir3c4: Genentech / Roche - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir3c5",
    "Description": "Q9Ir3c5: Pfizer - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir3c6",
    "Description": "Q9Ir3c6: Janssen / Johnson & Johnson - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir3c7",
    "Description": "Q9Ir3c7: Bayer - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir3c8",
    "Description": "Q9Ir3c8: Abbvie - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir3c9",
    "Description": "Q9Ir3c9: Sanofi - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir3c10",
    "Description": "Q9Ir3c10: Lilly - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir3c11",
    "Description": "Q9Ir3c11: Novartis - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir3c12",
    "Description": "Q9Ir3c12: Daiichi-Sankyo - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir3c13",
    "Description": "Q9Ir3c13: Amgen - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir3c14",
    "Description": "Q9Ir3c14: Seattle Genetics - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir3c15",
    "Description": "Q9Ir3c15: GSK - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir3c16",
    "Description": "Q9Ir3c16: AstraZeneca - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir3c17",
    "Description": "Q9Ir3c17: Immunomedics - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir4c1",
    "Description": "Q9Ir4c1: Astellas - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir4c2",
    "Description": "Q9Ir4c2: Merck - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir4c3",
    "Description": "Q9Ir4c3: Bristol-Myers Squibb (BMS) - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir4c4",
    "Description": "Q9Ir4c4: Genentech / Roche - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir4c5",
    "Description": "Q9Ir4c5: Pfizer - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir4c6",
    "Description": "Q9Ir4c6: Janssen / Johnson & Johnson - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir4c7",
    "Description": "Q9Ir4c7: Bayer - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir4c8",
    "Description": "Q9Ir4c8: Abbvie - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir4c9",
    "Description": "Q9Ir4c9: Sanofi - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir4c10",
    "Description": "Q9Ir4c10: Lilly - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir4c11",
    "Description": "Q9Ir4c11: Novartis - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir4c12",
    "Description": "Q9Ir4c12: Daiichi-Sankyo - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir4c13",
    "Description": "Q9Ir4c13: Amgen - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir4c14",
    "Description": "Q9Ir4c14: Seattle Genetics - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir4c15",
    "Description": "Q9Ir4c15: GSK - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir4c16",
    "Description": "Q9Ir4c16: AstraZeneca - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir4c17",
    "Description": "Q9Ir4c17: Immunomedics - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir5c1",
    "Description": "Q9Ir5c1: Astellas - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir5c2",
    "Description": "Q9Ir5c2: Merck - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir5c3",
    "Description": "Q9Ir5c3: Bristol-Myers Squibb (BMS) - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir5c4",
    "Description": "Q9Ir5c4: Genentech / Roche - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir5c5",
    "Description": "Q9Ir5c5: Pfizer - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir5c6",
    "Description": "Q9Ir5c6: Janssen / Johnson & Johnson - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir5c7",
    "Description": "Q9Ir5c7: Bayer - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir5c8",
    "Description": "Q9Ir5c8: Abbvie - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir5c9",
    "Description": "Q9Ir5c9: Sanofi - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir5c10",
    "Description": "Q9Ir5c10: Lilly - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir5c11",
    "Description": "Q9Ir5c11: Novartis - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir5c12",
    "Description": "Q9Ir5c12: Daiichi-Sankyo - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir5c13",
    "Description": "Q9Ir5c13: Amgen - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir5c14",
    "Description": "Q9Ir5c14: Seattle Genetics - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir5c15",
    "Description": "Q9Ir5c15: GSK - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir5c16",
    "Description": "Q9Ir5c16: AstraZeneca - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir5c17",
    "Description": "Q9Ir5c17: Immunomedics - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir6c1",
    "Description": "Q9Ir6c1: Astellas - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir6c2",
    "Description": "Q9Ir6c2: Merck - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir6c3",
    "Description": "Q9Ir6c3: Bristol-Myers Squibb (BMS) - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir6c4",
    "Description": "Q9Ir6c4: Genentech / Roche - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir6c5",
    "Description": "Q9Ir6c5: Pfizer - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir6c6",
    "Description": "Q9Ir6c6: Janssen / Johnson & Johnson - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir6c7",
    "Description": "Q9Ir6c7: Bayer - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir6c8",
    "Description": "Q9Ir6c8: Abbvie - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir6c9",
    "Description": "Q9Ir6c9: Sanofi - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir6c10",
    "Description": "Q9Ir6c10: Lilly - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir6c11",
    "Description": "Q9Ir6c11: Novartis - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir6c12",
    "Description": "Q9Ir6c12: Daiichi-Sankyo - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir6c13",
    "Description": "Q9Ir6c13: Amgen - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir6c14",
    "Description": "Q9Ir6c14: Seattle Genetics - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir6c15",
    "Description": "Q9Ir6c15: GSK - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir6c16",
    "Description": "Q9Ir6c16: AstraZeneca - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir6c17",
    "Description": "Q9Ir6c17: Immunomedics - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir7c1",
    "Description": "Q9Ir7c1: Astellas - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir7c2",
    "Description": "Q9Ir7c2: Merck - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir7c3",
    "Description": "Q9Ir7c3: Bristol-Myers Squibb (BMS) - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir7c4",
    "Description": "Q9Ir7c4: Genentech / Roche - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir7c5",
    "Description": "Q9Ir7c5: Pfizer - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir7c6",
    "Description": "Q9Ir7c6: Janssen / Johnson & Johnson - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir7c7",
    "Description": "Q9Ir7c7: Bayer - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir7c8",
    "Description": "Q9Ir7c8: Abbvie - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir7c9",
    "Description": "Q9Ir7c9: Sanofi - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir7c10",
    "Description": "Q9Ir7c10: Lilly - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir7c11",
    "Description": "Q9Ir7c11: Novartis - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir7c12",
    "Description": "Q9Ir7c12: Daiichi-Sankyo - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir7c13",
    "Description": "Q9Ir7c13: Amgen - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir7c14",
    "Description": "Q9Ir7c14: Seattle Genetics - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir7c15",
    "Description": "Q9Ir7c15: GSK - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir7c16",
    "Description": "Q9Ir7c16: AstraZeneca - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir7c17",
    "Description": "Q9Ir7c17: Immunomedics - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir8c1",
    "Description": "Q9Ir8c1: Astellas - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir8c2",
    "Description": "Q9Ir8c2: Merck - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir8c3",
    "Description": "Q9Ir8c3: Bristol-Myers Squibb (BMS) - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir8c4",
    "Description": "Q9Ir8c4: Genentech / Roche - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir8c5",
    "Description": "Q9Ir8c5: Pfizer - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir8c6",
    "Description": "Q9Ir8c6: Janssen / Johnson & Johnson - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir8c7",
    "Description": "Q9Ir8c7: Bayer - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir8c8",
    "Description": "Q9Ir8c8: Abbvie - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir8c9",
    "Description": "Q9Ir8c9: Sanofi - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir8c10",
    "Description": "Q9Ir8c10: Lilly - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir8c11",
    "Description": "Q9Ir8c11: Novartis - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir8c12",
    "Description": "Q9Ir8c12: Daiichi-Sankyo - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir8c13",
    "Description": "Q9Ir8c13: Amgen - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir8c14",
    "Description": "Q9Ir8c14: Seattle Genetics - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir8c15",
    "Description": "Q9Ir8c15: GSK - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir8c16",
    "Description": "Q9Ir8c16: AstraZeneca - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir8c17",
    "Description": "Q9Ir8c17: Immunomedics - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir9c1",
    "Description": "Q9Ir9c1: Astellas - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir9c2",
    "Description": "Q9Ir9c2: Merck - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir9c3",
    "Description": "Q9Ir9c3: Bristol-Myers Squibb (BMS) - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir9c4",
    "Description": "Q9Ir9c4: Genentech / Roche - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir9c5",
    "Description": "Q9Ir9c5: Pfizer - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir9c6",
    "Description": "Q9Ir9c6: Janssen / Johnson & Johnson - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir9c7",
    "Description": "Q9Ir9c7: Bayer - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir9c8",
    "Description": "Q9Ir9c8: Abbvie - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir9c9",
    "Description": "Q9Ir9c9: Sanofi - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir9c10",
    "Description": "Q9Ir9c10: Lilly - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir9c11",
    "Description": "Q9Ir9c11: Novartis - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir9c12",
    "Description": "Q9Ir9c12: Daiichi-Sankyo - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir9c13",
    "Description": "Q9Ir9c13: Amgen - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir9c14",
    "Description": "Q9Ir9c14: Seattle Genetics - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir9c15",
    "Description": "Q9Ir9c15: GSK - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir9c16",
    "Description": "Q9Ir9c16: AstraZeneca - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir9c17",
    "Description": "Q9Ir9c17: Immunomedics - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir10c1",
    "Description": "Q9Ir10c1: Astellas - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir10c2",
    "Description": "Q9Ir10c2: Merck - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir10c3",
    "Description": "Q9Ir10c3: Bristol-Myers Squibb (BMS) - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir10c4",
    "Description": "Q9Ir10c4: Genentech / Roche - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir10c5",
    "Description": "Q9Ir10c5: Pfizer - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir10c6",
    "Description": "Q9Ir10c6: Janssen / Johnson & Johnson - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir10c7",
    "Description": "Q9Ir10c7: Bayer - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir10c8",
    "Description": "Q9Ir10c8: Abbvie - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir10c9",
    "Description": "Q9Ir10c9: Sanofi - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir10c10",
    "Description": "Q9Ir10c10: Lilly - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir10c11",
    "Description": "Q9Ir10c11: Novartis - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir10c12",
    "Description": "Q9Ir10c12: Daiichi-Sankyo - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir10c13",
    "Description": "Q9Ir10c13: Amgen - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir10c14",
    "Description": "Q9Ir10c14: Seattle Genetics - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir10c15",
    "Description": "Q9Ir10c15: GSK - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir10c16",
    "Description": "Q9Ir10c16: AstraZeneca - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir10c17",
    "Description": "Q9Ir10c17: Immunomedics - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir11c1",
    "Description": "Q9Ir11c1: Astellas - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir11c2",
    "Description": "Q9Ir11c2: Merck - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir11c3",
    "Description": "Q9Ir11c3: Bristol-Myers Squibb (BMS) - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir11c4",
    "Description": "Q9Ir11c4: Genentech / Roche - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir11c5",
    "Description": "Q9Ir11c5: Pfizer - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir11c6",
    "Description": "Q9Ir11c6: Janssen / Johnson & Johnson - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir11c7",
    "Description": "Q9Ir11c7: Bayer - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir11c8",
    "Description": "Q9Ir11c8: Abbvie - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir11c9",
    "Description": "Q9Ir11c9: Sanofi - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir11c10",
    "Description": "Q9Ir11c10: Lilly - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir11c11",
    "Description": "Q9Ir11c11: Novartis - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir11c12",
    "Description": "Q9Ir11c12: Daiichi-Sankyo - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir11c13",
    "Description": "Q9Ir11c13: Amgen - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir11c14",
    "Description": "Q9Ir11c14: Seattle Genetics - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir11c15",
    "Description": "Q9Ir11c15: GSK - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir11c16",
    "Description": "Q9Ir11c16: AstraZeneca - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir11c17",
    "Description": "Q9Ir11c17: Immunomedics - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir12c1",
    "Description": "Q9Ir12c1: Astellas - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir12c2",
    "Description": "Q9Ir12c2: Merck - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir12c3",
    "Description": "Q9Ir12c3: Bristol-Myers Squibb (BMS) - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir12c4",
    "Description": "Q9Ir12c4: Genentech / Roche - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir12c5",
    "Description": "Q9Ir12c5: Pfizer - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir12c6",
    "Description": "Q9Ir12c6: Janssen / Johnson & Johnson - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir12c7",
    "Description": "Q9Ir12c7: Bayer - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir12c8",
    "Description": "Q9Ir12c8: Abbvie - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir12c9",
    "Description": "Q9Ir12c9: Sanofi - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir12c10",
    "Description": "Q9Ir12c10: Lilly - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir12c11",
    "Description": "Q9Ir12c11: Novartis - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir12c12",
    "Description": "Q9Ir12c12: Daiichi-Sankyo - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir12c13",
    "Description": "Q9Ir12c13: Amgen - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir12c14",
    "Description": "Q9Ir12c14: Seattle Genetics - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir12c15",
    "Description": "Q9Ir12c15: GSK - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir12c16",
    "Description": "Q9Ir12c16: AstraZeneca - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir12c17",
    "Description": "Q9Ir12c17: Immunomedics - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir13c1",
    "Description": "Q9Ir13c1: Astellas - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir13c2",
    "Description": "Q9Ir13c2: Merck - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir13c3",
    "Description": "Q9Ir13c3: Bristol-Myers Squibb (BMS) - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir13c4",
    "Description": "Q9Ir13c4: Genentech / Roche - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir13c5",
    "Description": "Q9Ir13c5: Pfizer - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir13c6",
    "Description": "Q9Ir13c6: Janssen / Johnson & Johnson - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir13c7",
    "Description": "Q9Ir13c7: Bayer - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir13c8",
    "Description": "Q9Ir13c8: Abbvie - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir13c9",
    "Description": "Q9Ir13c9: Sanofi - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir13c10",
    "Description": "Q9Ir13c10: Lilly - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir13c11",
    "Description": "Q9Ir13c11: Novartis - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir13c12",
    "Description": "Q9Ir13c12: Daiichi-Sankyo - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir13c13",
    "Description": "Q9Ir13c13: Amgen - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir13c14",
    "Description": "Q9Ir13c14: Seattle Genetics - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir13c15",
    "Description": "Q9Ir13c15: GSK - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir13c16",
    "Description": "Q9Ir13c16: AstraZeneca - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir13c17",
    "Description": "Q9Ir13c17: Immunomedics - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir14c1",
    "Description": "Q9Ir14c1: Astellas - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir14c2",
    "Description": "Q9Ir14c2: Merck - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir14c3",
    "Description": "Q9Ir14c3: Bristol-Myers Squibb (BMS) - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir14c4",
    "Description": "Q9Ir14c4: Genentech / Roche - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir14c5",
    "Description": "Q9Ir14c5: Pfizer - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir14c6",
    "Description": "Q9Ir14c6: Janssen / Johnson & Johnson - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir14c7",
    "Description": "Q9Ir14c7: Bayer - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir14c8",
    "Description": "Q9Ir14c8: Abbvie - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir14c9",
    "Description": "Q9Ir14c9: Sanofi - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir14c10",
    "Description": "Q9Ir14c10: Lilly - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir14c11",
    "Description": "Q9Ir14c11: Novartis - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir14c12",
    "Description": "Q9Ir14c12: Daiichi-Sankyo - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir14c13",
    "Description": "Q9Ir14c13: Amgen - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir14c14",
    "Description": "Q9Ir14c14: Seattle Genetics - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir14c15",
    "Description": "Q9Ir14c15: GSK - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir14c16",
    "Description": "Q9Ir14c16: AstraZeneca - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir14c17",
    "Description": "Q9Ir14c17: Immunomedics - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir15c1",
    "Description": "Q9Ir15c1: Astellas - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir15c2",
    "Description": "Q9Ir15c2: Merck - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir15c3",
    "Description": "Q9Ir15c3: Bristol-Myers Squibb (BMS) - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir15c4",
    "Description": "Q9Ir15c4: Genentech / Roche - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir15c5",
    "Description": "Q9Ir15c5: Pfizer - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir15c6",
    "Description": "Q9Ir15c6: Janssen / Johnson & Johnson - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir15c7",
    "Description": "Q9Ir15c7: Bayer - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir15c8",
    "Description": "Q9Ir15c8: Abbvie - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir15c9",
    "Description": "Q9Ir15c9: Sanofi - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir15c10",
    "Description": "Q9Ir15c10: Lilly - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir15c11",
    "Description": "Q9Ir15c11: Novartis - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir15c12",
    "Description": "Q9Ir15c12: Daiichi-Sankyo - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir15c13",
    "Description": "Q9Ir15c13: Amgen - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir15c14",
    "Description": "Q9Ir15c14: Seattle Genetics - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir15c15",
    "Description": "Q9Ir15c15: GSK - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir15c16",
    "Description": "Q9Ir15c16: AstraZeneca - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q9Ir15c17",
    "Description": "Q9Ir15c17: Immunomedics - - For each of the following companies, please indicate which oncology medications you associate with each.",
    "Answer_Options": "NA",
    "ParentQuestion": "Q9I"
  },
  {
    "Column": "Q10_12_PM",
    "Description": "Q10_12_PM: Listfill for Secondary PM",
    "Answer_Options": "1=PC TREATER PM,2=AML TREATER PM,3=BLADDER CANCER TREATER PM"
  },
  {
    "Column": "Q10_AMLr1",
    "Description": "Q10_AMLr1: Xospata (gilteritinib) - For your acute myeloid leukemia (AML) patients, which of the following medications have you personally prescribed in the last 6 months (include both new and refill prescriptions)?",
    "Answer_Options": "0=NO TO: Xospata (gilteritinib),1=Xospata (gilteritinib)",
    "ParentQuestion": "Q10_AML"
  },
  {
    "Column": "Q10_AMLr2",
    "Description": "Q10_AMLr2: RYDAPT (midostaurin) - For your acute myeloid leukemia (AML) patients, which of the following medications have you personally prescribed in the last 6 months (include both new and refill prescriptions)?",
    "Answer_Options": "0=NO TO: RYDAPT (midostaurin),1=RYDAPT (midostaurin)",
    "ParentQuestion": "Q10_AML"
  },
  {
    "Column": "Q10_AMLr3",
    "Description": "Q10_AMLr3: Mylotarg (gemtuzumab ozogamicin) - For your acute myeloid leukemia (AML) patients, which of the following medications have you personally prescribed in the last 6 months (include both new and refill prescriptions)?",
    "Answer_Options": "0=NO TO: Mylotarg (gemtuzumab ozogamicin),1=Mylotarg (gemtuzumab ozogamicin)",
    "ParentQuestion": "Q10_AML"
  },
  {
    "Column": "Q10_AMLr4",
    "Description": "Q10_AMLr4: Tibsovo (Ivosidenib) - For your acute myeloid leukemia (AML) patients, which of the following medications have you personally prescribed in the last 6 months (include both new and refill prescriptions)?",
    "Answer_Options": "0=NO TO: Tibsovo (Ivosidenib),1=Tibsovo (Ivosidenib)",
    "ParentQuestion": "Q10_AML"
  },
  {
    "Column": "Q10_AMLr5",
    "Description": "Q10_AMLr5: Idhifa (enasidenib) - For your acute myeloid leukemia (AML) patients, which of the following medications have you personally prescribed in the last 6 months (include both new and refill prescriptions)?",
    "Answer_Options": "0=NO TO: Idhifa (enasidenib),1=Idhifa (enasidenib)",
    "ParentQuestion": "Q10_AML"
  },
  {
    "Column": "Q10_AMLr6",
    "Description": "Q10_AMLr6: Daurismo (glasdegib) - For your acute myeloid leukemia (AML) patients, which of the following medications have you personally prescribed in the last 6 months (include both new and refill prescriptions)?",
    "Answer_Options": "0=NO TO: Daurismo (glasdegib),1=Daurismo (glasdegib)",
    "ParentQuestion": "Q10_AML"
  },
  {
    "Column": "Q10_AMLr7",
    "Description": "Q10_AMLr7: Venclexta (venetoclax) - For your acute myeloid leukemia (AML) patients, which of the following medications have you personally prescribed in the last 6 months (include both new and refill prescriptions)?",
    "Answer_Options": "0=NO TO: Venclexta (venetoclax),1=Venclexta (venetoclax)",
    "ParentQuestion": "Q10_AML"
  },
  {
    "Column": "Q10_AMLr8",
    "Description": "Q10_AMLr8: Nexavar (sorafenib) - For your acute myeloid leukemia (AML) patients, which of the following medications have you personally prescribed in the last 6 months (include both new and refill prescriptions)?",
    "Answer_Options": "0=NO TO: Nexavar (sorafenib),1=Nexavar (sorafenib)",
    "ParentQuestion": "Q10_AML"
  },
  {
    "Column": "Q10_AMLr9",
    "Description": "Q10_AMLr9: VYXEOS (daunorubicin - cytarabine) - For your acute myeloid leukemia (AML) patients, which of the following medications have you personally prescribed in the last 6 months (include both new and refill prescriptions)?",
    "Answer_Options": "0=NO TO: VYXEOS (daunorubicin - cytarabine),1=VYXEOS (daunorubicin - cytarabine)",
    "ParentQuestion": "Q10_AML"
  },
  {
    "Column": "Q10_AMLr10",
    "Description": "Q10_AMLr10: None of the above - For your acute myeloid leukemia (AML) patients, which of the following medications have you personally prescribed in the last 6 months (include both new and refill prescriptions)?",
    "Answer_Options": "0=NO TO: None of the above,1=None of the above",
    "ParentQuestion": "Q10_AML"
  },
  {
    "Column": "Q11_AML_Lr1r1",
    "Description": "Q11_AML_Lr1r1: Overall experience prescribing drug - Please rate your experience with each of the following AML treatment(s) on the following attributes: Xospata (gilteritinib)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_AML_Lr1"
  },
  {
    "Column": "Q11_AML_Lr1r2",
    "Description": "Q11_AML_Lr1r2: Ease of access - Please rate your experience with each of the following AML treatment(s) on the following attributes: Xospata (gilteritinib)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_AML_Lr1"
  },
  {
    "Column": "Q11_AML_Lr1r3",
    "Description": "Q11_AML_Lr1r3: Availability of financial support from manufacturer - Please rate your experience with each of the following AML treatment(s) on the following attributes: Xospata (gilteritinib)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_AML_Lr1"
  },
  {
    "Column": "Q11_AML_Lr1r4",
    "Description": "Q11_AML_Lr1r4: Experience with drug rep - Please rate your experience with each of the following AML treatment(s) on the following attributes: Xospata (gilteritinib)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_AML_Lr1"
  },
  {
    "Column": "Q11_AML_Lr2r1",
    "Description": "Q11_AML_Lr2r1: Overall experience prescribing drug - Please rate your experience with each of the following AML treatment(s) on the following attributes: RYDAPT (midostaurin)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_AML_Lr2"
  },
  {
    "Column": "Q11_AML_Lr2r2",
    "Description": "Q11_AML_Lr2r2: Ease of access - Please rate your experience with each of the following AML treatment(s) on the following attributes: RYDAPT (midostaurin)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_AML_Lr2"
  },
  {
    "Column": "Q11_AML_Lr2r3",
    "Description": "Q11_AML_Lr2r3: Availability of financial support from manufacturer - Please rate your experience with each of the following AML treatment(s) on the following attributes: RYDAPT (midostaurin)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_AML_Lr2"
  },
  {
    "Column": "Q11_AML_Lr2r4",
    "Description": "Q11_AML_Lr2r4: Experience with drug rep - Please rate your experience with each of the following AML treatment(s) on the following attributes: RYDAPT (midostaurin)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_AML_Lr2"
  },
  {
    "Column": "Q11_AML_Lr3r1",
    "Description": "Q11_AML_Lr3r1: Overall experience prescribing drug - Please rate your experience with each of the following AML treatment(s) on the following attributes: Mylotarg (gemtuzumab ozogamicin)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_AML_Lr3"
  },
  {
    "Column": "Q11_AML_Lr3r2",
    "Description": "Q11_AML_Lr3r2: Ease of access - Please rate your experience with each of the following AML treatment(s) on the following attributes: Mylotarg (gemtuzumab ozogamicin)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_AML_Lr3"
  },
  {
    "Column": "Q11_AML_Lr3r3",
    "Description": "Q11_AML_Lr3r3: Availability of financial support from manufacturer - Please rate your experience with each of the following AML treatment(s) on the following attributes: Mylotarg (gemtuzumab ozogamicin)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_AML_Lr3"
  },
  {
    "Column": "Q11_AML_Lr3r4",
    "Description": "Q11_AML_Lr3r4: Experience with drug rep - Please rate your experience with each of the following AML treatment(s) on the following attributes: Mylotarg (gemtuzumab ozogamicin)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_AML_Lr3"
  },
  {
    "Column": "Q11_AML_Lr4r1",
    "Description": "Q11_AML_Lr4r1: Overall experience prescribing drug - Please rate your experience with each of the following AML treatment(s) on the following attributes: Tibsovo (Ivosidenib)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_AML_Lr4"
  },
  {
    "Column": "Q11_AML_Lr4r2",
    "Description": "Q11_AML_Lr4r2: Ease of access - Please rate your experience with each of the following AML treatment(s) on the following attributes: Tibsovo (Ivosidenib)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_AML_Lr4"
  },
  {
    "Column": "Q11_AML_Lr4r3",
    "Description": "Q11_AML_Lr4r3: Availability of financial support from manufacturer - Please rate your experience with each of the following AML treatment(s) on the following attributes: Tibsovo (Ivosidenib)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_AML_Lr4"
  },
  {
    "Column": "Q11_AML_Lr4r4",
    "Description": "Q11_AML_Lr4r4: Experience with drug rep - Please rate your experience with each of the following AML treatment(s) on the following attributes: Tibsovo (Ivosidenib)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_AML_Lr4"
  },
  {
    "Column": "Q11_AML_Lr5r1",
    "Description": "Q11_AML_Lr5r1: Overall experience prescribing drug - Please rate your experience with each of the following AML treatment(s) on the following attributes: Idhifa (enasidenib)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_AML_Lr5"
  },
  {
    "Column": "Q11_AML_Lr5r2",
    "Description": "Q11_AML_Lr5r2: Ease of access - Please rate your experience with each of the following AML treatment(s) on the following attributes: Idhifa (enasidenib)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_AML_Lr5"
  },
  {
    "Column": "Q11_AML_Lr5r3",
    "Description": "Q11_AML_Lr5r3: Availability of financial support from manufacturer - Please rate your experience with each of the following AML treatment(s) on the following attributes: Idhifa (enasidenib)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_AML_Lr5"
  },
  {
    "Column": "Q11_AML_Lr5r4",
    "Description": "Q11_AML_Lr5r4: Experience with drug rep - Please rate your experience with each of the following AML treatment(s) on the following attributes: Idhifa (enasidenib)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_AML_Lr5"
  },
  {
    "Column": "Q11_AML_Lr6r1",
    "Description": "Q11_AML_Lr6r1: Overall experience prescribing drug - Please rate your experience with each of the following AML treatment(s) on the following attributes: Daurismo (glasdegib)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_AML_Lr6"
  },
  {
    "Column": "Q11_AML_Lr6r2",
    "Description": "Q11_AML_Lr6r2: Ease of access - Please rate your experience with each of the following AML treatment(s) on the following attributes: Daurismo (glasdegib)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_AML_Lr6"
  },
  {
    "Column": "Q11_AML_Lr6r3",
    "Description": "Q11_AML_Lr6r3: Availability of financial support from manufacturer - Please rate your experience with each of the following AML treatment(s) on the following attributes: Daurismo (glasdegib)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_AML_Lr6"
  },
  {
    "Column": "Q11_AML_Lr6r4",
    "Description": "Q11_AML_Lr6r4: Experience with drug rep - Please rate your experience with each of the following AML treatment(s) on the following attributes: Daurismo (glasdegib)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_AML_Lr6"
  },
  {
    "Column": "Q11_AML_Lr7r1",
    "Description": "Q11_AML_Lr7r1: Overall experience prescribing drug - Please rate your experience with each of the following AML treatment(s) on the following attributes: Venclexta (venetoclax)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_AML_Lr7"
  },
  {
    "Column": "Q11_AML_Lr7r2",
    "Description": "Q11_AML_Lr7r2: Ease of access - Please rate your experience with each of the following AML treatment(s) on the following attributes: Venclexta (venetoclax)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_AML_Lr7"
  },
  {
    "Column": "Q11_AML_Lr7r3",
    "Description": "Q11_AML_Lr7r3: Availability of financial support from manufacturer - Please rate your experience with each of the following AML treatment(s) on the following attributes: Venclexta (venetoclax)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_AML_Lr7"
  },
  {
    "Column": "Q11_AML_Lr7r4",
    "Description": "Q11_AML_Lr7r4: Experience with drug rep - Please rate your experience with each of the following AML treatment(s) on the following attributes: Venclexta (venetoclax)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_AML_Lr7"
  },
  {
    "Column": "Q11_AML_Lr8r1",
    "Description": "Q11_AML_Lr8r1: Overall experience prescribing drug - Please rate your experience with each of the following AML treatment(s) on the following attributes: Nexavar (sorafenib)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_AML_Lr8"
  },
  {
    "Column": "Q11_AML_Lr8r2",
    "Description": "Q11_AML_Lr8r2: Ease of access - Please rate your experience with each of the following AML treatment(s) on the following attributes: Nexavar (sorafenib)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_AML_Lr8"
  },
  {
    "Column": "Q11_AML_Lr8r3",
    "Description": "Q11_AML_Lr8r3: Availability of financial support from manufacturer - Please rate your experience with each of the following AML treatment(s) on the following attributes: Nexavar (sorafenib)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_AML_Lr8"
  },
  {
    "Column": "Q11_AML_Lr8r4",
    "Description": "Q11_AML_Lr8r4: Experience with drug rep - Please rate your experience with each of the following AML treatment(s) on the following attributes: Nexavar (sorafenib)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_AML_Lr8"
  },
  {
    "Column": "Q11_AML_Lr9r1",
    "Description": "Q11_AML_Lr9r1: Overall experience prescribing drug - Please rate your experience with each of the following AML treatment(s) on the following attributes: VYXEOS (daunorubicin - cytarabine)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_AML_Lr9"
  },
  {
    "Column": "Q11_AML_Lr9r2",
    "Description": "Q11_AML_Lr9r2: Ease of access - Please rate your experience with each of the following AML treatment(s) on the following attributes: VYXEOS (daunorubicin - cytarabine)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_AML_Lr9"
  },
  {
    "Column": "Q11_AML_Lr9r3",
    "Description": "Q11_AML_Lr9r3: Availability of financial support from manufacturer - Please rate your experience with each of the following AML treatment(s) on the following attributes: VYXEOS (daunorubicin - cytarabine)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_AML_Lr9"
  },
  {
    "Column": "Q11_AML_Lr9r4",
    "Description": "Q11_AML_Lr9r4: Experience with drug rep - Please rate your experience with each of the following AML treatment(s) on the following attributes: VYXEOS (daunorubicin - cytarabine)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_AML_Lr9"
  },
  {
    "Column": "Q11_AML_Lr10r1",
    "Description": "Q11_AML_Lr10r1: Overall experience prescribing drug - Please rate your experience with each of the following AML treatment(s) on the following attributes:",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_AML_Lr10"
  },
  {
    "Column": "Q11_AML_Lr10r2",
    "Description": "Q11_AML_Lr10r2: Ease of access - Please rate your experience with each of the following AML treatment(s) on the following attributes:",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_AML_Lr10"
  },
  {
    "Column": "Q11_AML_Lr10r3",
    "Description": "Q11_AML_Lr10r3: Availability of financial support from manufacturer - Please rate your experience with each of the following AML treatment(s) on the following attributes:",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_AML_Lr10"
  },
  {
    "Column": "Q11_AML_Lr10r4",
    "Description": "Q11_AML_Lr10r4: Experience with drug rep - Please rate your experience with each of the following AML treatment(s) on the following attributes:",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_AML_Lr10"
  },
  {
    "Column": "Q12_AMLc1",
    "Description": "Q12_AMLc1: Xospata (Gilteritinib) - How do you expect your prescribing of each of the following AML treatment(s) will change in the next year?",
    "Answer_Options": "1=Prescribe more,2=Prescribe less,3=Prescribe about the same",
    "ParentQuestion": "Q12_AML"
  },
  {
    "Column": "Q12_AMLc2",
    "Description": "Q12_AMLc2: RYDAPT (midostaurin) - How do you expect your prescribing of each of the following AML treatment(s) will change in the next year?",
    "Answer_Options": "1=Prescribe more,2=Prescribe less,3=Prescribe about the same",
    "ParentQuestion": "Q12_AML"
  },
  {
    "Column": "Q12_AMLc3",
    "Description": "Q12_AMLc3: Mylotarg (gemtuzumab ozogamicin) - How do you expect your prescribing of each of the following AML treatment(s) will change in the next year?",
    "Answer_Options": "1=Prescribe more,2=Prescribe less,3=Prescribe about the same",
    "ParentQuestion": "Q12_AML"
  },
  {
    "Column": "Q12_AMLc4",
    "Description": "Q12_AMLc4: Tibsovo (Ivosidenib) - How do you expect your prescribing of each of the following AML treatment(s) will change in the next year?",
    "Answer_Options": "1=Prescribe more,2=Prescribe less,3=Prescribe about the same",
    "ParentQuestion": "Q12_AML"
  },
  {
    "Column": "Q12_AMLc5",
    "Description": "Q12_AMLc5: Idhifa (enasidenib) - How do you expect your prescribing of each of the following AML treatment(s) will change in the next year?",
    "Answer_Options": "1=Prescribe more,2=Prescribe less,3=Prescribe about the same",
    "ParentQuestion": "Q12_AML"
  },
  {
    "Column": "Q12_AMLc6",
    "Description": "Q12_AMLc6: Daurismo (glasdegib) - How do you expect your prescribing of each of the following AML treatment(s) will change in the next year?",
    "Answer_Options": "1=Prescribe more,2=Prescribe less,3=Prescribe about the same",
    "ParentQuestion": "Q12_AML"
  },
  {
    "Column": "Q12_AMLc7",
    "Description": "Q12_AMLc7: Venclexta (venetoclax) - How do you expect your prescribing of each of the following AML treatment(s) will change in the next year?",
    "Answer_Options": "1=Prescribe more,2=Prescribe less,3=Prescribe about the same",
    "ParentQuestion": "Q12_AML"
  },
  {
    "Column": "Q12_AMLc8",
    "Description": "Q12_AMLc8: Nexavar (sorafenib) - How do you expect your prescribing of each of the following AML treatment(s) will change in the next year?",
    "Answer_Options": "1=Prescribe more,2=Prescribe less,3=Prescribe about the same",
    "ParentQuestion": "Q12_AML"
  },
  {
    "Column": "Q12_AMLc9",
    "Description": "Q12_AMLc9: VYXEOS (daunorubicin - cytarabine) - How do you expect your prescribing of each of the following AML treatment(s) will change in the next year?",
    "Answer_Options": "1=Prescribe more,2=Prescribe less,3=Prescribe about the same",
    "ParentQuestion": "Q12_AML"
  },
  {
    "Column": "Q12_AMLc10",
    "Description": "Q12_AMLc10: $ {Q10_AML.r10.open} - How do you expect your prescribing of each of the following AML treatment(s) will change in the next year?",
    "Answer_Options": "1=Prescribe more,2=Prescribe less,3=Prescribe about the same",
    "ParentQuestion": "Q12_AML"
  },
  {
    "Column": "Q12_AMLc11",
    "Description": "Q12_AMLc11: None of the above - How do you expect your prescribing of each of the following AML treatment(s) will change in the next year?",
    "Answer_Options": "1=Prescribe more,2=Prescribe less,3=Prescribe about the same",
    "ParentQuestion": "Q12_AML"
  },
  {
    "Column": "Q10a_AMLr1",
    "Description": "Q10a_AMLr1: Xospata (gilteritinib) - Which of the following medications are prescribed for the acute myeloid leukemia (AML) patients treated in your practice in the last 6 months (include both new and refill prescriptions)?",
    "Answer_Options": "0=NO TO: Xospata (gilteritinib),1=Xospata (gilteritinib)",
    "ParentQuestion": "Q10a_AML"
  },
  {
    "Column": "Q10a_AMLr2",
    "Description": "Q10a_AMLr2: RYDAPT (midostaurin) - Which of the following medications are prescribed for the acute myeloid leukemia (AML) patients treated in your practice in the last 6 months (include both new and refill prescriptions)?",
    "Answer_Options": "0=NO TO: RYDAPT (midostaurin),1=RYDAPT (midostaurin)",
    "ParentQuestion": "Q10a_AML"
  },
  {
    "Column": "Q10a_AMLr3",
    "Description": "Q10a_AMLr3: Mylotarg (gemtuzumab ozogamicin) - Which of the following medications are prescribed for the acute myeloid leukemia (AML) patients treated in your practice in the last 6 months (include both new and refill prescriptions)?",
    "Answer_Options": "0=NO TO: Mylotarg (gemtuzumab ozogamicin),1=Mylotarg (gemtuzumab ozogamicin)",
    "ParentQuestion": "Q10a_AML"
  },
  {
    "Column": "Q10a_AMLr4",
    "Description": "Q10a_AMLr4: Tibsovo (Ivosidenib) - Which of the following medications are prescribed for the acute myeloid leukemia (AML) patients treated in your practice in the last 6 months (include both new and refill prescriptions)?",
    "Answer_Options": "0=NO TO: Tibsovo (Ivosidenib),1=Tibsovo (Ivosidenib)",
    "ParentQuestion": "Q10a_AML"
  },
  {
    "Column": "Q10a_AMLr5",
    "Description": "Q10a_AMLr5: Idhifa (enasidenib) - Which of the following medications are prescribed for the acute myeloid leukemia (AML) patients treated in your practice in the last 6 months (include both new and refill prescriptions)?",
    "Answer_Options": "0=NO TO: Idhifa (enasidenib),1=Idhifa (enasidenib)",
    "ParentQuestion": "Q10a_AML"
  },
  {
    "Column": "Q10a_AMLr6",
    "Description": "Q10a_AMLr6: Daurismo (glasdegib) - Which of the following medications are prescribed for the acute myeloid leukemia (AML) patients treated in your practice in the last 6 months (include both new and refill prescriptions)?",
    "Answer_Options": "0=NO TO: Daurismo (glasdegib),1=Daurismo (glasdegib)",
    "ParentQuestion": "Q10a_AML"
  },
  {
    "Column": "Q10a_AMLr7",
    "Description": "Q10a_AMLr7: Venclexta (venetoclax) - Which of the following medications are prescribed for the acute myeloid leukemia (AML) patients treated in your practice in the last 6 months (include both new and refill prescriptions)?",
    "Answer_Options": "0=NO TO: Venclexta (venetoclax),1=Venclexta (venetoclax)",
    "ParentQuestion": "Q10a_AML"
  },
  {
    "Column": "Q10a_AMLr8",
    "Description": "Q10a_AMLr8: Nexavar (sorafenib) - Which of the following medications are prescribed for the acute myeloid leukemia (AML) patients treated in your practice in the last 6 months (include both new and refill prescriptions)?",
    "Answer_Options": "0=NO TO: Nexavar (sorafenib),1=Nexavar (sorafenib)",
    "ParentQuestion": "Q10a_AML"
  },
  {
    "Column": "Q10a_AMLr9",
    "Description": "Q10a_AMLr9: VYXEOS (daunorubicin - cytarabine) - Which of the following medications are prescribed for the acute myeloid leukemia (AML) patients treated in your practice in the last 6 months (include both new and refill prescriptions)?",
    "Answer_Options": "0=NO TO: VYXEOS (daunorubicin - cytarabine),1=VYXEOS (daunorubicin - cytarabine)",
    "ParentQuestion": "Q10a_AML"
  },
  {
    "Column": "Q10a_AMLr10",
    "Description": "Q10a_AMLr10: Other, please specify: - Which of the following medications are prescribed for the acute myeloid leukemia (AML) patients treated in your practice in the last 6 months (include both new and refill prescriptions)?",
    "Answer_Options": "0=NO TO: Other, please specify:,1=Other, please specify:",
    "ParentQuestion": "Q10a_AML"
  },
  {
    "Column": "Q10a_AMLr11",
    "Description": "Q10a_AMLr11: None of the above - Which of the following medications are prescribed for the acute myeloid leukemia (AML) patients treated in your practice in the last 6 months (include both new and refill prescriptions)?",
    "Answer_Options": "0=NO TO: None of the above,1=None of the above",
    "ParentQuestion": "Q10a_AML"
  },
  {
    "Column": "Q10a_AMLr10oe",
    "Description": "Q10a_AMLr10oe: Which of the following medications are prescribed for the acute myeloid leukemia (AML) patients treated in your practice in the last 6 months (include both new and refill prescriptions)? - Other, please specify:",
    "Answer_Options": "NA",
    "ParentQuestion": "Q10a_AML"
  },
  {
    "Column": "Q11a_AML_Lr1r1",
    "Description": "Q11a_AML_Lr1r1: Overall experience with the drug - Please rate your experience with each of the following AML treatment(s) on the following attributes: Xospata (gilteritinib)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_AML_Lr1"
  },
  {
    "Column": "Q11a_AML_Lr1r2",
    "Description": "Q11a_AML_Lr1r2: Ease of access - Please rate your experience with each of the following AML treatment(s) on the following attributes: Xospata (gilteritinib)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_AML_Lr1"
  },
  {
    "Column": "Q11a_AML_Lr1r3",
    "Description": "Q11a_AML_Lr1r3: Availability of financial support from manufacturer - Please rate your experience with each of the following AML treatment(s) on the following attributes: Xospata (gilteritinib)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_AML_Lr1"
  },
  {
    "Column": "Q11a_AML_Lr1r4",
    "Description": "Q11a_AML_Lr1r4: Experience with drug rep - Please rate your experience with each of the following AML treatment(s) on the following attributes: Xospata (gilteritinib)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_AML_Lr1"
  },
  {
    "Column": "Q11a_AML_Lr2r1",
    "Description": "Q11a_AML_Lr2r1: Overall experience with the drug - Please rate your experience with each of the following AML treatment(s) on the following attributes: RYDAPT (midostaurin)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_AML_Lr2"
  },
  {
    "Column": "Q11a_AML_Lr2r2",
    "Description": "Q11a_AML_Lr2r2: Ease of access - Please rate your experience with each of the following AML treatment(s) on the following attributes: RYDAPT (midostaurin)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_AML_Lr2"
  },
  {
    "Column": "Q11a_AML_Lr2r3",
    "Description": "Q11a_AML_Lr2r3: Availability of financial support from manufacturer - Please rate your experience with each of the following AML treatment(s) on the following attributes: RYDAPT (midostaurin)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_AML_Lr2"
  },
  {
    "Column": "Q11a_AML_Lr2r4",
    "Description": "Q11a_AML_Lr2r4: Experience with drug rep - Please rate your experience with each of the following AML treatment(s) on the following attributes: RYDAPT (midostaurin)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_AML_Lr2"
  },
  {
    "Column": "Q11a_AML_Lr3r1",
    "Description": "Q11a_AML_Lr3r1: Overall experience with the drug - Please rate your experience with each of the following AML treatment(s) on the following attributes: Mylotarg (gemtuzumab ozogamicin)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_AML_Lr3"
  },
  {
    "Column": "Q11a_AML_Lr3r2",
    "Description": "Q11a_AML_Lr3r2: Ease of access - Please rate your experience with each of the following AML treatment(s) on the following attributes: Mylotarg (gemtuzumab ozogamicin)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_AML_Lr3"
  },
  {
    "Column": "Q11a_AML_Lr3r3",
    "Description": "Q11a_AML_Lr3r3: Availability of financial support from manufacturer - Please rate your experience with each of the following AML treatment(s) on the following attributes: Mylotarg (gemtuzumab ozogamicin)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_AML_Lr3"
  },
  {
    "Column": "Q11a_AML_Lr3r4",
    "Description": "Q11a_AML_Lr3r4: Experience with drug rep - Please rate your experience with each of the following AML treatment(s) on the following attributes: Mylotarg (gemtuzumab ozogamicin)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_AML_Lr3"
  },
  {
    "Column": "Q11a_AML_Lr4r1",
    "Description": "Q11a_AML_Lr4r1: Overall experience with the drug - Please rate your experience with each of the following AML treatment(s) on the following attributes: Tibsovo (Ivosidenib)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_AML_Lr4"
  },
  {
    "Column": "Q11a_AML_Lr4r2",
    "Description": "Q11a_AML_Lr4r2: Ease of access - Please rate your experience with each of the following AML treatment(s) on the following attributes: Tibsovo (Ivosidenib)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_AML_Lr4"
  },
  {
    "Column": "Q11a_AML_Lr4r3",
    "Description": "Q11a_AML_Lr4r3: Availability of financial support from manufacturer - Please rate your experience with each of the following AML treatment(s) on the following attributes: Tibsovo (Ivosidenib)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_AML_Lr4"
  },
  {
    "Column": "Q11a_AML_Lr4r4",
    "Description": "Q11a_AML_Lr4r4: Experience with drug rep - Please rate your experience with each of the following AML treatment(s) on the following attributes: Tibsovo (Ivosidenib)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_AML_Lr4"
  },
  {
    "Column": "Q11a_AML_Lr5r1",
    "Description": "Q11a_AML_Lr5r1: Overall experience with the drug - Please rate your experience with each of the following AML treatment(s) on the following attributes: Idhifa (enasidenib)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_AML_Lr5"
  },
  {
    "Column": "Q11a_AML_Lr5r2",
    "Description": "Q11a_AML_Lr5r2: Ease of access - Please rate your experience with each of the following AML treatment(s) on the following attributes: Idhifa (enasidenib)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_AML_Lr5"
  },
  {
    "Column": "Q11a_AML_Lr5r3",
    "Description": "Q11a_AML_Lr5r3: Availability of financial support from manufacturer - Please rate your experience with each of the following AML treatment(s) on the following attributes: Idhifa (enasidenib)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_AML_Lr5"
  },
  {
    "Column": "Q11a_AML_Lr5r4",
    "Description": "Q11a_AML_Lr5r4: Experience with drug rep - Please rate your experience with each of the following AML treatment(s) on the following attributes: Idhifa (enasidenib)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_AML_Lr5"
  },
  {
    "Column": "Q11a_AML_Lr6r1",
    "Description": "Q11a_AML_Lr6r1: Overall experience with the drug - Please rate your experience with each of the following AML treatment(s) on the following attributes: Daurismo (glasdegib)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_AML_Lr6"
  },
  {
    "Column": "Q11a_AML_Lr6r2",
    "Description": "Q11a_AML_Lr6r2: Ease of access - Please rate your experience with each of the following AML treatment(s) on the following attributes: Daurismo (glasdegib)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_AML_Lr6"
  },
  {
    "Column": "Q11a_AML_Lr6r3",
    "Description": "Q11a_AML_Lr6r3: Availability of financial support from manufacturer - Please rate your experience with each of the following AML treatment(s) on the following attributes: Daurismo (glasdegib)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_AML_Lr6"
  },
  {
    "Column": "Q11a_AML_Lr6r4",
    "Description": "Q11a_AML_Lr6r4: Experience with drug rep - Please rate your experience with each of the following AML treatment(s) on the following attributes: Daurismo (glasdegib)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_AML_Lr6"
  },
  {
    "Column": "Q11a_AML_Lr7r1",
    "Description": "Q11a_AML_Lr7r1: Overall experience with the drug - Please rate your experience with each of the following AML treatment(s) on the following attributes: Venclexta (venetoclax)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_AML_Lr7"
  },
  {
    "Column": "Q11a_AML_Lr7r2",
    "Description": "Q11a_AML_Lr7r2: Ease of access - Please rate your experience with each of the following AML treatment(s) on the following attributes: Venclexta (venetoclax)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_AML_Lr7"
  },
  {
    "Column": "Q11a_AML_Lr7r3",
    "Description": "Q11a_AML_Lr7r3: Availability of financial support from manufacturer - Please rate your experience with each of the following AML treatment(s) on the following attributes: Venclexta (venetoclax)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_AML_Lr7"
  },
  {
    "Column": "Q11a_AML_Lr7r4",
    "Description": "Q11a_AML_Lr7r4: Experience with drug rep - Please rate your experience with each of the following AML treatment(s) on the following attributes: Venclexta (venetoclax)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_AML_Lr7"
  },
  {
    "Column": "Q11a_AML_Lr8r1",
    "Description": "Q11a_AML_Lr8r1: Overall experience with the drug - Please rate your experience with each of the following AML treatment(s) on the following attributes: Nexavar (sorafenib)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_AML_Lr8"
  },
  {
    "Column": "Q11a_AML_Lr8r2",
    "Description": "Q11a_AML_Lr8r2: Ease of access - Please rate your experience with each of the following AML treatment(s) on the following attributes: Nexavar (sorafenib)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_AML_Lr8"
  },
  {
    "Column": "Q11a_AML_Lr8r3",
    "Description": "Q11a_AML_Lr8r3: Availability of financial support from manufacturer - Please rate your experience with each of the following AML treatment(s) on the following attributes: Nexavar (sorafenib)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_AML_Lr8"
  },
  {
    "Column": "Q11a_AML_Lr8r4",
    "Description": "Q11a_AML_Lr8r4: Experience with drug rep - Please rate your experience with each of the following AML treatment(s) on the following attributes: Nexavar (sorafenib)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_AML_Lr8"
  },
  {
    "Column": "Q11a_AML_Lr9r1",
    "Description": "Q11a_AML_Lr9r1: Overall experience with the drug - Please rate your experience with each of the following AML treatment(s) on the following attributes: VYXEOS (daunorubicin - cytarabine)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_AML_Lr9"
  },
  {
    "Column": "Q11a_AML_Lr9r2",
    "Description": "Q11a_AML_Lr9r2: Ease of access - Please rate your experience with each of the following AML treatment(s) on the following attributes: VYXEOS (daunorubicin - cytarabine)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_AML_Lr9"
  },
  {
    "Column": "Q11a_AML_Lr9r3",
    "Description": "Q11a_AML_Lr9r3: Availability of financial support from manufacturer - Please rate your experience with each of the following AML treatment(s) on the following attributes: VYXEOS (daunorubicin - cytarabine)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_AML_Lr9"
  },
  {
    "Column": "Q11a_AML_Lr9r4",
    "Description": "Q11a_AML_Lr9r4: Experience with drug rep - Please rate your experience with each of the following AML treatment(s) on the following attributes: VYXEOS (daunorubicin - cytarabine)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_AML_Lr9"
  },
  {
    "Column": "Q11a_AML_Lr10r1",
    "Description": "Q11a_AML_Lr10r1: Overall experience with the drug - Please rate your experience with each of the following AML treatment(s) on the following attributes:",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_AML_Lr10"
  },
  {
    "Column": "Q11a_AML_Lr10r2",
    "Description": "Q11a_AML_Lr10r2: Ease of access - Please rate your experience with each of the following AML treatment(s) on the following attributes:",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_AML_Lr10"
  },
  {
    "Column": "Q11a_AML_Lr10r3",
    "Description": "Q11a_AML_Lr10r3: Availability of financial support from manufacturer - Please rate your experience with each of the following AML treatment(s) on the following attributes:",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_AML_Lr10"
  },
  {
    "Column": "Q11a_AML_Lr10r4",
    "Description": "Q11a_AML_Lr10r4: Experience with drug rep - Please rate your experience with each of the following AML treatment(s) on the following attributes:",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_AML_Lr10"
  },
  {
    "Column": "Q10_PCr1",
    "Description": "Q10_PCr1: Xtandi (enzalutamide) - For your non-curative prostate cancer patients, which of the following medications have you personally prescribed in the last 6 months (include both new and refill prescriptions)?",
    "Answer_Options": "0=NO TO: Xtandi (enzalutamide),1=Xtandi (enzalutamide)",
    "ParentQuestion": "Q10_PC"
  },
  {
    "Column": "Q10_PCr2",
    "Description": "Q10_PCr2: Provenge (sipuleucel-T) - For your non-curative prostate cancer patients, which of the following medications have you personally prescribed in the last 6 months (include both new and refill prescriptions)?",
    "Answer_Options": "0=NO TO: Provenge (sipuleucel-T),1=Provenge (sipuleucel-T)",
    "ParentQuestion": "Q10_PC"
  },
  {
    "Column": "Q10_PCr3",
    "Description": "Q10_PCr3: Xofigo (radium RA 223 dichloride) - For your non-curative prostate cancer patients, which of the following medications have you personally prescribed in the last 6 months (include both new and refill prescriptions)?",
    "Answer_Options": "0=NO TO: Xofigo (radium RA 223 dichloride),1=Xofigo (radium RA 223 dichloride)",
    "ParentQuestion": "Q10_PC"
  },
  {
    "Column": "Q10_PCr4",
    "Description": "Q10_PCr4: Casodex (bicalutamide) - For your non-curative prostate cancer patients, which of the following medications have you personally prescribed in the last 6 months (include both new and refill prescriptions)?",
    "Answer_Options": "0=NO TO: Casodex (bicalutamide),1=Casodex (bicalutamide)",
    "ParentQuestion": "Q10_PC"
  },
  {
    "Column": "Q10_PCr5",
    "Description": "Q10_PCr5: Zytiga (abiraterone acetate) - For your non-curative prostate cancer patients, which of the following medications have you personally prescribed in the last 6 months (include both new and refill prescriptions)?",
    "Answer_Options": "0=NO TO: Zytiga (abiraterone acetate),1=Zytiga (abiraterone acetate)",
    "ParentQuestion": "Q10_PC"
  },
  {
    "Column": "Q10_PCr6",
    "Description": "Q10_PCr6: Erleada (apalutamide) - For your non-curative prostate cancer patients, which of the following medications have you personally prescribed in the last 6 months (include both new and refill prescriptions)?",
    "Answer_Options": "0=NO TO: Erleada (apalutamide),1=Erleada (apalutamide)",
    "ParentQuestion": "Q10_PC"
  },
  {
    "Column": "Q10_PCr7",
    "Description": "Q10_PCr7: Other (Please specify) - For your non-curative prostate cancer patients, which of the following medications have you personally prescribed in the last 6 months (include both new and refill prescriptions)?",
    "Answer_Options": "0=NO TO: Other (Please specify),1=Other (Please specify)",
    "ParentQuestion": "Q10_PC"
  },
  {
    "Column": "Q10_PCr8",
    "Description": "Q10_PCr8: None of the above - For your non-curative prostate cancer patients, which of the following medications have you personally prescribed in the last 6 months (include both new and refill prescriptions)?",
    "Answer_Options": "0=NO TO: None of the above,1=None of the above",
    "ParentQuestion": "Q10_PC"
  },
  {
    "Column": "Q11_PC_Lr1r1",
    "Description": "Q11_PC_Lr1r1: Overall experience prescribing drug - Please rate your experience with each of the following non-curative prostate cancer treatments on the following attributes: Xtandi (enzalutamide)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_PC_Lr1"
  },
  {
    "Column": "Q11_PC_Lr1r2",
    "Description": "Q11_PC_Lr1r2: Ease of access - Please rate your experience with each of the following non-curative prostate cancer treatments on the following attributes: Xtandi (enzalutamide)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_PC_Lr1"
  },
  {
    "Column": "Q11_PC_Lr1r3",
    "Description": "Q11_PC_Lr1r3: Availability of financial support from manufacturer - Please rate your experience with each of the following non-curative prostate cancer treatments on the following attributes: Xtandi (enzalutamide)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_PC_Lr1"
  },
  {
    "Column": "Q11_PC_Lr1r4",
    "Description": "Q11_PC_Lr1r4: Experience with drug rep - Please rate your experience with each of the following non-curative prostate cancer treatments on the following attributes: Xtandi (enzalutamide)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_PC_Lr1"
  },
  {
    "Column": "Q11_PC_Lr2r1",
    "Description": "Q11_PC_Lr2r1: Overall experience prescribing drug - Please rate your experience with each of the following non-curative prostate cancer treatments on the following attributes: Provenge (sipuleucel-T)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_PC_Lr2"
  },
  {
    "Column": "Q11_PC_Lr2r2",
    "Description": "Q11_PC_Lr2r2: Ease of access - Please rate your experience with each of the following non-curative prostate cancer treatments on the following attributes: Provenge (sipuleucel-T)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_PC_Lr2"
  },
  {
    "Column": "Q11_PC_Lr2r3",
    "Description": "Q11_PC_Lr2r3: Availability of financial support from manufacturer - Please rate your experience with each of the following non-curative prostate cancer treatments on the following attributes: Provenge (sipuleucel-T)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_PC_Lr2"
  },
  {
    "Column": "Q11_PC_Lr2r4",
    "Description": "Q11_PC_Lr2r4: Experience with drug rep - Please rate your experience with each of the following non-curative prostate cancer treatments on the following attributes: Provenge (sipuleucel-T)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_PC_Lr2"
  },
  {
    "Column": "Q11_PC_Lr3r1",
    "Description": "Q11_PC_Lr3r1: Overall experience prescribing drug - Please rate your experience with each of the following non-curative prostate cancer treatments on the following attributes: Xofigo (radium RA 223 dichloride)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_PC_Lr3"
  },
  {
    "Column": "Q11_PC_Lr3r2",
    "Description": "Q11_PC_Lr3r2: Ease of access - Please rate your experience with each of the following non-curative prostate cancer treatments on the following attributes: Xofigo (radium RA 223 dichloride)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_PC_Lr3"
  },
  {
    "Column": "Q11_PC_Lr3r3",
    "Description": "Q11_PC_Lr3r3: Availability of financial support from manufacturer - Please rate your experience with each of the following non-curative prostate cancer treatments on the following attributes: Xofigo (radium RA 223 dichloride)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_PC_Lr3"
  },
  {
    "Column": "Q11_PC_Lr3r4",
    "Description": "Q11_PC_Lr3r4: Experience with drug rep - Please rate your experience with each of the following non-curative prostate cancer treatments on the following attributes: Xofigo (radium RA 223 dichloride)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_PC_Lr3"
  },
  {
    "Column": "Q11_PC_Lr4r1",
    "Description": "Q11_PC_Lr4r1: Overall experience prescribing drug - Please rate your experience with each of the following non-curative prostate cancer treatments on the following attributes: Casodex (bicalutamide)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_PC_Lr4"
  },
  {
    "Column": "Q11_PC_Lr4r2",
    "Description": "Q11_PC_Lr4r2: Ease of access - Please rate your experience with each of the following non-curative prostate cancer treatments on the following attributes: Casodex (bicalutamide)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_PC_Lr4"
  },
  {
    "Column": "Q11_PC_Lr4r3",
    "Description": "Q11_PC_Lr4r3: Availability of financial support from manufacturer - Please rate your experience with each of the following non-curative prostate cancer treatments on the following attributes: Casodex (bicalutamide)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_PC_Lr4"
  },
  {
    "Column": "Q11_PC_Lr4r4",
    "Description": "Q11_PC_Lr4r4: Experience with drug rep - Please rate your experience with each of the following non-curative prostate cancer treatments on the following attributes: Casodex (bicalutamide)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_PC_Lr4"
  },
  {
    "Column": "Q11_PC_Lr5r1",
    "Description": "Q11_PC_Lr5r1: Overall experience prescribing drug - Please rate your experience with each of the following non-curative prostate cancer treatments on the following attributes: Zytiga (abiraterone acetate)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_PC_Lr5"
  },
  {
    "Column": "Q11_PC_Lr5r2",
    "Description": "Q11_PC_Lr5r2: Ease of access - Please rate your experience with each of the following non-curative prostate cancer treatments on the following attributes: Zytiga (abiraterone acetate)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_PC_Lr5"
  },
  {
    "Column": "Q11_PC_Lr5r3",
    "Description": "Q11_PC_Lr5r3: Availability of financial support from manufacturer - Please rate your experience with each of the following non-curative prostate cancer treatments on the following attributes: Zytiga (abiraterone acetate)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_PC_Lr5"
  },
  {
    "Column": "Q11_PC_Lr5r4",
    "Description": "Q11_PC_Lr5r4: Experience with drug rep - Please rate your experience with each of the following non-curative prostate cancer treatments on the following attributes: Zytiga (abiraterone acetate)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_PC_Lr5"
  },
  {
    "Column": "Q11_PC_Lr6r1",
    "Description": "Q11_PC_Lr6r1: Overall experience prescribing drug - Please rate your experience with each of the following non-curative prostate cancer treatments on the following attributes: Erleada (apalutamide)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_PC_Lr6"
  },
  {
    "Column": "Q11_PC_Lr6r2",
    "Description": "Q11_PC_Lr6r2: Ease of access - Please rate your experience with each of the following non-curative prostate cancer treatments on the following attributes: Erleada (apalutamide)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_PC_Lr6"
  },
  {
    "Column": "Q11_PC_Lr6r3",
    "Description": "Q11_PC_Lr6r3: Availability of financial support from manufacturer - Please rate your experience with each of the following non-curative prostate cancer treatments on the following attributes: Erleada (apalutamide)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_PC_Lr6"
  },
  {
    "Column": "Q11_PC_Lr6r4",
    "Description": "Q11_PC_Lr6r4: Experience with drug rep - Please rate your experience with each of the following non-curative prostate cancer treatments on the following attributes: Erleada (apalutamide)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_PC_Lr6"
  },
  {
    "Column": "Q11_PC_Lr7r1",
    "Description": "Q11_PC_Lr7r1: Overall experience prescribing drug - Please rate your experience with each of the following non-curative prostate cancer treatments on the following attributes:",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_PC_Lr7"
  },
  {
    "Column": "Q11_PC_Lr7r2",
    "Description": "Q11_PC_Lr7r2: Ease of access - Please rate your experience with each of the following non-curative prostate cancer treatments on the following attributes:",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_PC_Lr7"
  },
  {
    "Column": "Q11_PC_Lr7r3",
    "Description": "Q11_PC_Lr7r3: Availability of financial support from manufacturer - Please rate your experience with each of the following non-curative prostate cancer treatments on the following attributes:",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_PC_Lr7"
  },
  {
    "Column": "Q11_PC_Lr7r4",
    "Description": "Q11_PC_Lr7r4: Experience with drug rep - Please rate your experience with each of the following non-curative prostate cancer treatments on the following attributes:",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_PC_Lr7"
  },
  {
    "Column": "Q11_PC_Lr8r1",
    "Description": "Q11_PC_Lr8r1: Overall experience prescribing drug - Please rate your experience with each of the following non-curative prostate cancer treatments on the following attributes: None of the above",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_PC_Lr8"
  },
  {
    "Column": "Q11_PC_Lr8r2",
    "Description": "Q11_PC_Lr8r2: Ease of access - Please rate your experience with each of the following non-curative prostate cancer treatments on the following attributes: None of the above",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_PC_Lr8"
  },
  {
    "Column": "Q11_PC_Lr8r3",
    "Description": "Q11_PC_Lr8r3: Availability of financial support from manufacturer - Please rate your experience with each of the following non-curative prostate cancer treatments on the following attributes: None of the above",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_PC_Lr8"
  },
  {
    "Column": "Q11_PC_Lr8r4",
    "Description": "Q11_PC_Lr8r4: Experience with drug rep - Please rate your experience with each of the following non-curative prostate cancer treatments on the following attributes: None of the above",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10",
    "ParentQuestion": "Q11_PC_Lr8"
  },
  {
    "Column": "Q12_PCc1",
    "Description": "Q12_PCc1: Xtandi (enzalutamide) - How do you expect your prescribing of each of the following non-curative prostate cancer treatment(s) will change in the next year?",
    "Answer_Options": "1=Prescribe more,2=Prescribe less,3=Prescribe about the same",
    "ParentQuestion": "Q12_PC"
  },
  {
    "Column": "Q12_PCc2",
    "Description": "Q12_PCc2: Provenge (sipuleucel-T) - How do you expect your prescribing of each of the following non-curative prostate cancer treatment(s) will change in the next year?",
    "Answer_Options": "1=Prescribe more,2=Prescribe less,3=Prescribe about the same",
    "ParentQuestion": "Q12_PC"
  },
  {
    "Column": "Q12_PCc3",
    "Description": "Q12_PCc3: Xofigo (radium RA 223 dichloride) - How do you expect your prescribing of each of the following non-curative prostate cancer treatment(s) will change in the next year?",
    "Answer_Options": "1=Prescribe more,2=Prescribe less,3=Prescribe about the same",
    "ParentQuestion": "Q12_PC"
  },
  {
    "Column": "Q12_PCc4",
    "Description": "Q12_PCc4: Casodex (bicalutamide) - How do you expect your prescribing of each of the following non-curative prostate cancer treatment(s) will change in the next year?",
    "Answer_Options": "1=Prescribe more,2=Prescribe less,3=Prescribe about the same",
    "ParentQuestion": "Q12_PC"
  },
  {
    "Column": "Q12_PCc5",
    "Description": "Q12_PCc5: Zytiga (abiraterone acetate) - How do you expect your prescribing of each of the following non-curative prostate cancer treatment(s) will change in the next year?",
    "Answer_Options": "1=Prescribe more,2=Prescribe less,3=Prescribe about the same",
    "ParentQuestion": "Q12_PC"
  },
  {
    "Column": "Q12_PCc6",
    "Description": "Q12_PCc6: Erleada (apalutamide) - How do you expect your prescribing of each of the following non-curative prostate cancer treatment(s) will change in the next year?",
    "Answer_Options": "1=Prescribe more,2=Prescribe less,3=Prescribe about the same",
    "ParentQuestion": "Q12_PC"
  },
  {
    "Column": "Q12_PCc7",
    "Description": "Q12_PCc7: $ {Q10_PC.r7.open} - How do you expect your prescribing of each of the following non-curative prostate cancer treatment(s) will change in the next year?",
    "Answer_Options": "1=Prescribe more,2=Prescribe less,3=Prescribe about the same",
    "ParentQuestion": "Q12_PC"
  },
  {
    "Column": "Q12_PCc8",
    "Description": "Q12_PCc8: None of the above - How do you expect your prescribing of each of the following non-curative prostate cancer treatment(s) will change in the next year?",
    "Answer_Options": "1=Prescribe more,2=Prescribe less,3=Prescribe about the same",
    "ParentQuestion": "Q12_PC"
  },
  {
    "Column": "Q10a_PCr1",
    "Description": "Q10a_PCr1: Xtandi (enzalutamide) - Which of the following medications are prescribed for the non-curative prostate cancer patients treated in your practice in the last 6 months (include both new and refill prescriptions)?",
    "Answer_Options": "0=NO TO: Xtandi (enzalutamide),1=Xtandi (enzalutamide)",
    "ParentQuestion": "Q10a_PC"
  },
  {
    "Column": "Q10a_PCr2",
    "Description": "Q10a_PCr2: Provenge (sipuleucel-T) - Which of the following medications are prescribed for the non-curative prostate cancer patients treated in your practice in the last 6 months (include both new and refill prescriptions)?",
    "Answer_Options": "0=NO TO: Provenge (sipuleucel-T),1=Provenge (sipuleucel-T)",
    "ParentQuestion": "Q10a_PC"
  },
  {
    "Column": "Q10a_PCr3",
    "Description": "Q10a_PCr3: Xofigo (radium RA 223 dichloride) - Which of the following medications are prescribed for the non-curative prostate cancer patients treated in your practice in the last 6 months (include both new and refill prescriptions)?",
    "Answer_Options": "0=NO TO: Xofigo (radium RA 223 dichloride),1=Xofigo (radium RA 223 dichloride)",
    "ParentQuestion": "Q10a_PC"
  },
  {
    "Column": "Q10a_PCr4",
    "Description": "Q10a_PCr4: Casodex (bicalutamide) - Which of the following medications are prescribed for the non-curative prostate cancer patients treated in your practice in the last 6 months (include both new and refill prescriptions)?",
    "Answer_Options": "0=NO TO: Casodex (bicalutamide),1=Casodex (bicalutamide)",
    "ParentQuestion": "Q10a_PC"
  },
  {
    "Column": "Q10a_PCr5",
    "Description": "Q10a_PCr5: Zytiga (abiraterone acetate) - Which of the following medications are prescribed for the non-curative prostate cancer patients treated in your practice in the last 6 months (include both new and refill prescriptions)?",
    "Answer_Options": "0=NO TO: Zytiga (abiraterone acetate),1=Zytiga (abiraterone acetate)",
    "ParentQuestion": "Q10a_PC"
  },
  {
    "Column": "Q10a_PCr6",
    "Description": "Q10a_PCr6: Erleada (apalutamide) - Which of the following medications are prescribed for the non-curative prostate cancer patients treated in your practice in the last 6 months (include both new and refill prescriptions)?",
    "Answer_Options": "0=NO TO: Erleada (apalutamide),1=Erleada (apalutamide)",
    "ParentQuestion": "Q10a_PC"
  },
  {
    "Column": "Q10a_PCr7",
    "Description": "Q10a_PCr7: Other (Please specify) - Which of the following medications are prescribed for the non-curative prostate cancer patients treated in your practice in the last 6 months (include both new and refill prescriptions)?",
    "Answer_Options": "0=NO TO: Other (Please specify),1=Other (Please specify)",
    "ParentQuestion": "Q10a_PC"
  },
  {
    "Column": "Q10a_PCr8",
    "Description": "Q10a_PCr8: None of the above - Which of the following medications are prescribed for the non-curative prostate cancer patients treated in your practice in the last 6 months (include both new and refill prescriptions)?",
    "Answer_Options": "0=NO TO: None of the above,1=None of the above",
    "ParentQuestion": "Q10a_PC"
  },
  {
    "Column": "Q10a_PCr7oe",
    "Description": "Q10a_PCr7oe: Which of the following medications are prescribed for the non-curative prostate cancer patients treated in your practice in the last 6 months (include both new and refill prescriptions)? - Other (Please specify)",
    "Answer_Options": "NA",
    "ParentQuestion": "Q10a_PC"
  },
  {
    "Column": "Q11a_PC_Lr1r1",
    "Description": "Q11a_PC_Lr1r1: Overall experience with the drug - Please rate your experience with each of the following non-curative prostate cancer treatments on the following attributes: Xtandi (enzalutamide)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_PC_Lr1"
  },
  {
    "Column": "Q11a_PC_Lr1r2",
    "Description": "Q11a_PC_Lr1r2: Ease of access - Please rate your experience with each of the following non-curative prostate cancer treatments on the following attributes: Xtandi (enzalutamide)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_PC_Lr1"
  },
  {
    "Column": "Q11a_PC_Lr1r3",
    "Description": "Q11a_PC_Lr1r3: Availability of financial support from manufacturer - Please rate your experience with each of the following non-curative prostate cancer treatments on the following attributes: Xtandi (enzalutamide)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_PC_Lr1"
  },
  {
    "Column": "Q11a_PC_Lr1r4",
    "Description": "Q11a_PC_Lr1r4: Experience with drug rep - Please rate your experience with each of the following non-curative prostate cancer treatments on the following attributes: Xtandi (enzalutamide)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_PC_Lr1"
  },
  {
    "Column": "Q11a_PC_Lr2r1",
    "Description": "Q11a_PC_Lr2r1: Overall experience with the drug - Please rate your experience with each of the following non-curative prostate cancer treatments on the following attributes: Provenge (sipuleucel-T)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_PC_Lr2"
  },
  {
    "Column": "Q11a_PC_Lr2r2",
    "Description": "Q11a_PC_Lr2r2: Ease of access - Please rate your experience with each of the following non-curative prostate cancer treatments on the following attributes: Provenge (sipuleucel-T)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_PC_Lr2"
  },
  {
    "Column": "Q11a_PC_Lr2r3",
    "Description": "Q11a_PC_Lr2r3: Availability of financial support from manufacturer - Please rate your experience with each of the following non-curative prostate cancer treatments on the following attributes: Provenge (sipuleucel-T)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_PC_Lr2"
  },
  {
    "Column": "Q11a_PC_Lr2r4",
    "Description": "Q11a_PC_Lr2r4: Experience with drug rep - Please rate your experience with each of the following non-curative prostate cancer treatments on the following attributes: Provenge (sipuleucel-T)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_PC_Lr2"
  },
  {
    "Column": "Q11a_PC_Lr3r1",
    "Description": "Q11a_PC_Lr3r1: Overall experience with the drug - Please rate your experience with each of the following non-curative prostate cancer treatments on the following attributes: Xofigo (radium RA 223 dichloride)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_PC_Lr3"
  },
  {
    "Column": "Q11a_PC_Lr3r2",
    "Description": "Q11a_PC_Lr3r2: Ease of access - Please rate your experience with each of the following non-curative prostate cancer treatments on the following attributes: Xofigo (radium RA 223 dichloride)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_PC_Lr3"
  },
  {
    "Column": "Q11a_PC_Lr3r3",
    "Description": "Q11a_PC_Lr3r3: Availability of financial support from manufacturer - Please rate your experience with each of the following non-curative prostate cancer treatments on the following attributes: Xofigo (radium RA 223 dichloride)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_PC_Lr3"
  },
  {
    "Column": "Q11a_PC_Lr3r4",
    "Description": "Q11a_PC_Lr3r4: Experience with drug rep - Please rate your experience with each of the following non-curative prostate cancer treatments on the following attributes: Xofigo (radium RA 223 dichloride)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_PC_Lr3"
  },
  {
    "Column": "Q11a_PC_Lr4r1",
    "Description": "Q11a_PC_Lr4r1: Overall experience with the drug - Please rate your experience with each of the following non-curative prostate cancer treatments on the following attributes: Casodex (bicalutamide)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_PC_Lr4"
  },
  {
    "Column": "Q11a_PC_Lr4r2",
    "Description": "Q11a_PC_Lr4r2: Ease of access - Please rate your experience with each of the following non-curative prostate cancer treatments on the following attributes: Casodex (bicalutamide)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_PC_Lr4"
  },
  {
    "Column": "Q11a_PC_Lr4r3",
    "Description": "Q11a_PC_Lr4r3: Availability of financial support from manufacturer - Please rate your experience with each of the following non-curative prostate cancer treatments on the following attributes: Casodex (bicalutamide)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_PC_Lr4"
  },
  {
    "Column": "Q11a_PC_Lr4r4",
    "Description": "Q11a_PC_Lr4r4: Experience with drug rep - Please rate your experience with each of the following non-curative prostate cancer treatments on the following attributes: Casodex (bicalutamide)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_PC_Lr4"
  },
  {
    "Column": "Q11a_PC_Lr5r1",
    "Description": "Q11a_PC_Lr5r1: Overall experience with the drug - Please rate your experience with each of the following non-curative prostate cancer treatments on the following attributes: Zytiga (abiraterone acetate)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_PC_Lr5"
  },
  {
    "Column": "Q11a_PC_Lr5r2",
    "Description": "Q11a_PC_Lr5r2: Ease of access - Please rate your experience with each of the following non-curative prostate cancer treatments on the following attributes: Zytiga (abiraterone acetate)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_PC_Lr5"
  },
  {
    "Column": "Q11a_PC_Lr5r3",
    "Description": "Q11a_PC_Lr5r3: Availability of financial support from manufacturer - Please rate your experience with each of the following non-curative prostate cancer treatments on the following attributes: Zytiga (abiraterone acetate)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_PC_Lr5"
  },
  {
    "Column": "Q11a_PC_Lr5r4",
    "Description": "Q11a_PC_Lr5r4: Experience with drug rep - Please rate your experience with each of the following non-curative prostate cancer treatments on the following attributes: Zytiga (abiraterone acetate)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_PC_Lr5"
  },
  {
    "Column": "Q11a_PC_Lr6r1",
    "Description": "Q11a_PC_Lr6r1: Overall experience with the drug - Please rate your experience with each of the following non-curative prostate cancer treatments on the following attributes: Erleada (apalutamide)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_PC_Lr6"
  },
  {
    "Column": "Q11a_PC_Lr6r2",
    "Description": "Q11a_PC_Lr6r2: Ease of access - Please rate your experience with each of the following non-curative prostate cancer treatments on the following attributes: Erleada (apalutamide)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_PC_Lr6"
  },
  {
    "Column": "Q11a_PC_Lr6r3",
    "Description": "Q11a_PC_Lr6r3: Availability of financial support from manufacturer - Please rate your experience with each of the following non-curative prostate cancer treatments on the following attributes: Erleada (apalutamide)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_PC_Lr6"
  },
  {
    "Column": "Q11a_PC_Lr6r4",
    "Description": "Q11a_PC_Lr6r4: Experience with drug rep - Please rate your experience with each of the following non-curative prostate cancer treatments on the following attributes: Erleada (apalutamide)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_PC_Lr6"
  },
  {
    "Column": "Q11a_PC_Lr7r1",
    "Description": "Q11a_PC_Lr7r1: Overall experience with the drug - Please rate your experience with each of the following non-curative prostate cancer treatments on the following attributes:",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_PC_Lr7"
  },
  {
    "Column": "Q11a_PC_Lr7r2",
    "Description": "Q11a_PC_Lr7r2: Ease of access - Please rate your experience with each of the following non-curative prostate cancer treatments on the following attributes:",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_PC_Lr7"
  },
  {
    "Column": "Q11a_PC_Lr7r3",
    "Description": "Q11a_PC_Lr7r3: Availability of financial support from manufacturer - Please rate your experience with each of the following non-curative prostate cancer treatments on the following attributes:",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_PC_Lr7"
  },
  {
    "Column": "Q11a_PC_Lr7r4",
    "Description": "Q11a_PC_Lr7r4: Experience with drug rep - Please rate your experience with each of the following non-curative prostate cancer treatments on the following attributes:",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_PC_Lr7"
  },
  {
    "Column": "Q11a_PC_Lr8r1",
    "Description": "Q11a_PC_Lr8r1: Overall experience with the drug - Please rate your experience with each of the following non-curative prostate cancer treatments on the following attributes: None of the above",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_PC_Lr8"
  },
  {
    "Column": "Q11a_PC_Lr8r2",
    "Description": "Q11a_PC_Lr8r2: Ease of access - Please rate your experience with each of the following non-curative prostate cancer treatments on the following attributes: None of the above",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_PC_Lr8"
  },
  {
    "Column": "Q11a_PC_Lr8r3",
    "Description": "Q11a_PC_Lr8r3: Availability of financial support from manufacturer - Please rate your experience with each of the following non-curative prostate cancer treatments on the following attributes: None of the above",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_PC_Lr8"
  },
  {
    "Column": "Q11a_PC_Lr8r4",
    "Description": "Q11a_PC_Lr8r4: Experience with drug rep - Please rate your experience with each of the following non-curative prostate cancer treatments on the following attributes: None of the above",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_PC_Lr8"
  },
  {
    "Column": "Q10_BCr1",
    "Description": "Q10_BCr1: PADCEV (enfortumab vedotin) - For your bladder cancer patients, which of the following medications have you personally prescribed in the last 6 months?",
    "Answer_Options": "0=NO TO: PADCEV (enfortumab vedotin),1=PADCEV (enfortumab vedotin)",
    "ParentQuestion": "Q10_BC"
  },
  {
    "Column": "Q10_BCr2",
    "Description": "Q10_BCr2: Balversa (erdafitinib) - For your bladder cancer patients, which of the following medications have you personally prescribed in the last 6 months?",
    "Answer_Options": "0=NO TO: Balversa (erdafitinib),1=Balversa (erdafitinib)",
    "ParentQuestion": "Q10_BC"
  },
  {
    "Column": "Q10_BCr3",
    "Description": "Q10_BCr3: Tecentriq (atezolizumab) - For your bladder cancer patients, which of the following medications have you personally prescribed in the last 6 months?",
    "Answer_Options": "0=NO TO: Tecentriq (atezolizumab),1=Tecentriq (atezolizumab)",
    "ParentQuestion": "Q10_BC"
  },
  {
    "Column": "Q10_BCr4",
    "Description": "Q10_BCr4: Keytruda (pembrolizumab) - For your bladder cancer patients, which of the following medications have you personally prescribed in the last 6 months?",
    "Answer_Options": "0=NO TO: Keytruda (pembrolizumab),1=Keytruda (pembrolizumab)",
    "ParentQuestion": "Q10_BC"
  },
  {
    "Column": "Q10_BCr5",
    "Description": "Q10_BCr5: Opdivo (nivolumab) - For your bladder cancer patients, which of the following medications have you personally prescribed in the last 6 months?",
    "Answer_Options": "0=NO TO: Opdivo (nivolumab),1=Opdivo (nivolumab)",
    "ParentQuestion": "Q10_BC"
  },
  {
    "Column": "Q10_BCr6",
    "Description": "Q10_BCr6: None of the above - For your bladder cancer patients, which of the following medications have you personally prescribed in the last 6 months?",
    "Answer_Options": "0=NO TO: None of the above,1=None of the above",
    "ParentQuestion": "Q10_BC"
  },
  {
    "Column": "Q11_BC_Lr1r1",
    "Description": "Q11_BC_Lr1r1: Overall experience prescribing drug - Please rate your experience with each of the following bladder cancer treatments on the following attributes:PADCEV (enfortumab vedotin)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10",
    "ParentQuestion": "Q11_BC_Lr1"
  },
  {
    "Column": "Q11_BC_Lr1r2",
    "Description": "Q11_BC_Lr1r2: Ease of access - Please rate your experience with each of the following bladder cancer treatments on the following attributes:PADCEV (enfortumab vedotin)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10",
    "ParentQuestion": "Q11_BC_Lr1"
  },
  {
    "Column": "Q11_BC_Lr1r3",
    "Description": "Q11_BC_Lr1r3: Availability of financial support from manufacturer - Please rate your experience with each of the following bladder cancer treatments on the following attributes:PADCEV (enfortumab vedotin)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10",
    "ParentQuestion": "Q11_BC_Lr1"
  },
  {
    "Column": "Q11_BC_Lr1r4",
    "Description": "Q11_BC_Lr1r4: Experience with drug rep - Please rate your experience with each of the following bladder cancer treatments on the following attributes:PADCEV (enfortumab vedotin)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10",
    "ParentQuestion": "Q11_BC_Lr1"
  },
  {
    "Column": "Q11_BC_Lr2r1",
    "Description": "Q11_BC_Lr2r1: Overall experience prescribing drug - Please rate your experience with each of the following bladder cancer treatments on the following attributes:Balversa (erdafitinib)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10",
    "ParentQuestion": "Q11_BC_Lr2"
  },
  {
    "Column": "Q11_BC_Lr2r2",
    "Description": "Q11_BC_Lr2r2: Ease of access - Please rate your experience with each of the following bladder cancer treatments on the following attributes:Balversa (erdafitinib)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10",
    "ParentQuestion": "Q11_BC_Lr2"
  },
  {
    "Column": "Q11_BC_Lr2r3",
    "Description": "Q11_BC_Lr2r3: Availability of financial support from manufacturer - Please rate your experience with each of the following bladder cancer treatments on the following attributes:Balversa (erdafitinib)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10",
    "ParentQuestion": "Q11_BC_Lr2"
  },
  {
    "Column": "Q11_BC_Lr2r4",
    "Description": "Q11_BC_Lr2r4: Experience with drug rep - Please rate your experience with each of the following bladder cancer treatments on the following attributes:Balversa (erdafitinib)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10",
    "ParentQuestion": "Q11_BC_Lr2"
  },
  {
    "Column": "Q11_BC_Lr3r1",
    "Description": "Q11_BC_Lr3r1: Overall experience prescribing drug - Please rate your experience with each of the following bladder cancer treatments on the following attributes:Tecentriq (atezolizumab)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10",
    "ParentQuestion": "Q11_BC_Lr3"
  },
  {
    "Column": "Q11_BC_Lr3r2",
    "Description": "Q11_BC_Lr3r2: Ease of access - Please rate your experience with each of the following bladder cancer treatments on the following attributes:Tecentriq (atezolizumab)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10",
    "ParentQuestion": "Q11_BC_Lr3"
  },
  {
    "Column": "Q11_BC_Lr3r3",
    "Description": "Q11_BC_Lr3r3: Availability of financial support from manufacturer - Please rate your experience with each of the following bladder cancer treatments on the following attributes:Tecentriq (atezolizumab)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10",
    "ParentQuestion": "Q11_BC_Lr3"
  },
  {
    "Column": "Q11_BC_Lr3r4",
    "Description": "Q11_BC_Lr3r4: Experience with drug rep - Please rate your experience with each of the following bladder cancer treatments on the following attributes:Tecentriq (atezolizumab)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10",
    "ParentQuestion": "Q11_BC_Lr3"
  },
  {
    "Column": "Q11_BC_Lr4r1",
    "Description": "Q11_BC_Lr4r1: Overall experience prescribing drug - Please rate your experience with each of the following bladder cancer treatments on the following attributes:Keytruda (pembrolizumab)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10",
    "ParentQuestion": "Q11_BC_Lr4"
  },
  {
    "Column": "Q11_BC_Lr4r2",
    "Description": "Q11_BC_Lr4r2: Ease of access - Please rate your experience with each of the following bladder cancer treatments on the following attributes:Keytruda (pembrolizumab)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10",
    "ParentQuestion": "Q11_BC_Lr4"
  },
  {
    "Column": "Q11_BC_Lr4r3",
    "Description": "Q11_BC_Lr4r3: Availability of financial support from manufacturer - Please rate your experience with each of the following bladder cancer treatments on the following attributes:Keytruda (pembrolizumab)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10",
    "ParentQuestion": "Q11_BC_Lr4"
  },
  {
    "Column": "Q11_BC_Lr4r4",
    "Description": "Q11_BC_Lr4r4: Experience with drug rep - Please rate your experience with each of the following bladder cancer treatments on the following attributes:Keytruda (pembrolizumab)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10",
    "ParentQuestion": "Q11_BC_Lr4"
  },
  {
    "Column": "Q11_BC_Lr5r1",
    "Description": "Q11_BC_Lr5r1: Overall experience prescribing drug - Please rate your experience with each of the following bladder cancer treatments on the following attributes:Opdivo (nivolumab)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10",
    "ParentQuestion": "Q11_BC_Lr5"
  },
  {
    "Column": "Q11_BC_Lr5r2",
    "Description": "Q11_BC_Lr5r2: Ease of access - Please rate your experience with each of the following bladder cancer treatments on the following attributes:Opdivo (nivolumab)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10",
    "ParentQuestion": "Q11_BC_Lr5"
  },
  {
    "Column": "Q11_BC_Lr5r3",
    "Description": "Q11_BC_Lr5r3: Availability of financial support from manufacturer - Please rate your experience with each of the following bladder cancer treatments on the following attributes:Opdivo (nivolumab)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10",
    "ParentQuestion": "Q11_BC_Lr5"
  },
  {
    "Column": "Q11_BC_Lr5r4",
    "Description": "Q11_BC_Lr5r4: Experience with drug rep - Please rate your experience with each of the following bladder cancer treatments on the following attributes:Opdivo (nivolumab)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10",
    "ParentQuestion": "Q11_BC_Lr5"
  },
  {
    "Column": "Q12_BCc1",
    "Description": "Q12_BCc1: PADCEV (enfortumab vedotin) - How do you expect your prescribing of each of the following bladder cancer treatment(s) will change in the next year?",
    "Answer_Options": "1=Prescribe more,2=Prescribe less,3=Prescribe about the same",
    "ParentQuestion": "Q12_BC"
  },
  {
    "Column": "Q12_BCc2",
    "Description": "Q12_BCc2: Balversa (erdafitinib) - How do you expect your prescribing of each of the following bladder cancer treatment(s) will change in the next year?",
    "Answer_Options": "1=Prescribe more,2=Prescribe less,3=Prescribe about the same",
    "ParentQuestion": "Q12_BC"
  },
  {
    "Column": "Q12_BCc3",
    "Description": "Q12_BCc3: Tecentriq (atezolizumab) - How do you expect your prescribing of each of the following bladder cancer treatment(s) will change in the next year?",
    "Answer_Options": "1=Prescribe more,2=Prescribe less,3=Prescribe about the same",
    "ParentQuestion": "Q12_BC"
  },
  {
    "Column": "Q12_BCc4",
    "Description": "Q12_BCc4: Keytruda (pembrolizumab) - How do you expect your prescribing of each of the following bladder cancer treatment(s) will change in the next year?",
    "Answer_Options": "1=Prescribe more,2=Prescribe less,3=Prescribe about the same",
    "ParentQuestion": "Q12_BC"
  },
  {
    "Column": "Q12_BCc5",
    "Description": "Q12_BCc5: Opdivo (nivolumab) - How do you expect your prescribing of each of the following bladder cancer treatment(s) will change in the next year?",
    "Answer_Options": "1=Prescribe more,2=Prescribe less,3=Prescribe about the same",
    "ParentQuestion": "Q12_BC"
  },
  {
    "Column": "Q10a_BCr1",
    "Description": "Q10a_BCr1: PADCEV (enfortumab vedotin) - Which of the following medications are prescribed for the bladder cancer patients treated in your practice in the last 6 months?",
    "Answer_Options": "0=NO TO: PADCEV (enfortumab vedotin),1=PADCEV (enfortumab vedotin)",
    "ParentQuestion": "Q10a_BC"
  },
  {
    "Column": "Q10a_BCr2",
    "Description": "Q10a_BCr2: Balversa (erdafitinib) - Which of the following medications are prescribed for the bladder cancer patients treated in your practice in the last 6 months?",
    "Answer_Options": "0=NO TO: Balversa (erdafitinib),1=Balversa (erdafitinib)",
    "ParentQuestion": "Q10a_BC"
  },
  {
    "Column": "Q10a_BCr3",
    "Description": "Q10a_BCr3: Tecentriq (atezolizumab) - Which of the following medications are prescribed for the bladder cancer patients treated in your practice in the last 6 months?",
    "Answer_Options": "0=NO TO: Tecentriq (atezolizumab),1=Tecentriq (atezolizumab)",
    "ParentQuestion": "Q10a_BC"
  },
  {
    "Column": "Q10a_BCr4",
    "Description": "Q10a_BCr4: Keytruda (pembrolizumab) - Which of the following medications are prescribed for the bladder cancer patients treated in your practice in the last 6 months?",
    "Answer_Options": "0=NO TO: Keytruda (pembrolizumab),1=Keytruda (pembrolizumab)",
    "ParentQuestion": "Q10a_BC"
  },
  {
    "Column": "Q10a_BCr5",
    "Description": "Q10a_BCr5: Opdivo (nivolumab) - Which of the following medications are prescribed for the bladder cancer patients treated in your practice in the last 6 months?",
    "Answer_Options": "0=NO TO: Opdivo (nivolumab),1=Opdivo (nivolumab)",
    "ParentQuestion": "Q10a_BC"
  },
  {
    "Column": "Q10a_BCr6",
    "Description": "Q10a_BCr6: None of the above - Which of the following medications are prescribed for the bladder cancer patients treated in your practice in the last 6 months?",
    "Answer_Options": "0=NO TO: None of the above,1=None of the above",
    "ParentQuestion": "Q10a_BC"
  },
  {
    "Column": "Q11a_BC_Lr1r1",
    "Description": "Q11a_BC_Lr1r1: Overall experience prescribing drug - Please rate your experience with each of the following bladder cancer treatments on the following attributes:PADCEV (enfortumab vedotin)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_BC_Lr1"
  },
  {
    "Column": "Q11a_BC_Lr1r2",
    "Description": "Q11a_BC_Lr1r2: Ease of access - Please rate your experience with each of the following bladder cancer treatments on the following attributes:PADCEV (enfortumab vedotin)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_BC_Lr1"
  },
  {
    "Column": "Q11a_BC_Lr1r3",
    "Description": "Q11a_BC_Lr1r3: Availability of financial support from manufacturer - Please rate your experience with each of the following bladder cancer treatments on the following attributes:PADCEV (enfortumab vedotin)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_BC_Lr1"
  },
  {
    "Column": "Q11a_BC_Lr1r4",
    "Description": "Q11a_BC_Lr1r4: Experience with drug rep - Please rate your experience with each of the following bladder cancer treatments on the following attributes:PADCEV (enfortumab vedotin)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_BC_Lr1"
  },
  {
    "Column": "Q11a_BC_Lr2r1",
    "Description": "Q11a_BC_Lr2r1: Overall experience prescribing drug - Please rate your experience with each of the following bladder cancer treatments on the following attributes:Balversa (erdafitinib)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_BC_Lr2"
  },
  {
    "Column": "Q11a_BC_Lr2r2",
    "Description": "Q11a_BC_Lr2r2: Ease of access - Please rate your experience with each of the following bladder cancer treatments on the following attributes:Balversa (erdafitinib)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_BC_Lr2"
  },
  {
    "Column": "Q11a_BC_Lr2r3",
    "Description": "Q11a_BC_Lr2r3: Availability of financial support from manufacturer - Please rate your experience with each of the following bladder cancer treatments on the following attributes:Balversa (erdafitinib)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_BC_Lr2"
  },
  {
    "Column": "Q11a_BC_Lr2r4",
    "Description": "Q11a_BC_Lr2r4: Experience with drug rep - Please rate your experience with each of the following bladder cancer treatments on the following attributes:Balversa (erdafitinib)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_BC_Lr2"
  },
  {
    "Column": "Q11a_BC_Lr3r1",
    "Description": "Q11a_BC_Lr3r1: Overall experience prescribing drug - Please rate your experience with each of the following bladder cancer treatments on the following attributes:Tecentriq (atezolizumab)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_BC_Lr3"
  },
  {
    "Column": "Q11a_BC_Lr3r2",
    "Description": "Q11a_BC_Lr3r2: Ease of access - Please rate your experience with each of the following bladder cancer treatments on the following attributes:Tecentriq (atezolizumab)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_BC_Lr3"
  },
  {
    "Column": "Q11a_BC_Lr3r3",
    "Description": "Q11a_BC_Lr3r3: Availability of financial support from manufacturer - Please rate your experience with each of the following bladder cancer treatments on the following attributes:Tecentriq (atezolizumab)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_BC_Lr3"
  },
  {
    "Column": "Q11a_BC_Lr3r4",
    "Description": "Q11a_BC_Lr3r4: Experience with drug rep - Please rate your experience with each of the following bladder cancer treatments on the following attributes:Tecentriq (atezolizumab)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_BC_Lr3"
  },
  {
    "Column": "Q11a_BC_Lr4r1",
    "Description": "Q11a_BC_Lr4r1: Overall experience prescribing drug - Please rate your experience with each of the following bladder cancer treatments on the following attributes:Keytruda (pembrolizumab)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_BC_Lr4"
  },
  {
    "Column": "Q11a_BC_Lr4r2",
    "Description": "Q11a_BC_Lr4r2: Ease of access - Please rate your experience with each of the following bladder cancer treatments on the following attributes:Keytruda (pembrolizumab)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_BC_Lr4"
  },
  {
    "Column": "Q11a_BC_Lr4r3",
    "Description": "Q11a_BC_Lr4r3: Availability of financial support from manufacturer - Please rate your experience with each of the following bladder cancer treatments on the following attributes:Keytruda (pembrolizumab)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_BC_Lr4"
  },
  {
    "Column": "Q11a_BC_Lr4r4",
    "Description": "Q11a_BC_Lr4r4: Experience with drug rep - Please rate your experience with each of the following bladder cancer treatments on the following attributes:Keytruda (pembrolizumab)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_BC_Lr4"
  },
  {
    "Column": "Q11a_BC_Lr5r1",
    "Description": "Q11a_BC_Lr5r1: Overall experience prescribing drug - Please rate your experience with each of the following bladder cancer treatments on the following attributes:Opdivo (nivolumab)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_BC_Lr5"
  },
  {
    "Column": "Q11a_BC_Lr5r2",
    "Description": "Q11a_BC_Lr5r2: Ease of access - Please rate your experience with each of the following bladder cancer treatments on the following attributes:Opdivo (nivolumab)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_BC_Lr5"
  },
  {
    "Column": "Q11a_BC_Lr5r3",
    "Description": "Q11a_BC_Lr5r3: Availability of financial support from manufacturer - Please rate your experience with each of the following bladder cancer treatments on the following attributes:Opdivo (nivolumab)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_BC_Lr5"
  },
  {
    "Column": "Q11a_BC_Lr5r4",
    "Description": "Q11a_BC_Lr5r4: Experience with drug rep - Please rate your experience with each of the following bladder cancer treatments on the following attributes:Opdivo (nivolumab)",
    "Answer_Options": "1=Not at all Satisfied1,2=2,3=3,4=4,5=5,6=6,7=7,8=8,9=9,10=Extremely Satisfied 10,11=Don’t Know / N/A",
    "ParentQuestion": "Q11a_BC_Lr5"
  },
  {
    "Column": "Q13r1c1",
    "Description": "Q13r1c1: Commercial Insurance (i.e. HMO/PPO) - We have just one final question for classification purposes. What is the distribution of your oncology patients at your primary practice setting/organization by insurance type?",
    "Answer_Options": "NA",
    "ParentQuestion": "Q13"
  },
  {
    "Column": "Q13r2c1",
    "Description": "Q13r2c1: Medicare - We have just one final question for classification purposes. What is the distribution of your oncology patients at your primary practice setting/organization by insurance type?",
    "Answer_Options": "NA",
    "ParentQuestion": "Q13"
  },
  {
    "Column": "Q13r3c1",
    "Description": "Q13r3c1: Medicaid - We have just one final question for classification purposes. What is the distribution of your oncology patients at your primary practice setting/organization by insurance type?",
    "Answer_Options": "NA",
    "ParentQuestion": "Q13"
  },
  {
    "Column": "Q13r4c1",
    "Description": "Q13r4c1: VA/DoD - We have just one final question for classification purposes. What is the distribution of your oncology patients at your primary practice setting/organization by insurance type?",
    "Answer_Options": "NA",
    "ParentQuestion": "Q13"
  },
  {
    "Column": "Q13r5c1",
    "Description": "Q13r5c1: Uninsured - We have just one final question for classification purposes. What is the distribution of your oncology patients at your primary practice setting/organization by insurance type?",
    "Answer_Options": "NA",
    "ParentQuestion": "Q13"
  },
  {
    "Column": "Q13r6c1",
    "Description": "Q13r6c1: Other - We have just one final question for classification purposes. What is the distribution of your oncology patients at your primary practice setting/organization by insurance type?",
    "Answer_Options": "NA",
    "ParentQuestion": "Q13"
  },
  {
    "Column": "Q13r6oe",
    "Description": "Q13r6oe: We have just one final question for classification purposes. What is the distribution of your oncology patients at your primary practice setting/organization by insurance type? - Other",
    "Answer_Options": "NA",
    "ParentQuestion": "Q13"
  },
  {
    "Column": "qtime",
    "Description": "qtime: Total Interview Time",
    "Answer_Options": "NA"
  },
  {
    "Column": "start_date",
    "Description": "start_date: Survey start time",
    "Answer_Options": "NA"
  },
  {
    "Column": "Prostate_Master_for_Programming_xlsx_state",
    "Description": "Prostate_Master_for_Programming_xlsx_state: state",
    "Answer_Options": "NA"
  },
  {
    "Column": "Prostate_Master_for_Programming_xlsx_tier",
    "Description": "Prostate_Master_for_Programming_xlsx_tier: tier",
    "Answer_Options": "NA"
  },
  {
    "Column": "Prostate_Master_for_Programming_xlsx_List",
    "Description": "Prostate_Master_for_Programming_xlsx_List: List",
    "Answer_Options": "NA"
  },
  {
    "Column": "Prostate_Master_for_Programming_xlsx_AST_Specialty",
    "Description": "Prostate_Master_for_Programming_xlsx_AST_Specialty: AST Specialty",
    "Answer_Options": "NA"
  },
  {
    "Column": "Prostate_Master_for_Programming_xlsx_Physician_Segment",
    "Description": "Prostate_Master_for_Programming_xlsx_Physician_Segment: Physician Segment",
    "Answer_Options": "NA"
  },
  {
    "Column": "Prostate_Master_for_Programming_xlsx_AAID",
    "Description": "Prostate_Master_for_Programming_xlsx_AAID: AAID",
    "Answer_Options": "NA"
  },
  {
    "Column": "AAID",
    "Description": "AAID: Captured variable",
    "Answer_Options": "NA"
  }
]